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The epigenetic mechanism DNA methylation
Deoxyribonucleic acid (DNA) stores the information necessary for all forms of life, including 
humans. DNA is a complex molecule composed of two DNA strands that coil around each 
other, known as the double helix. The building blocks of the DNA (nucleotides) are cytosine 
(C), guanine (G), adenine (A) and thymine (T), where the C is always coupled to the G and 
the A is always coupled to the T in the double helix structure. The specific order of the four 
different nucleotides is referred to as the genomic sequence and determines whether an 
individual has blue or brown eyes for example. DNA regions that code for a functional 
molecule (protein) are what we call genes and the average length of a human gene is 
67,000 nucleotides1. Humans have approximately 19,000 protein-coding genes and these 
comprise 1-2% of the complete human genomic sequence2. 
Inside the nucleus of the cell, the DNA sequence of a gene is transcribed into messenger 
RNA (mRNA), a molecule that functions as an information-carrier between DNA and 
protein. This mRNA is then translated into protein and the different proteins that are 
produced within a cell largely determine the function of that cell. However, not all genes 
are translated into protein, genes can be active, producing a lot of protein, or silenced, 
producing little to no protein, this is referred to as gene expression levels. 
Tight regulation of gene expression is essential in maintaining proper cell function and 
this regulation is done by epigenetic mechanisms. These epigenetic mechanisms influence 
gene expression without changing the underlying genomic sequence of the DNA and 
therefore represent the interface between the genomic information and the environment. 
Three main categories of epigenetic mechanisms can be identified3 (Figure 1). The 
first is DNA methylation, which is the covalent addition of a methyl-group (CH3) to the 
cytosine in the DNA and, to this day, the most studied and best-understood epigenetic 
mechanism. The second category is post-translational modifications of histones, these are 
the proteins around which the DNA is wrapped. Modifications of histone proteins involve 
acetylation, phosphorylation, methylation and more. The third category is the higher-order 
3-dimensional structure of the DNA such as loop formation and positioning of the DNA 
inside the nucleus. All these epigenetic mechanisms together determine whether a specific 
gene is accessible for gene transcription. In this thesis we will focus on DNA methylation as 
the epigenetic mechanism of interest.
DNA methylation in mammals occurs almost exclusively on cytosines (C) that are followed 
by a guanine (G) in the DNA, referred to as a CpG dinucleotide or CpG site. The methyl-
group is present on both strands of the DNA and is copied onto the daughter-strand during 
DNA replication by the enzyme DNA methyltransferase 1 (DNMT1). DNA methylation 
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can also be introduced to previously unmethylated sites by de novo methyltransferases 
(DNMT3a, DNMT3b). Removal of the methyl-group occurs either passively during cell 
division or actively by ten-eleven translocating enzymes (TET)4. In most cases, high DNA 
methylation in the promoter of a gene is associated with gene silencing. The methylation 
complicates binding of transcription factors to initiate transcription and may recruit 
other gene repressing epigenetic marks5. Whilst promoter DNA methylation regulates 
gene expression at close proximity in the genome, the effect of DNA methylation outside 
promoter regions is less clear6. Recently, more research is focused on DNA methylation 
within enhancer regions, which are regulatory regions typically located far away from the 
genes they regulate7.
Cellular identity and differentiation
As explained previously, DNA methylation changes gene expression without changing the 
underlying DNA sequence. This is a crucial concept in cellular identity, since essentially all 
Histone proteins
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Figure 1. The three main categories of epigenetic mechanisms. The light blue hexagons 
represent DNA methylation, which is depicted in more detail within the square. The DNA 
double helix is wrapped around 8 histone proteins, the histone tails can be modified to 
repress gene expression (red dots) or to activate gene expression (green dots). In genomic 
regions where the DNA is tightly packed genes are silenced and in open genomic areas 
genes can be expressed.
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cells in the body have the same DNA sequence whilst different cell types have very different 
functions. Changes in DNA methylation profiles play a critical role in the differentiation 
of stem cells and progenitor cells towards differentiated cell types8. For example T cells, 
which are derived from hematopoietic stem cells and play a central role in adaptive 
immunity, experience demethylation of lineage-specific genes during hematopoietic 
differentiation9,10. Once the T cells are matured and the CD4 (T helper cells) and CD8 
(cytotoxic T cells) phenotypes are established, they leave the thymus as naive T cells. Naive 
T cells are characterized by high DNA methylation of T cell effector genes such as interferon 
gamma (IFNγ)8 and programmed death 1 (PD1)11. Upon recognition of antigen via the T-cell 
receptor, naive T cells will differentiate into effector cells and eventually memory cells. 
During differentiation, demethylation of effector genes ensures that the appropriate gene 
expression profile is established12,13.
DNA methylation as biomarker
Even though cell identity is largely determined by the DNA methylation profile, there 
is a degree of plasticity in DNA methylation. Environmental conditions such as diet5, 
psychological stress14 and exposure to chemical components15 have shown to affect 
DNA methylation, leading to long-term phenotypic effects. An excellent model to study 
environmental effects are identical twins16,17; they have exactly the same DNA sequence 
whilst different environmental conditions can lead to different DNA methylation profiles18. 
Disease-discordant twin studies have been used to identify DNA methylation differences 
associated with autoimmune disorders such as systemic lupus erythematosus19 and 
psychiatric disorders such as bipolar disease20. In addition, epigenome-wide association 
studies (EWAS) are increasingly identifying DNA methylation differences associated to 
disease21, highlighting the potential of DNA methylation as biomarker. In oncology there 
are several well-established DNA methylation biomarkers such as VIM methylation for 
colorectal cancer22, SHOX2 for lung cancer23,24 and MGMT for glioblastoma25.  The current 
challenge in the field of epigenetics is to move from demonstrating an association with 
disease to elucidating the etiological role of DNA methylation changes in human disease26,27.
Measuring DNA methylation
Methylated cytosines are not detectable by regular DNA sequencing methods and if 
the DNA needs amplification by polymerase chain reaction (PCR), the methyl-group 
disappears. To circumvent this problem, the DNA can be treated with sodium bisulfite 
to induce methylation dependent changes to the DNA. With this chemical treatment, 
unmethylated cytosines are converted to uracil (U), which is usually found in RNA, whilst 
methylated cytosines are protected from this conversion28 (Figure 2A). During subsequent 
PCR the uracil is then copied as a thymine (T) (Figure 2B). 
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After bisulfite treatment, several methods are available to measure DNA methylation at 
a single site resolution. An example of a targeted method to measure DNA methylation is 
pyrosequencing, which can quantitatively measure DNA methylation of a region of up to 
200 base pair (bp) per sequence reaction29. After bisulfite treatment and PCR of the target 
sequence, the real-time incorporation of nucleotides is detected by an enzyme-mediated 
light flash whenever a specific nucleotide is built in. The percentage methylation for a single 
CpG site is then calculated from the ratio of the thymidine and cytosine peak intensities at 
the site of interest. Within a single cell two chromosomes, thus two copies of each CpG site, 
are present and the percentage methylation can be 0%, 50% or 100%. Most often a sample 
contains multiple cells and the percentage therefore represents the average methylation 
for all the DNA molecules within the sample. 
There are also methods that measure DNA methylation at a genome-wide scale such 
as the 450k (>450.000 CpG sites) or EPIC (>850.000 CpG sites) methylation arrays by 
Illumina30. These arrays consist of a glass slide with small pieces of DNA (probes) attached 
that specifically bind sequences of the bisulfite treated DNA, the probes are specific for 
a methylated or an unmethylated site. The array covers not only 99% of known human 
genes but also intergenic regions, microRNA promoters and regions that were previously 
identified as differentially methylated in a wide range of tumor types. The EPIC array 
additionally covers many recently identified enhancers31. The methylation values are 
expressed as a beta-value between 0-1, where 0 represents unmethylated and 1 represents 
fully methylated.
Organ transplantation
Organ transplantation is the best treatment option for patients experiencing end-stage 
organ failure32. Heart, lung, liver and kidney are among the majority of transplanted organs, 
whereby liver and kidney transplantation occur most frequently. In the Netherlands, 950 
to 1000 kidney transplantations are performed each year33 of which around 200 in our 
center, Erasmus MC. To prevent an immune response by the recipient towards the donor 
organ, transplant recipients require lifelong immunosuppressive treatment. Nowadays, 
maintenance immunosuppressive treatment after kidney transplantation consist of a 
proliferation inhibitor such as mycophenolate mofetil (MMF), and a calcineurin inhibitor 
(CNI) such as tacrolimus34. These immunosuppressive drugs suppress immune cells, 
including T cells since these cells play a key role in the recipients’ immune response towards 
the allograft.
Complications after kidney transplantation
Even though quality of life improves significantly after transplantation, there are several 
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complications that transplant recipients can experience. Despite immunosuppressive 
treatment, acute rejection of the graft still occurs in up to 20% of the kidney transplant 
recipients35. Acute rejection is defined as a rejection episode that develops within a short 
time-frame and is associated with a sharp decrease in kidney function. Acute rejection 
is, in most cases, treated successfully with high dosages of steroids36. Chronic rejection, 
a process that develops on the long-term, is more difficult to treat and may lead to graft 
failure and even death. The current gold standard to diagnose a rejection is a biopsy, in 
which tissue damage and infiltrating immune cells can be assessed. This is an invasive 
method with sub-optimal sensitivity37, specific and sensitive prediction tools for rejection 
that can be analyzed non-invasively are still lacking38.
T cells play a key role in the rejection process. Before encountering any antigen, T cells 
are in a naive cell state. After recognizing the donor antigen, presented to the T cells by 
antigen presenting cells (APC), T cells will differentiate towards the effector cell state and 
produce immune signaling molecules called cytokines to alert and recruit other immune 
cells to the organ. These cytokines induce proliferation and differentiation of the T cells 
and, once recruited to the allograft, the CD8-compartment of the T cells (cytotoxic T cells) 
will induce cell death by apoptosis of the target (donor) cells. As a result of encountering 
an antigen, some T cells will differentiate into a memory state that, upon re-encountering 
the same antigen, can more rapidly respond than naive T cells. In addition to the cellular 
immune response, T cells may also activate B cells to produce donor specific antibodies, 
thereby contributing to a humoral immune response. These immune processes can lead to 
tissue damage and thereby compromise the function of the allograft. For these reasons, 
immunosuppressive treatment to suppress T-cell activity is an essential part of post-
transplant care. 
Complications other than rejection are often related to the systemic suppression of the 
immune system in transplant recipients which affects all immune responses, not only 
those directed at the graft. Increased incidences of infections and malignancies are very 
common in transplant recipients39,40, associated with high morbidity and mortality in 
these patients41. Skin cancer is the most common malignancy in transplant recipients42, 
specifically cutaneous squamous cell carcinoma (cSCC). Studies have shown a 65 to 
200 times increased incidence of cSCC in transplant recipients compared to the general 
population43,44 and a 30-year cumulative incidence of over 60%45. Risk factors include 
human papilloma virus (HPV) infection, history of sunburn, fair skin color, exposure to 
ultraviolet (UV) radiation, but most importantly a previous cSCC42; indicating that cSCC is 
often a recurring disease in these patients. 
cSCC represents a high burden for transplant recipients and can significantly decrease 
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their quality of life. Treatment requires frequent hospital visits where surgical excision of 
the cSCC is often the treatment of choice for non-metastatic disease46,47. Early recognition 
and treatment of a pre-cancerous lesions such as warts or actinic keratosis reduces the 
burden for patients and may prevent development of an invasive malignancy. Preventing 
the development of cSCC is difficult, reducing sun exposure and applying adequate sun 
protection in combination with frequent screening to facilitate early detection is currently 
the recommended approach47. 
The immune system plays a conflicting role in post-transplant skin cancer patients: it needs 
to be suppressed to prevent rejection but at the same time it must be activated to provide 
anti-tumor immune surveillance. With this in mind, several studies have been conducted 
towards immune phenotypes associated to post-transplant cSCC. High number of T 
regulatory cells (Treg) and senescent T cells (CD8+CD57+) have been associated to post-
transplant cSCC48-50, but only to a recurrence of the cSCC. Tools to predict the development 
of a first post-transplant cSCC are currently unavailable.
Objectives of this thesis
Despite advances in surgical procedures and the development of better and more specific 
immunosuppressive drugs in kidney transplantation, complications such as rejection 
and malignancy remain problematic for transplant recipients. There is a need to explore 
novel and innovative methods to identify transplant recipients at increased risk for 
complications and thereby improve and personalize treatment for these patients. Since 
epigenetic mechanisms such as DNA methylation underlie changes in functional behavior, 
studying changes in DNA methylation may improve risk assessment for post-transplant 
complications.
The main objective of this thesis is to explore the role of DNA methylation changes in 
complications after kidney transplantation. To answer this two complementary approaches 
were employed. 
•	 First, we aim to unravel if environmental conditions relevant in transplantation 
affect DNA methylation; by investigating the stability of DNA methylation in 
experimental, in vitro systems in the presence of immunosuppressive drugs and 
cytokines. 
•	 Second, we explore whether DNA methylation profiles can identify kidney 
transplant recipients who are at increased risk for rejection or skin cancer after 
kidney transplantation.
Chapter 1
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In chapter 2, we describe the effect of the immunosuppressive drugs tacrolimus and MMF 
(active ingredient MPA), on DNA methylation of T cells. We investigated the changes 
in IFNγ DNA methylation after stimulation of the T cells in the presence of these drugs, 
both in total T cells and in naive and memory T cells. Chapter 3  focuses on the effect of 
cytokines added to the in vitro culture system as well as culture expansion alone, on the 
DNA methylation profiles of mesenchymal stromal cells (MSCs) as a model system. MSCs 
are an interesting cell type to study in transplantation since they have immunomodulatory 
and regenerative capacities. Here we applied a genome-wide analysis of DNA methylation 
instead of a targeted analysis. 
In chapter 4, the potential of DNA methylation in organ transplantation is introduced. We 
reviewed the literature and provide an overview of the clinical potential of DNA methylation 
as a  biomarker for complications after transplantation and for monitoring the immune 
system. Chapter 5 describes DNA methylation of IFNγ and PD1 in patients who developed 
a rejection after kidney transplantation. We focused on DNA methylation within the naive 
and memory subsets of the CD8+ T cell compartment. In chapter 6 we describe a different 
complication after transplantation: skin cancer. Genome-wide DNA methylation profiles 
of T cells were studied before transplantation, to identify patients at increased risk for skin 
cancer after transplantation. Chapter 7 then describes a disrupted regulation of serpinB9 as 
risk factor for post-transplant skin cancer. Here we studied DNA methylation profiles, RNA 
and protein expression of serpinB9 in circulating T cells after transplantation. 
Chapter 8 summarizes and discusses the results described in this thesis and provides a 
perspective on the future implications of our findings.
General introduction and objectives
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Abstract
Immunosuppressive drug therapy is required to treat patients with autoimmune 
disease and patients who have undergone organ transplantation. The main targets 
of the immunosuppressive drugs tacrolimus and mycophenolic acid (MPA; the active 
metabolite of mycophenolate mofetil) are T cells. It is currently unknown whether these 
immunosuppressive drugs have an effect on DNA methylation - an epigenetic regulator 
of cellular function. Here, we determined the effect of tacrolimus and MPA on DNA 
methylation of the gene promoter region of interferon gamma (IFNγ), a pro-inflammatory 
cytokine. Total T cells, naive T cells (CCR7+CD45RO-) and memory T cells (CD45RO+ and 
CCR7-CD45RO-) were isolated from CMV seropositive healthy controls and stimulated 
with α-CD3/CD28 in the presence or absence of tacrolimus or MPA. DNA methylation 
of the IFNγ promoter region was quantified by pyrosequencing at 4 hours, day 1, 3 and 
4 after stimulation. In parallel, T-cell differentiation, and IFNγ protein production were 
analyzed by flow cytometry at day 1 and 3 after stimulation. Our results show that MPA 
induced changes in IFNγ DNA methylation of naive T cells; MPA counteracted the decrease 
in methylation after stimulation. Tacrolimus did not affect IFNγ DNA methylation of 
naive T cells. In the memory T cells, both immunosuppressive drugs did not affect IFNγ 
DNA methylation. Differentiation of naive T cells into a central-memory-like phenotype 
(CD45RO+) was inhibited by both immunosuppressive drugs, while differentiation of 
memory T cells remained unaffected by both MPA and tacrolimus. IFNγ protein production 
was suppressed by tacrolimus. Our results demonstrate that MPA influenced IFNγ DNA 
methylation of naive T cells after stimulation of T cells, while tacrolimus had no effect. Both 
tacrolimus and MPA did not affect IFNγ DNA methylation of memory T cells. 
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Introduction
Patients who have undergone organ transplantation as well as patients with autoimmune 
disease require lifelong immunosuppression to inhibit the immune response towards 
alloantigen or autoantigen. This immune response involves interaction between different 
immune cells including dendritic cells, macrophages, T and B cells. T cells proliferate, 
differentiate and produce effector cytokines in response to antigen1,2 and therefore 
immunosuppressive drugs are often designed to suppress T-cell activity.
After activation, the differentiation of T cells is regulated to great extent by DNA methylation 
– an essential epigenetic regulator of several cellular functions3-5. DNA methylation is the 
addition of a methyl group on a cytosine (C) that is followed by a guanine (G) in the DNA, 
also known as a CpG dinucleotide. High methylation in the promoter region of a gene is 
related to a closed chromatin structure and transcriptional silencing of the gene6,7. When 
T cells differentiate during an immune response, the promoter regions of various effector 
genes become demethylated, thereby allowing the cells to upregulate these genes and 
produce effector cytokines8,9. Naive T cells are therefore characterized by methylated 
promoter regions of effector genes, whereas effector and memory T cells are demethylated 
at those regions. 
Epigenetic regulators such as DNA methylation are dynamic and susceptible to cues 
from the environment10,11. These cues include internal factors such as cytokines and 
hormones as well as external factors such as food, toxins and drugs. Several common-
used pharmaceutical drugs, not designed as epigenetic drugs, have an effect on epigenetic 
mechanisms in the cell12,13. These findings suggest that immunosuppressive drugs could 
affect DNA methylation in T cells and thereby modulate T-cell function.
Today, the immunosuppressive drugs that are most often prescribed to organ transplant 
recipients include tacrolimus and mycophenolate mofetil14,15. Tacrolimus represses the 
calcineurin pathway downstream of the T-cell receptor (TCR). It inhibits calcineurin 
phosphatase activity, thereby reducing levels of dephosphorylated nuclear factor 
of activated T lymphocytes (NFAT), which ultimately inhibits T-cell activation16,17. 
Mycophenolate mofetil’s active ingredient is mycophenolic acid (MPA). MPA is an inhibitor 
of inosine monophosphate dehydrogenase (IMPDH), a key enzyme in de novo purine 
synthesis18. Inhibition of IMPDH reduces synthesis of guanosine nucleotides, which are 
essential for DNA synthesis in T cells, resulting in reduced proliferation of T cells19,20. 
Despite the fact that the mechanism of action is largely known for these two drugs, it is not 
known whether their effect on cellular function involves epigenetic regulation, nor whether 
they affect the epigenetic regulation of cytokine expression. A further understanding of 
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the effect of different immunosuppressive drugs on epigenetic regulators of T-cell function 
will contribute to optimization of the immunosuppressive regimen. 
We hypothesized that tacrolimus and MPA induce changes in DNA methylation of T cells. 
We focus on promoter DNA methylation of the pro-inflammatory cytokine IFNγ which 
plays a prominent role in immune responses. Not only have high expression levels of IFNγ 
been linked to acute rejection after organ transplantation21-23, it is also highly expressed 
during the inflammation seen in autoimmunity24,25. IFNγ expression – along with that of 
many other cytokines – is known to be regulated by DNA methylation26-28. To study the 
effect of immunosuppressive drugs on IFNγ DNA methylation after activation of T cells, 
we stimulated T cells in vitro in the absence or presence of tacrolimus or MPA. After 
stimulation, DNA methylation was measured at two sites within the IFNγ promoter. Since 
DNA methylation is cell-type specific29, the experiments were performed on total T cells as 
well as on isolated naive and memory T cells. 
Materials and methods
Study subjects 
Our study population consisted of 19 healthy individuals aged between 26-75 (68% female). 
Peripheral blood of these subjects was collected after informed consent and according to 
biobank protocol with approval of the local ethics committee (MEC-2010-022). We chose to 
study healthy individuals to eliminate confounding effects of disease on DNA methylation30. 
It is also known that IFNγ DNA methylation is significantly lower in CMV seropositive 
individuals than in CMV seronegative individuals31. To compose a homogeneous group 
and eliminate CMV effects on inter-individual differences in methylation levels, only CMV 
seropositive individuals were included in the study.
Isolation of total T cells, naive T cells and memory T cells
Peripheral blood mononuclear cells (PBMCs) were isolated from the peripheral blood 
by density gradient centrifugation using Ficoll-Paque (GE Healthcare, Chicago, IL, US). 
Isolated PBMCs were stored at -140°C until further use. Total T cells were isolated from 
the PBMCs by magnetic cell separation on the autoMACS (Miltenyi Biotech, Bergisch 
Gladbach, Germany) according to the pan T cell protocol using the deplete S settings. 
Purities were >90% CD3+ cells after isolation. 
The naive and memory T-cell populations were isolated from the PBMCs using fluorescence-
activated cell sorting (FACS) by the BD FACSAriaTM II (BD Biosciences, San Jose, CA, US). 
The PBMCs were stained with CD3 Brilliant Violet 510 (Biolegend, San Diego, CA, US), CD4 
Pacific Blue (BD Biosciences), CD8 APC-cy7 (BD Biosciences), CD45RO APC (Biolegend), 
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CCR7 PE-cy7 (BD Biosciences) and to exclude nonviable cells the cells were also stained 
with 7AAD PerCP (BD Biosciences). Naive cells were defined as CCR7+CD45RO-, central 
memory (CM) cells as CCR7+CD45RO+, effector memory (EM) as CCR7-CD45RO+ and the 
highly differentiated EMRA cells as CCR7-CD45RO-32. After cell sorting, the purities were 
>95% for each sorted fraction. 
T-cell stimulation
The T cells were stimulated for 4 days with α-CD3/CD28 coated Dynabeads® (Gibco, 
Waltham, MA, US) in a bead to cell ratio of 1:1 at day 0. 50,000 cells were cultured per 
well in a 96-well plate. The cells were cultured in the absence or presence of tacrolimus, 
MPA or 5-aza-2’deoxycytidine (decitabine). Tacrolimus (Prograf®, Astellas Pharma, Tokyo, 
Japan) was added to the cells in a concentration of 10 ng/mL which is a clinically relevant 
concentration that is reached in transplant recipients33. MPA (Sigma-Aldrich, St. Louis, MO, 
USA) was added to the cells in a concentration of 0.2 µg/mL, a concentration at which the 
cells are still able to proliferate. Our positive control, the demethylating agent decitabine 
(Sigma-Aldrich)34, was added to the cells in a concentration of 10-6 M, a concentration 
at which the cells are still able to proliferate. Each drug-treated sample has a matched 
negative control (stimulation alone). 
The cells were incubated at 37°C in 5% CO2 and harvested at 4 hours, day 1, 3, and 4 for 
DNA methylation analysis and at day 1 and 3 for flow cytometry analysis. To assess viability 
and proliferation, the cells were counted before and after stimulation using conventional 
light microscopy and Trypan Blue staining (Thermo Fisher Scientific, Waltham, MA, US).
Flow cytometry
Flow cytometry was used to determine the phenotype of T cells immediately after isolation 
and at day 1 and 3 after stimulation. We also measured the percentage of IFNγ producing 
cells at these time points. The samples were treated with Brefeldin A (GolgiPlugTM, BD 
Biosciences) for 16 hours prior to flow cytometry analysis. The monoclonal antibodies used 
for cell surface staining were the same as previously described for the FACS cell sorting. In 
addition, the cells were permeabilized using permeabilize solution 2 (BD Biosciences), and 
stained for intracellular IFNγ with FITC labelled IFNγ (BD Biosciences). The cells were then 
analyzed on the FACSCanto II (BD Biosciences) with FACSDiva software. All flow cytometry 
data were analyzed using Kaluza software 1.3 (Beckman Coulter, Brea, CA, US). 
DNA isolation, bisulfite conversion and PCR
After harvesting, the cells they were pelleted, frozen in liquid nitrogen and stored at -80°C 
until bisulfite conversion. The T-cell pellets were digested with proteinase K and bisulfite 
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treatment was performed using the EZ DNA Methylation-Direct kit (Zymo Research, 
Irvine, CA, US) according to the manufacturer’s protocol. Bisulfite treatment introduces 
methylation-dependent changes in the DNA, demethylated cytosines are converted 
into uracil whereas methylated cytosines remain unchanged. The bisulfite treated DNA 
was amplified by PCR. A 230 base pair (bp) region of the IFNγ promoter was amplified 
using the Pyromark PCR kit (Qiagen, Venlo, The Netherlands). A forward primer with the 
sequence 5’-ATGGTATAGGTGGGTATAATGG-3’ and a biotin-labelled reverse primer with 
the sequence 5’-CAATATACTACACCTCCTCTAACTAC-3’ (Sigma-Aldrich) were used, both 
at a concentration of 10 pmol/µL31. The PCR conditions were 15 minutes at 95°C, 45 cycles 
of 30 seconds 94°C, 30 s 58°C, 30 s 72°C followed by 10 min at 72°C and final storage at 
room temperature (21°C). Prior to pyrosequencing, the PCR product was visualized on a 
1% agarose gel to verify the size of the amplicon. Two important CpG sites are inside this 
amplicon, CpG -186 and CpG -54. These sites are within binding domains of transcription 
factors26,31. 
Pyrosequencing
Pyrosequencing is an excellent technique to quantitatively measure DNA methylation 
at single CpG-site resolution, yielding accurate and reproducible results35,36. The IFNγ 
PCR product was sequenced using a PyroMark Q24 pyrosequencer (Qiagen). Minor 
adjustments were made to the manufacturer’s protocol: to immobilize the PCR product 
1 µL Streptadivin Sepharose High Performance Beads (GE Healthcare) was used per 
sequence reaction and annealing of the sequence primers was done for 3 minutes at 80°C. 
The CpG -186 sequence primer was 5’- GGTGGGTATAATGGG-3’ and the CpG -54 sequence 
primer was 5’- ATTATTTTATTTTAAAAAATTTGTG-3’, both at a concentration of 10 µM31. 
Two DNA methylation standards were used as control, human high and low methylated 
DNA (EpigenDx, Hopkinton, MA, US). Research shows that methylation at adjacent sites is 
correlated37 therefore the methylation percentages of the two CpG sites, site -54 and -186, 
were pooled per individual and the mean DNA methylation percentage is presented in the 
results. 
Statistical analysis
Statistical analyses were performed with SPSS Statistics version 21.0 (IBM Corp., Armonk, 
NY, US). The Mann-Whitney U test was used for unpaired analysis to identify differences 
between the conditions at a certain time point. The Wilcoxon signed rank test was used for 
paired analysis when comparing different time points within a condition. A p value < 0.05 
was considered statistically significant.
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Results
Effect of tacrolimus and MPA on IFNγ DNA methylation of total T cells
To exclude complete cell cycle arrest as a cause for methylation differences, we compared 
cell numbers under the different conditions after stimulation. Cell numbers were lower if 
cells were cultured with either tacrolimus, MPA or decitabine than if the cells were cultured 
without those factors, but due to overlapping ranges this difference was not statistically 
significant (Supplementary Figure S1). Our results suggest that the cells were still able to 
proliferate under the chosen concentrations of the different drugs.
To determine the changes in DNA methylation after T-cell stimulation, we analyzed IFNγ 
promoter methylation at several time points after stimulation. IFNγ DNA methylation of 
total T cells increased significantly after stimulation with α-CD3/CD28 (p=0.002; Figure 
1B). Stimulated T cells showed a median DNA methylation percentage of 47% (range: 35%-
59%) at day 0 and this was significantly increased at day 4 (59%; 46%-66%).
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DNA methylation of T cells cultured in the presence of tacrolimus increased significantly 
from 49% (42%-59%) to 53% (44%-67%) (p=0.043) and did not differ significantly from the 
stimulated condition at any of the given time points (Figure 1B). DNA methylation of T 
cells cultured in the presence of MPA increased from 48% (43%-56%) to 61% (46%-66%) 
and also did not differ significantly from the stimulated condition (Figure 1B). Our positive 
Figure 1. A) A representative example of the CD3+ purity and viability after MACS isolation. 
B) Median and interquartile range of IFNγ DNA methylation at day 0, 1, 3 and 4 after 
α-CD3/CD28 stimulation of total T cells under the different culture conditions: stimulated 
(n=15), decitabine (n=7), tacrolimus (n=5), MPA (n=4). P values were calculated with a 
Wilcoxon matched pairs test.
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control, T cells cultured in the presence of decitabine, significantly decreased in DNA 
methylation between day 0 and day 4 (p=0.028; Figure 1B). 
Since our total T-cell population was a heterogeneous mixture of naive and memory T cells 
with different methylation profiles29, we continued to study isolated cell populations to 
infer whether tacrolimus or MPA did influence these cell types individually. 
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Figure 2. A) A representative example of the naive CCR7+CD45RO- T cells after sorting. B) 
Median and interquartile range of IFNγ DNA methylation of sorted naive T cells stimulated 
in the absence (n=9) or presence of tacrolimus (n=3) or MPA (n=4). C) A representative 
example of the memory CD45RO+ and CCR7-CD45RO- T cells after sorting. D) Median and 
interquartile range of IFNγ DNA methylation of the sorted memory T cells stimulated in the 
absence (n=9) or presence of tacrolimus (n=3) or MPA (n=3). The pink dots in the FACS plots 
(A,C) represent the CD4+ cells and the blue dots the CD8+ cells. P values were calculated 
with a Wilcoxon matched pairs test (T=0 vs T=3 within one condition) or Mann-Whitney U 
test (between conditions).
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Effect of tacrolimus and MPA on IFNγ DNA methylation of naive and memory T cells
Pure naive (CCR7+CD45RO-) (Figure 2A) and memory (CD45RO+ and CCR7-CD45RO-) 
(Figure 2C) T-cell subsets were stimulated separately. IFNγ DNA methylation significantly 
decreased in the naive start population in the absence of tacrolimus or MPA, from 78% (75%-
83%) at day 0 to 67% (61%-77%) at day 4 (p=0.011; Figure 2B). The two immunosuppressive 
drugs had differential effects on this reduction in DNA methylation. While tacrolimus had 
no effect, MPA neutralized the effect of stimulation significantly and DNA methylation did 
not decrease (78%;76%-82% at day 0 and 77%;75%-78% at day 4). This differential effect 
resulted in a significant difference between stimulation only and the addition of MPA on 
day 3 (p=0.005) and day 4 (p=0.014; Figure 2B).
In the total memory start population, IFNγ DNA methylation significantly increased in the 
absence of tacrolimus or MPA, from 24% (19%-31%) at day 0 to 38% (30%-46%) at day 4 
(p=0.012; Figure 2D). This increase was not affected by tacrolimus nor MPA, both these 
conditions were not significantly different from stimulation alone.
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As explained in the introduction, we 
expected effector-gene promoters to 
demethylate after activation to allow 
transcription of the corresponding effector 
gene. We observed this in the naive T cells, 
demethylation of the IFNγ promoter took 
place after 3 days of stimulation (Figure 
2B). However, the IFNγ promoter of the 
memory T cells did not demethylate after 1, 
3 or 4 days after stimulation (Figure 2D). 
Therefore we speculated that 
demethylation occurred in a shorter 
timeframe than 24 hours, to allow memory 
T cells to produce IFNγ protein. To address 
this question we harvested memory T cells 
at 4 hours after stimulation and indeed we 
observed a significant decrease (3-12%; 
p=0.043) in methylation followed by remethylation to base levels after 24 hours (Figure 3).
Phenotypic changes after α-CD3/CD28 stimulation of the naive T cells
The isolated naive T cells, which were CCR7+CD45RO- at day 0, were analyzed for the 
expression of CD45RO and CCR7 after 1 and 3 days of stimulation in the absence and 
Figure 3. Median and interquartile 
range of IFNγ DNA methylation of the 
sorted memory T cells at 0, 4 and 24 hours 
after α-CD3/CD28 stimulation (n=5). P 
value was calculated with a Wilcoxon 
matched pairs test. 
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presence of tacrolimus or MPA. CD4+ and CD8+ T cells were gated separately (Figure 4), the 
percentages CD4+/CD8+ do not differ significantly between the conditions (Supplementary 
Figure S2). After one day of stimulation the phenotype did not differ significantly from day 
0 in both CD4+ and CD8+ T cells. On day 3 there was a significant shift towards CD45RO+ 
cells in the stimulated condition (p=0.008). The shift was observed in all three conditions 
T = 1
CCR7+CD45RO- CCR7+CD45RO+ CCR7-CD45RO+ CCR7-CD45RO-Legend: 
A
B
C
T = 0 T = 3
CD45RO
CC
R7
CD45RO
CC
R7
CD45RO
CC
R7
CD4 T=0
Stimulated Tacrolimus MPA
0
20
40
60
80
100
%
CD4 T=1
Stimulated Tacrolimus MPA
0
20
40
60
80
100
%
CD4 T=3
Stimulated Tacrolimus MPA
0
20
40
60
80
100
%
CD8  T=0
Stimulated Tacrolimus MPA
0
20
40
60
80
100
%
CD8 T=1
Stimulated Tacrolimus MPA
0
20
40
60
80
100
%
CD8 T=3
Stimulated Tacrolimus MPA
0
20
40
60
80
100
%
* *
*
# #
*# #
Figure 4. Phenotypic changes of the naive T cells in the absence or presence of 
tacrolimus or MPA: stimulated (n=9), tacrolimus (n=3) and MPA (n=4). A) A representative 
gating example of the CD4+ T cells directly after isolation (T=0) and at day 1 (T=1) and 
day 3 (T=3) after stimulation. B) Median percentages of CD4+ subsets in the absence or 
presence of tacrolimus or MPA at day 0, 1 and 3. C) Median percentages of CD8+ subsets in 
the absence or presence of tacrolimus or MPA at day 0, 1 and 3. *p<0.05 (Mann-Whitney 
U test to compare two conditions) #p<0.05 (Wilcoxon matched pairs test to compare T=0 
with T=3 within one condition).
The effect of MPA and tacrolimus on IFNγ DNA methylation 
2
35
and in both the CD4+ and CD8+ T cells (Figure 4B,C). These cells, which were CD45RO- at 
day 0, upregulated their CD45RO expression showing a central-memory-like phenotype 
at day 3. When we compared the different conditions with stimulation only at day 3, 
tacrolimus (p=0.013) and MPA (p=0.039) significantly repressed CD4+ differentiation and 
MPA also significantly repressed CD8+ differentiation (p=0.014; Figure 4B,C).
Phenotypic changes after α-CD3/CD28 stimulation of the memory T cells
The isolated memory T cells, which were CD45RO+ and CCR7-CD45RO- at day 0, were also 
analyzed by flow cytometry after 1 and 3 days of stimulation in the absence or presence 
of tacrolimus or MPA. CD4+ and CD8+ T cells were gated separately (Figure 5). The 
percentage of CD8+CD45RO+ cells increased significantly after 3 days of stimulation, both 
in the CCR7+ (p=0.008) and CCR7- (p=0.021) population (Figure 5C). In the CD4+ population 
we observed an increase in the CCR7+CD45RO+ population (p=0.011) and a decrease in the 
CCR7- population (p=0.021) (Figure 5B). When we compared the different conditions with 
stimulation only at day 3, no significant differences were found. 
IFNγ protein production of the memory population
IFNγ protein production was measured using intracellular staining in both the sorted naive 
T cells and the sorted memory T cells (Figure 6). The sorted naive T cells did not produce 
IFNγ protein at day 1 after stimulation (data not shown) while 10% (3%-19%) of the sorted 
memory T cells did produce IFNγ. Tacrolimus significantly inhibited IFNγ production, hardly 
any cells produced IFNγ in the presence of tacrolimus (Figure 6B). MPA did not have a 
significant effect on IFNγ production and the percentage IFNγ producing cells did not differ 
from stimulation only. Three days after stimulation of the sorted memory T cells, few cells 
still produce IFNγ both in the presence and absence of tacrolimus or MPA. 
Discussion
To our knowledge, this is the first study to investigate the effect of immunosuppressive 
medication on DNA methylation of primary T cells38,39. The study design allowed us to 
track changes over time after activation. Also, by combining the results of our analyses 
of DNA methylation, phenotype and protein production, we were able to determine the 
effects of immunosuppressive drugs on cellular dynamics after T-cell activation. Our results 
show that after T-cell activation, MPA affected IFNγ DNA methylation of naive T cells but 
notthat of memory T cells, while tacrolimus had no effect on IFNγ DNA methylation of T 
cells (Figure 1,2).
The mechanism by which MPA counteracts the effect of T-cell stimulation on IFNγ DNA 
methylation is unknown. We can however suggest a possible mechanism by looking at the 
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different enzymes that regulate DNA methylation in general. DNA methyl transferases 
(DNMTs) are a family of enzymes that maintain DNA methylation during cell division 
(DNMT1) and cause de novo DNA methylation (DNMT3a,b)4. Lower activity of DNMT1 
leads to passive demethylation, the methylation “dilutes” during cell division5,40. Possibly, 
MPA has a direct or indirect effect on DNMT1 activity during differentiation of naive T cells. 
A similar suggestion was made by He et al.41 in relation to an increased CD70 expression 
Figure 5. Phenotypic changes of the memory T cells in the absence or presence of 
tacrolimus or MPA: stimulated (n=9), tacrolimus (n=3) and MPA (n=3). A) A representative 
gating example of the CD8+ subsets of the stimulated cells directly after isolation (T=0) at 
day 1 (T=1) and day 3 (T=3) after stimulation. B) Median percentages of CD4+ subsets in 
the absence or presence of tacrolimus or MPA at day 0, 1 and 3. C) Median percentages of 
CD8+ in the absence or presence of tacrolimus or MPA at day 0, 1 and 3. #p<0.05 (Wilcoxon 
matched pairs test to compare T=0 with T=3 within one condition).
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induced by MPA.
While the two drugs’ effects on DNA methylation were different, their effects on T-cell 
differentiation were similar (Figure 4,5). Tacrolimus and MPA both suppressed the 
differentiation of naive T cells (CD45RO-) towards CD45RO+ cells. This phenotypic 
marker is a characteristic marker for memory T cells32 but it has been described as an 
activation marker as well42,43. Since tacrolimus inhibited differentiation of the naive T cells 
significantly but did not influence IFNγ DNA methylation of those cells, we believe that the 
differentiation can occur independently from changes in IFNγ DNA methylation. On the 
other hand, the changes in T-cell phenotype and IFNγ DNA methylation after stimulation 
alone both occur after three days, indicating a relation between these two parameters. 
Taken together, the exact relationship between phenotypic changes and changes in IFNγ 
DNA methylation after stimulation remains unclear. 
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While we had expected T cells to become demethylated on their IFNγ promoter upon 
stimulation, we were surprised to note that, in both total T cells and memory T cells, IFNγ 
promoter methylation actually increased (Figure 1B,2D). In line with the results of previous 
studies44,45, IFNγ DNA methylation decreased shortly after stimulation of the memory 
T cells (Figure 3). After the demethylation phase of these cells, IFNγ DNA methylation 
returned to base-level and from day 1 onwards DNA methylation steadily increased. 
Since the phenotype of the cells changed after stimulation, each time point reflected 
Figure 6. A) A representative gating example of IFNγ production by the sorted memory 
T-cell population on day 1 after stimulation. B) Percentages and median of IFNγ producing 
memory T cells on day 1 and 3 of all three conditions measured by intracellular staining and 
flow cytometry. P-values were obtained with the Mann-Whitney U test.
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a heterogeneous cell population. This makes it difficult to assign the increasing IFNγ 
DNA methylation to a specific cell type. The ideal situation would be to isolate pure cell 
populations at each time point using surface markers before analyzing their methylation 
profile – this is practically challenging however.
We are currently uncertain what the biological reason is behind the increase in IFNγ DNA 
methylation (remethylation) that we observed. Similar remethylation of gene promoters 
after stimulation has thus far been reported for PD1 and IL2. Youngblood et al.46 studied 
the PD1 locus in antigen-specific CD8+ T cells in mice and found that after 8 days of LCMV 
infection, the PD1 locus in effector cells had been partially remethylated. This finding was 
only seen in an acute infection model however: when the mice were chronically infected, 
the locus remained demethylated and the CD8+ cells became exhausted46. A study on IL2 
promoter DNA methylation in HIV-infected patients showed that IL2 DNA methylation 
was higher in all CD4+ effector memory subsets of HIV-infected patients than in those 
of healthy controls, indicating that chronic HIV infection increased methylation levels in 
these cell types47. The remethylation of the IFNγ promoter that we observed may be similar 
to that of the PD1 and IL2 promoters described in the above-mentioned papers.
Although DNA methylation of IFNy was not affected by the presence of tacrolimus, IFNγ 
protein production by the memory cells was suppressed in the presence of tacrolimus (Figure 
6). As mentioned in the introduction, the mechanism of action of tacrolimus is known. 
Tacrolimus-induced inhibition of the calcineurin pathway inhibits the activity of NFAT, a 
transcription factor that regulates IFNγ gene expression48,49. Our results demonstrate that 
this tacrolimus-induced suppression of IFNγ protein production is independent of changes 
in DNA methylation of IFNγ. 
MPA did not affect the percentage of IFNγ producing memory cells in our experiments but 
the results reported in literature vary. He et al.41 reported that MPA inhibited IFNγ production 
in CD4+ T cells after α-CD3/CD28 stimulation. Whereas Egli et al.50 did not find a strong 
decrease in IFNγ production after adding MPA to CMV-stimulated PBMCs. In both studies, 
IFNγ concentration was measured in the culture supernatant, and such concentration is 
strongly related to the number of cells present. Since proliferation decreases under the 
influence of MPA18,51, cytokine production should be corrected for cell numbers as we did 
by measuring intracellular IFNγ. In addition, Egli et al.50 did not measure T-cell specific IFNγ 
production and since NK cells are also capable of producing IFNγ this may have influenced 
their results. These experimental differences could explain the difference between our 
findings and the results reported in literature.
Here we focused on the IFNγ gene promoter to study differences in DNA methylation. 
Possibly, immunosuppressive drugs have much stronger effects on DNA methylation of 
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other genes or even at intergenic regions12. To find the most affected regions, a genome-
wide methylation study could be performed. Due to the explorative nature of this study a 
genome-wide approach was outside the scope of this paper. 
The findings presented here demonstrate that IFNγ DNA methylation in T cells was not 
affected in the same manner by tacrolimus and MPA and therefore we conclude that 
these immunosuppressive drugs differentially affect IFNγ DNA methylation in CMV 
seropositive individuals. Our study also shows that naive and memory T cells did not only 
have distinct DNA methylation profiles, but also that they were not affected equally by 
the immunosuppressive drugs studied. These findings may be of significance for future 
research into the efficacy of immunosuppressive drugs. Knowledge on the effect of 
immunosuppressive drugs on DNA methylation of T-cell effector genes and thereby 
T-cell function could optimize the treatment regimen. When developing and testing 
immunosuppressive drugs, we recommend to include DNA methylation studies thereby 
improving our understanding of their effect on the function of patients’ immune cells. 
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Supplementary Figure S1. Proliferation of total T cells presented as the median of 
cells per well in time. Stimulation (n=9), decitabine (n=7), tacrolimus (n=5) and MPA 
(n=4). 50,000 cells were stimulated at day 0 and the cells were counted at day 1 and 3 after 
stimulation with conventional light microscopy after staining the cells with Trypan Blue.
Supplementary Figure S2. Median percentages of CD4+ and CD8+ populations within 
the CD3+ cells of A) the naive start population (CCR7+CD45RO-) in the presence and 
absence of tacrolimus or MPA and B) the memory start population CD45RO+ and CCR7-
CD45RO-) in the presence and absence of tacrolimus or MPA.
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Abstract
Background
Mesenchymal stromal cells (MSC) are studied for their immunotherapeutic potential. Prior 
to therapeutic use MSC are culture expanded to obtain the required cell numbers and to 
improve their efficacy MSC may be primed in vitro. Culture expansion and priming induce 
phenotypical and functional changes in MSC and thus standardisation and quality control 
measurements come in need. We investigated the impact of priming and culturing on MSC 
DNA methylation and examined the use of epigenetic profiling as a quality control tool.
Methods
Human umbilical cord-derived MSC (ucMSC) were cultured for three days with IFNγ, TGFβ 
or a multi-factor combination (MC; IFNγ, TGFβ and retinoic acid). In addition, ucMSC were 
culture expanded for 14 days. Phenotypical changes and T-cell proliferation inhibition 
capacity were examined. Genome-wide DNA methylation was measured with Infinium 
MethylationEPIC Beadchip. 
Results
Upon priming, ucMSC exhibited a different immunophenotype and ucMSC(IFNγ) and 
ucMSC(MC) had an increased capacity to inhibit T-cell proliferation. DNA methylation 
patterns were minimally affected by priming, with only one significantly differentially 
methylated site (DMS) in IFNγ and MC-primed ucMSC associated with autophagy activity. 
In contrast, 14 days after culture expansion ucMSC displayed minor phenotypical and 
functional changes but showed more than 4000 significantly DMS, mostly concerning 
genes involved in membrane composition, cell adhesion and transmembrane signalling.
Discussion
These data show that DNA methylation of MSC is only marginally affected by priming, 
whereas culture expansion and subsequent increased cellular interactions have a large 
impact on methylation. On account of this study we suggest that DNA methylation analysis 
is a useful quality control tool for culture expanded therapeutic MSC.
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Introduction
Mesenchymal stromal cells (MSC) have been extensively examined in clinical trials 
regarding their immunotherapeutic potential1-4. Prior to their application in the clinic, MSC 
are commonly expanded to obtain clinically relevant numbers. However, during long-term 
in vitro culture expansion the phenotype and function of MSC is affected5-7. Previous studies 
have shown that during long-term expansion their proliferative capacity decreases7,8. In 
addition, long-term culture expansion affects the immunomodulatory properties of MSC, 
for instance their capacity to inhibit of T-cell proliferation8. Recently, there has been a 
growing interest in the optimization of the immunomodulatory properties of MSC in 
vitro. MSC can be primed with stimuli to enhance their immunomodulatory properties 
with the aim to improve their therapeutic efficacy9-17. Prior to their clinical application, 
MSC are routinely tested for multiple parameters to assess their safety and functionality, 
such as karyotype, morphology (spindle-shape) and viability as well as their cell surface 
protein expression and differentiation capacity according to the recommendations of 
the International Society for Cellular Therapy1-4,18-21. These tests give a global indication 
of the state of MSC. However, MSC have a great ability to adapt and culture expansion 
and priming may therefore modify MSC on a different level. Therefore, we endeavored to 
perform a more in depth analysis of the effects of culture expansion and stimulation on 
MSC.
Epigenetic modifications of the genome can be both hereditary as well as environmentally 
influenced. These epigenetic modifications affect gene expression without altering the 
genomic sequence and are important regulators of cellular function22-25. Methylation 
of cytosines at cytosine-phosphate-guanine (CpG) sites in the DNA, is one of the main 
mechanisms of epigenetic modifications. Methylation at a CpG site may block the start 
of transcription and in particular methylation of CpG islands at transcriptional start sites 
(TSSs) is associated with long-term gene silencing22. In vitro procedures may affect DNA 
methylation; potentially resulting in changes in their gene expression and subsequently 
their phenotype and function.
Previously, it was demonstrated that there is an association between osteogenic 
differentiation of MSC and their DNA methylation pattern26-29. In addition, other studies 
demonstrated that during long-term culture expansion, where MSC were cultured over 
10 passages, MSC became senescent and their DNA methylation patterns changed30,31. 
However, no study to date has addressed the effect of priming MSC in vitro with various 
stimuli to optimize their immunomodulatory properties on the DNA methylation. 
Furthermore, it remains unclear whether during culture expansion DNA methylation 
patterns of MSC are affected. Elucidation of the effects of MSC expansion and priming on 
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DNA methylation may result in additional quality control tools that help in development 
and application of MSC therapy in clinical setting. This will ensure the use of better 
standardized MSC therapeutic products. Therefore in this study we investigated the 
changes in methylation in the epigenome of MSC during priming by various stimuli and 
also after two weeks culture expansion.
Materials and Methods 
Isolation and culture of MSCs
Human umbilical cord tissue was collected by Tissue Solutions Ltd. (Glasgow, UK) from 
Caesarean section deliveries from virally screened healthy donors. Whole cord tissue of 
the neonatal side was used for MSC isolation. All cord tissues provided by Tissue Solutions 
were obtained according to the legal and ethical requirements of the country of collection, 
with the approval of an ethics committee (or similar) and with anonymous consent from 
the donor. Isolation of the CD362+ subset of ucMSC was performed according to previous 
manuscripts by de Witte et al.8,10. After isolation, each cell fraction was counted, seeded 
for expansion and cryopreserved at passage 2 for shipment to Erasmus Medical Center. 
Here ucMSC were cultured in minimum essential medium Eagle alpha modification 
(MEM-α; Sigma-Aldrich, St Louis, MO, USA) containing 2 mM L-glutamine (Lonza, 
Verviers, Belgium), 1% penicillin/streptomycin solution (P/S; 100IU/ml penicillin, 100IU/ml 
streptomycin; Lonza) and supplemented with 15% batch tested fetal bovine serum (FBS; 
Lonza) and 1 ng/ml basic fibroblast growth factor (bFGF) (Sigma) and kept at 37°C, 5% CO2 
and 20% O2. Once a week medium was refreshed and ucMSC were passaged using 0.05% 
trypsin-EDTA (Life technologies, Paisley, UK) at ~80-90% confluence. All ucMSC used in 
experiments were between passage 3-6. 
Characterization of ucMSC was performed by flow cytometric analysis of the cell surface 
markers: CD31 (PB, BD Biosciences), CD45 (APC-Cy, BD Biosciences), CD13 (PE-Cy7, BD 
Biosciences), CD73 (PE, BD Pharmingen), CD90 (APC, R&D systems) and CD105 (FITC, R&D 
systems). After labeling the cells were washed and measured on the FACSCanto II flow 
cytometer (BD Biosciences) (Supplementary Figure S1). 
Experimental design
The experimental design consists of two parts: ‘Priming of MSC’ and ‘Culture expansion of 
MSC’, see also Figure 1. 
Priming of ucMSC
ucMSC of 4 different umbilical cord donors were stimulated with factors were known to 
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modify MSC function or phenotype, as demonstrated in previous studies10,32. At day 0, MSC 
(confluent culture) were stimulated for three days with interferon gamma (IFNγ, 50 ng/
ml; Life technologies, transforming growth factor beta 1 (TGFβ, 10ng/ml; R&D systems, 
MN, USA) or a multi-factor combination (MC) of IFNγ, TGFβ and retinoic acid (RA, 100 μM; 
Sigma). At day 3, cells were trypsinised and either used for experiment or snap frozen in 
pellets containing 300,000 cells and stored at -80°C. 
Culture expansion of MSC
At day 0, MSC of 4 different umbilical cord donors were seeded (250,000 cells/T175 
flask). Medium was partly refreshed (50%) every 5/6 days. At day 14, cells were used for 
experiment or snap frozen as pellets for future use.
Figure 1. Study design. (Top) In the first part of the experimental design, ucMSCs were 
left unprimed or primed with IFNγ, TGFβ, or a multifactor combination of IFNγ + TGFβ + 
retinoic acid (MC) for 3 days. Thereafter, whole-genome DNA methylation analysis was 
performed on unprimed and primed ucMSCs. (Bottom) In the second part, ucMSCs were 
culture expanded for 14 days. Whole-genome DNA methylation analysis was performed 
on ucMSCs before and after culture expansion. 
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DNA extraction procedure 
DNA was isolated from ucMSC with the QIAamp DNA Micro kit (Qiagen; Germany) 
according to the manufacturer’s instructions. DNA concentration was measured with 
spectrophotometry (Nanodrop spectrometer, Thermo Scientific, USA). DNA quality of the 
samples was estimated by measuring the ratio of absorbance at 260/280nm (between 1.7-
2) and with agarose gel electrophoresis. 
Bisulfite treatment and DNA methylation measurement 
To determine DNA methylation profiles, samples underwent bisulfite conversion. During 
this conversion unmethylated cytosines were converted into uracil (Supplementary Figure 
S2). The bisulfite conversion was performed using 500 ng genomic DNA per sample 
and using the EZ-96 DNA Methylation Kit (Shallow; Zymo Research, CA, USA). Bisulfite 
converted samples were then hybridized to the Illumina 850k DNA methylation array 
(Infinium MethylationEPIC Beadchip; Illumina; USA) according to the manufacturer’s 
instructions.
In short, the Infinium MethylationEPIC BeadChip applies both Infinium I and II assay 
chemistry technologies. The infinium I assay uses two bead types: methylated (M) and 
unmethylated (U). Whereas Infinium II assay uses a single bead type, with the methylated 
state determined at the single base extension step after hybridization. This array provides 
methylation data of over 850,000 CpG sites in the genome. These CpG sites are located in 
CpG islands, shores and shelves, the 5’UTR, 3’UTR and bodies of RefSeq genes, FANTOM5 
enhancers, ENCODE open chromatin and ENCODE transcription factor binding sites. 
The raw data of the DNA methylation arrays is deposited at the Gene Expression Omnibus 
(GEO) of the National Center for Biotechnology Information (NCBI) under accession 
number GSE113527 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE113527).
Analysis
Analysis of the methylation data was performed using Rstudio (RStudio Desktop 1.1.3.83) 
and comb-p software. R Bioconductor packages DMRcate33,34, limma35,36, minfi37 and 
missMethyl38 were used. Firstly, the raw methylation data was imported in R. Subsequently 
the data were normalized (Subset quantile normalization: SQN (within and between 
array)). Probes on the sex chromosomes were removed from the dataset, resulting in a 
remaining 810,005 sites. Subsequently M-value (equation 1) and β-value (equation 2) were 
calculated. 
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The M-value is the log2 ratio of the intensities of methylated probe versus unmethylated 
probe. When M=0 there are equal amounts of methylated and unmethylated sites, when 
M>1 there are more methylated than unmethylated molecules and when M<1 there are 
more unmethylated than methylated molecules. β-value is the ratio of the methylated 
probe intensity and the overall intensity (with β=0: completely unmethylated and β =1: 
fully methylated). According to Du et al. the use of M-values is more appropriate when 
doing differential methylation analysis39. Therefore, M-values of 810,005 CpG sites were 
used for further analysis.
To determine differences in DNA methylation after culture expansion or priming, paired 
analyses were performed. Firstly, differences in methylation between the different 
conditions for each ucMSC donor were identified, followed by joining the differences across 
ucMSC donors to determine (significant) differences in the mean methylation level of each 
CpG site (paired testing). Sites with a padj<0.05 were considered significantly differentially 
methylated.
The lists of significantly differentially methylated CpG sites were subsequently used to 
perform gene ontology testing, using the gometh function in R. Furthermore, the list was 
used to find differentially methylated regions (DMRs) in a command line tool and python 
library: Comb-P40. By calculating auto-correlation, combining adjacent p-values Stouffer-
Liptak-Kechris correction, performing false discovery adjustment, finding regions of 
enrichment (i.e. series of adjacent low P-values) and assigning significance to regions with 
irregularly spaced p-values, Comb-P enables identification of significant DMRs. The size of 
the regions analyzed was set to 500 basepairs (bp) with the seed at p<0.01. Multiple testing 
was taken into account by correcting using a Šidák correction.
T cell proliferation assay
Primed and culture expanded ucMSC were seeded into 96-wells plates and left overnight 
to adhere in the incubator. The next day PBMC were labeled with Cell Trace CFSE (Life 
Technologies) according to the instructions of the manufacturer and seeded on top of the 
ucMSC, at different [MSC:PBMC] ratios: [1:10], [1:5] and [1:2.5] in RPMI supplemented 
with 2 mM L-glutamine, 100IU/ml penicillin, 100IU/ml streptomycin and 15% FBS. αCD3/
CD28 stimulation was added (0.5 μg / ml αCD3 antibody, 0.5 μg/ml αCD28 antibody and 1 
μg/ml goat-α-mouse antibody; Life Technologies). The co-cultures were left for 3 days and 
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PBMC were collected. PBMC were stained for CD4 (APC; eBioscience) and CD8 (Pe-cy7; 
eBioscience). With the use of the FACSCanto II flow cytometer the proliferation of PBMCs 
was measured.
RT-PCR
mRNA was isolated from ucMSC, from the same samples as the DNA extraction, using 
Trizol reagent (Invitrogen, Life Technologies, Carlsbad, CA, USA). cDNA was synthesized 
from 500ng mRNA with random primers (Promega Benelux B.V., The Netherlands). 
Quantitative gene expression was determined using TaqMan Gene Expression Master Mix 
(Life Technologies) and Assays-on-demand for HS1BP3 (Hs00916454_m1).
Results
Priming alters ucMSC immunophenotype and functionality 
ucMSC were cultured for three days in the presence of IFNγ, TGFβ or a combination of 
IFNγ, TGFβ and RA (MC). We observed that whilst ucMSC maintained their spindle 
shaped morphology (Figure 2A) and expression of MSC markers CD13, CD73, CD90 
and CD105 (Supplementary Figure S1) upon priming, expression of HLA type I, II and 
PD-L1 was increased (percentage expressing cells as well as the MFI) (Figure 2B). The 
immunomodulatory capacity of ucMSC, determined by their potential to inhibit CD4 and 
CD8 T-cell proliferation, significantly increased after priming ucMSC with IFNγ and MC 
(Figure 2C and Supplementary Figure S3). 
Impact of priming of ucMSC on DNA methylation 
To examine whether priming of ucMSC leaves an epigenetic imprint that can be used to 
identify MSC potency or as a inclusion or exclusion criterion of MSC for clinical use, genome-
wide DNA methylation profiles were generated of ucMSC after 3 days priming with IFNγ, 
TGFβ or MC. We compared DNA methylation profiles of unprimed ucMSC to those of 
primed ucMSC and demonstrated that priming of ucMSC with IFNγ and MC but not TGFβ 
led to differential methylation at a single site located on chromosome 2 (Figure 3A-D). This 
site, Cg00221794, was hypomethylated in ucMSC primed with IFNγ and MC compared to 
unprimed ucMSC (Figure 3E). No differentially methylated regions were detected in any of 
the primed ucMSC (Figure 3D). 
Modified expression near the IFNγ and MC induced hypomethylated site Cg00221794 
The CpG site Cg00221794 is located near an area annotated as the Hematopoietic 
Cell-Specific Lyn Substrate 1 binding protein 3 (HS1BP3) gene. To investigate whether 
hypomethylation of this site affects HS1BP3 gene expression levels, mRNA levels of 
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HS1BP3 were analyzed in unprimed and IFNγ, TGFβ or MC primed ucMSC. Gene expression 
levels of HS1BP3 were significantly upregulated upon priming of ucMSC with IFNγ or MC 
compared to unprimed ucMSC (Figure 4).
Culture expansion alters the immunophenotype of ucMSC 
To assess the effects of culture expansion the morphology, immunophenotype and capacity 
to suppress T cell proliferation of ucMSC were assessed before and after 14 days of culture 
expansion. After 14 days of culture expansion, the cultures were >90% confluent (Figure 
5A). There was no change in expression of the MSC markers CD13, CD73, CD90 and 
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Figure 2. Morphology, surface marker expression and immunosuppressive capacity 
of primed ucMSCs. A) Representative bright field photos of unprimed ucMSCs and after 
priming with IFNγ, TGFβ or the MC. B) Expression of HLA class I (top), HLA class II (middle) 
and PD-L1 (bottom) in percentage of positive cells (clear bars, on left axis of graph) or in 
MFI (striped bars, on right axis of graph). C) Inhibition of CD4 T-cell proliferation (top) and 
CD8 T-cells (bottom) by unprimed and primed ucMSCs, in different ratios. *P<0.05
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CD105 (Supplementary Figure S1) while 
there was significant increased protein 
expression of HLA type II and PD-L1 on 
ucMSC at day 14 compared to prior to 
culture expansion (day 0) (Figure 5B). 
Furthermore, there was no significant 
difference in the ability of day 0 versus day 
14 ucMSC to suppress T cell proliferation 
(Figure 5C). 
ucMSC undergo major epigenetic changes 
during culture expansion 
DNA methylation patterns were 
determined in MSC 14 days after culture 
expansion. In contrast to the minor effects 
of priming of ucMSC with IFNγ, TGFβ 
or MC on DNA methylation, 14 days of 
culture expansion led to 4831 significantly differentially methylated sites (DMS) (Figure 
6A). Gene ontology analyses revealed these differences were located in genes involved 
in plasma membrane composition, cell adhesion and transmembrane signaling. We 
furthermore observed 545 differentially methylated regions (DMR) (Figure 6B), of which 
47 were hypermethylated and 498 hypomethylated (Figure 6C). This suggests in general 
elevated expression of cell membrane associated proteins upon increase confluency 
following 14 days of culture of ucMSC.
The top 10 most significantly hyper or hypo-methylated regions are shown in Supplementary 
Tables S1 and S2. These results demonstrate that in contrast to priming of ucMSC with IFNγ, 
TGFβ or MC, culturing ucMSC for 14 days has a major impact on DNA methylation profiles 
of ucMSC. The significant changes in DNA methylation between newly seeded MSC and 
MSC cultured for 14 days suggest that methylation profiling can be used to differentiate 
between MSC cultures of different culture phase and potentially as an inclusion/exclusion 
assay for MSC for clinical therapy.
Discussion 
Our data demonstrate that priming of ucMSC, despite inducing immunophenotypical 
and functional changes, does not induce major epigenetic changes. In contrast, culture 
expansion over 14 days (one passage) has lesser effects on ucMSC phenotype and function, 
but has a major impact on the epigenetic profile of the cells. This suggests that ucMSC that 
Figure 4. mRNA expression levels 
of HS1BP3 in ucMSCs after 3 days of 
priming. *P<0.05
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Figure 5. Morphology, surface marker expression and immunosuppressive capacity 
of culture expanded ucMSCs. A) Representative bright field photos of ucMSCs after 14 
days of culture expansion. Original magnification 50x. B) Expression of HLA class I (top), 
HLA class II (middle) and PD-L1 (bottom) in percentage of positive cells (clear bars, on left 
axis of graph) or in MFI (striped bars, on right axis of graph). C) Inhibition of CD4 T-cell 
proliferation (top) and CD8 T cells (bottom) by ucMSCs prior to culture expansion (day 0) 
or post-culture expansion (day 14) in different ratios. *P<0.05 compared with aCD3CD28 
PBMC. 
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are immunophenotypically identical may represent cells of a different standard. Epigenetic 
analysis of MSC may therefore represent a useful tool to validate MSC according to set 
epigenetic profile standards. 
Culture expansion is a necessity when working with MSC to generate sufficient numbers of 
cells, although preferably MSC are used at a low passage for research and for clinical trials 
to minimize risks associated with their stability, safety and functionality. Long-term in vitro 
culture expansion of MSC increases the probability of genetic instabilities, and studies 
have reported increasing aneuploidy of MSC cultures during long-term expansion41-43. 
Recently, we showed that during long-term culture expansion, ucMSC remain genetically 
and phenotypical stable, but their immunosuppressive capacity decreases5. This is not 
observed for short-term culture expansion. In the present study, despite minor effects on 
immunophenotypical parameters, we identified major differences in the DNA methylation 
pattern of ucMSC after 14 days of culture expansion. 
We postulate that clonal expansion, aging of the cells or confluency of the culture may 
contribute to the major changes observed in DNA methylation. Firstly, ucMSC are a 
heterogeneous population, such that across MSC cultures there are differences in their 
secretome, surface marker expression, gene expression and also in their epigenome. 
Throughout the experiment, ucMSC were seeded and cultured in the same flask for 14 days, 
during which period extensive proliferation took place. It is plausible that certain ucMSC 
have higher proliferation rates, which would lead to an enrichment of this population, 
representing clonal expansion44. Secondly, the amount of proliferation and duration of 
the expansion may have led to ageing of the cells. DNA methylation levels have been 
demonstrated to change during cellular senescence of MSC45,46, with Dahl et al reporting a 
shift towards more DNA methylation over time in culture of MSC47. In contrast with these 
findings, we detected more hypomethylation after 14 days of culture expansion. During 
14 days of culture expansion a high cell density (up to >90% confluency) was reached. 
Under these conditions the cells are forced to increase intercellular interactions, which 
is likely to affect matrix and membrane composition and intercellular signaling. This is 
supported by our findings that genes related to membrane composition, cellular adhesion 
and transmembrane signaling were hypomethylated, suggesting increased expression. 
Confluency upon harvest will therefore affect MSC and DNA methylation analysis is a tool 
to monitor this in a quantitative manner.
DNA methylation affects gene expression, but this is not necessarily a direct consequence 
of methylation changes of the gene of interest itself22,23. When priming ucMSC with IFNγ or 
MC a single hypomethylated site, namely Cg00221794 was identified, which is located near 
the HS1BP3 gene. Hypomethylation in a promotor region is suggested to lead to increased 
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gene expression22. Although site Cg00221794 is not located in the promotor region of the 
HS1BP3 gene but in close proximity, HS1BP3 gene expression was increased in ucMSC 
after priming with IFNγ or MC, which suggests a role for site Cg00221794 in the regulation 
of HS1BP3. HS1BP3 has recently been identified as a regulator of autophagy48. Its depletion 
inhibits autophagosome formation by interacting with phosphatidic acid on endosomes 
thereby preventing endosomal development into autophagosomes49. MSC display a high 
level of autophagy under homeostatic conditions, which is up or downregulated under 
stress or during differentiation50. The role of HS1BP3 in MSC is unknown, but it may well be 
Figure 6. Analysis of DMSs and DMRs of ucMSCs at day 0 and after 14 days of culture. 
Manhattan plot of DMSs of A) ucMSCs after 14 days of culture expansion compared with 
ucMSCs before 14 days of culture expansion. Genome-wide significance levels of 1 x 10-6 
from the Bonferroni correction were used. B) Summarizing table of the number of DMSs 
and DMRs after culture expansion of the ucMSCs. C) Pie chart revealing the distribution of 
observed hypermethylated and hypomethylated regions. N=4 per condition.
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implicated in the regulation of MSC autophagy.
Whereas priming of ucMSC with IFNγ or MC had only minor effects on DNA methylation, it 
had a significant effect on the T cell inhibition capacity of MSC and their expression of PD-
L1 and HLA class I and II. On the contrary, 14 days of culture induced significant changes in 
DNA methylation, but had no effect on T cell inhibition capacity of MSC and small effects 
on PD-L1 and HLA expression. It is however possible that other functions of MSC that were 
not investigated, such as their capacity to modulate monocyte function or secrete trophic 
factors, are affected by the DNA methylation changes induced after 14 days of culture. 
Depending on the functional requirements of MSC for different types of applications, it 
becomes important to test the behavior of primed or prolonged culture expanded MSC in 
relevant assays. 
The NIH Roadmap Epigenomics Consortium generated reference epigenetic profiles 
of various human cell types, which supplies data concerning annotation and functional 
information of genomic sites and regions51, which we used to annotate functions to 
differentially methylated sites in ucMSC (Supplementary Tables S1, S2). However, the 
Roadmap relates to adipose tissue derived MSC and bone marrow derived MSC and 
there is no data available for ucMSC. Although MSC from various tissue sites resemble 
each other, it is also clear that there are tissue specific differences. Therefore it is possible 
that particular methylation sites have a different function in ucMSC than described in the 
Roadmap. 
The use of a standardized therapeutic MSC product, is crucial to guarantee safety and 
predictable functionality. Although, it is unclear what the full impact of changes in DNA 
methylation of ucMSC on safety and functionality is, methylation status offers a global 
view on the state of a cell culture. In our hands, T cell inhibitory capacity of ucMSC did not 
change in response to changes in methylation induced by prolonged culture, but it is likely 
that other properties of the cells were affected. The mechanisms of MSC therapy have 
not been fully elucidated and therefore at this moment it is not possible to test relevant 
functional properties of the cells in relation to methylation status. When more is known 
about the mechanisms of action of MSC therapy, the effect of epigenetic changes on these 
particular mechanisms can be determined. Therefore, DNA methylation profiling could be 
used as a part of the characterization of therapeutic MSC to ensure the use of MSC of a 
fixed state, for standardization properties.
To conclude, MSC can be subjected to in vitro manipulations that lead to various 
phenotypical and functional changes. Our data showed that priming MSC with various 
stimuli has a minor impact on their DNA methylation, whereas during in vitro culture 
expansion MSC exhibit more extensive changes in DNA methylation profiles. These major 
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changes in DNA methylation may influence the safety and efficacy of MSC therapy, which 
needs to be further investigated. Our results reveal that epigenetic profiles may be used as 
a quality control measure for MSC for experimental and in particular clinical use. Additional 
assessment of their DNA methylation pattern prior to their (pre)-clinical use, next to 
testing e.g. their karyotype, viability and phenotype will give a more in-depth analysis of 
their state. Moreover, assessment of their DNA methylation pattern as a quality control 
will contribute to the standardization of therapeutic MSC. 
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Supplementary Figures
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Supplementary Figure S1. Characterization of ucMSC. Immunophenotyping of ucMSC 
by flow cytometry. Representative histograms (green: ucMSC(-), blue: ucMSC(IFNy), light 
grey: ucMSC(TGFb), yellow: ucMSC(RA), pink: ucMSC(MC) and dark grey: unstained 
ucMSC(-)) of expression of characteristic MSC markers CD13, CD73, CD90, CD105 and 
negative expression of endothelial marker CD31 and hematopoietic marker and CD45 by 
ucMSC post 3 day priming (top) and after 14 days of culture expansion (bottom). 
Unmethylated DNA     Methylated DNA
5’- A G  T C G A A C T - 3’ 5’- A G  T C G A A C T - 3’
mm
Bisulte conversion
5’- A G  T U G A A U T - 3’ 5’- A G  T C G A A C T - 3’
mm
Supplementary Figure S2. Example of bisulfite conversion. All samples underwent 
bisulfite conversion: unmethylated cytosines are converted into uracil.
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Supplementary Figure S3. T cell suppression by ucMSC. UcMSC and αCD3CD28 
stimulated CSFE labeled PBMCs were co-cultured at a 1:2.5 ratio for 3 days. Representative 
histograms of CSFE in gated CD4 (A) and CD8 T-cells (B) co-cultured with primed ucMSC 
and with 14 days culture expanded ucMSC (C). 
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Supplementary Tables
Supplementary Table S1. Top 10 hypomethylated regions in ucMSC after 14 days of culture 
expansion. Annotated to ROADMAP reference data for adipose derived MSC and bone 
marrow derived MSC. The p-values of the regions and the number of CpG sites within the 
significantly hypomethylated regions are indicated.
# Chr Start In region Pregion #CpG
da
y 
0 
<>
 d
ay
 1
4 
uc
M
SC
1 7 23387365 This DMR is located in an area 
annotated to the Insulin like 
growth factor 2 mRNA binding 
protein 3 (IGF2BP3) gene and is 
present in a region known to be 
a strong enhancer region and an 
active TSS.
6.01 x 10-18 5
2 5 159894868 This DMR is located in an area 
annotated to the MIR3142 Host 
Gene (MIR3142HG) gene and is 
present in a region known to be 
(near) an active TSS.
2.39 x 10-17 5
3 5 73928997 This DMR is located in an area 
annotated to the Ectodermal-
Neural Cortex 1 (CCL28, ENC1) 
gene and is present in a region 
known to be a strong enhancer 
and transcription region.
9.4 x 10-18 3
4 9 118135710 This DMR is located in an area 
annotated to the Deleted In 
Esophageal Cancer 1 (DEC1) gene 
and is present in a  region known 
to be a strong enhancer region 
and an active TSS.
3.34 x 10-17 2
5 4 160319500 This DMR is located in an area 
annotated to the RP11-138A23.2 
gene and is present in a region 
known to be an enhancer and 
transcription region
4.34 x 10-15 3
6 4 123693559 This region was not annotated to 
a gene by ROADMAP reference 
data
8.26 x 10-15 2
7 7 18548468 This DMR is located in an area 
annotated to the Histone 
deacetylase 9 (HDAC9) gene and 
is present in a region known to be 
an active TSS.
5.8 x 10-14 4
Chapter 3
3
66
# Chr Start In region Pregion #CpG
8 6 29454623 This DMR is located in an area 
annotated to the MAS1 Proto-
Oncogene Like (MAS1L) gene and 
is present in a region known to be 
quiescent.
1.68 x 10-13 12
9 4 74606107 This DMR is located in an area 
annotated to the Interleukin-8 (IL-
8, CXCL8) gene and is present in 
a region known to be a enhancer 
region and an active TSS.
7.83 x 10-13 4
10 6 29429909 This DMR is located in an area 
annotated to the Olfactory 
receptor 2H1 (OR2H1) gene and 
is present in a region known to be 
quiescent.
8.34 x 10-13 6
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Supplementary Table S2. Top 10 hypermethylated regions in ucMSC after 14 days of 
culture expansion. Annotated to ROADMAP reference data for adipose derived MSC and 
bone marrow derived MSC. The p-values of the regions and the number of CpG sites within 
the significantly hypermethylated regions are indicated.
# Chr Start In region Pregion #CpG
da
y 
0 
<>
 d
ay
 1
4 
uc
M
SC
1 12 14996143 This DMR is located in an 
area annotated to the ADP-
Ribosyltransferase 4 (ART4) 
gene and is present in a region 
known to be an enhancer and 
transcription region, quiescent 
and near a TSS.
5.74 x10-12 11
2 17 77018501 This DMR is located in an area 
annotated to the C1QTNF1 
Antisense RNA 1 (C1QTNF1-AS1) 
gene and is present in a region 
known to be a strong enhancer 
region, quiescent and a repressed 
polycomb.
1.51 x10-11 8
3 8 72757787 This DMR is located in an area 
annotated to the MSC Antisense 
RNA 1 (MSC-AS1) gene and is 
present in a region known to be 
an enhancer region, near a TSS, 
bivalent promotor and a repressed 
polycomb.
4.67 x 10-9 5
4 15 74466337 This DMR is located in an area 
annotated to the Immunoglobulin 
superfamily containing leucine 
rich repeat (ISLR) gene and is 
present in a region known to be an 
active TSS.
4.67 x 10-9 6
5 12 16760040 This DMR is located in an area 
annotated to the LIM Domain 
Only 3; Microsomal Glutathione 
S-Transferase 1 ( LMO3) gene and 
is present in a region known to 
bea repressed polycomb, bivalent 
promotor and near a TSS. 
1.5 x 10-8 12
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# Chr Start In region Pregion #CpG
6 2 239799314 This DMR is located in an area 
annotated to the Twist Family 
BHLH Transcription Factor 2 
(TWIST2) gene and is present in a 
region known to be a transcription 
region and quiescent.
1.53 x 10-8 4
7 4 111561070 This DMR is located in an area 
annotated to the Paired Like 
Homeodomain 2 (PITX2) gene 
and is present in a region known 
to be repressed polycomb and 
quiescent.
1.55 x 10-8 3
8 12 3259078 This DMR is located in an area 
annotated to the Tetraspanin 9 
(TSPAN9-IT1/TSPAN9) gene and is 
present in a region known to be a 
enhancer region.
5.27 x 10-8 2
9 8 27468684 This DMR is located in an area 
annotated to the Clusterin (CLU) 
gene and is present in a region 
known to be a strong enhancer 
region and near a TSS.
1.83 x 10-7 9
10 4 99417260 This DMR is located in an area 
annotated to the  Tetraspanin 5 
(TSPAN5) gene and is present in 
a region known to be a enhancer 
and transcription region.
1.96x10-7 4
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Abstract
Identification of patients at risk for post-transplant complications is a major challenge and 
will improve clinical care and patient health after organ transplantation. The poor predictive 
values of current biomarkers strengthens the need to explore novel and innovative 
methods such as epigenetics for the discovery of biomarkers. Cell differentiation and 
function of immune cells is dependent on epigenetic mechanisms, which regulate gene 
expression without altering the original DNA sequence. These epigenetic mechanisms 
are dynamic, potentially heritable, change with age and can be regulated and influenced 
by environmental conditions. One of the most well-known epigenetic mechanism is DNA 
methylation, which comprises the methylation of a cytosine (C) next to a guanine (G; 
CpG dinucleotides). Aberrant DNA methylation is increasingly associated with diseases, 
including immune-mediated diseases, and these alterations precede the clinical phenotype. 
The impact of DNA methylation profiles on transplant acceptance and rejection as well 
as on other post-transplant complications is unknown. Here we will discuss the current 
evidence of the functional role of recipient and donor DNA methylation on outcome after 
organ transplantation. Changes in DNA methylation may predict the risk of developing 
post-transplant complications including infections, malignancies and allograft rejection. 
We speculate that identification of these changes in DNA methylation contributes to the 
earlier diagnosis and prevention of post-transplant complications leading to improved 
patient care. 
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Introduction
A major challenge in organ transplantation today is the identification of patients at risk 
for post-transplant complications. The current method for diagnosing rejection in heart 
transplantation is invasive and large variability is observed between pathologists in biopsy 
interpretation1,2. Crespo-Leiro et al.3 evaluated the ISHLT 2004 acute cellular rejection 
(ACR) grading scheme within the CARGO ΙΙ pathology panel and found low all-grade 
agreement, strengthening the need to discover and develop novel non-invasive methods 
to monitor the allograft. Ideally, rejection and other complications can be diagnosed and 
possibly predicted non-invasively from markers present in the peripheral blood or urine. 
Several methods have been investigated to assess their potential to identify patients at 
risk for post-transplant complications. Immune-related chemokines and cytokines in 
the peripheral blood have been studied as non-invasive markers for acute and chronic 
rejection4,5. The Clinical Trials in Organ Transplantation (CTOT)-05 is a recently published 
multicenter cohort study which analyzes the potential of several biomarkers previously 
studied in both heart and kidney transplant recipients6. Their results show no significant 
associations between the majority of tested biomarkers and biopsy-proven acute rejection 
(BPAR) or CAV, including reactive T cell panels (interferon-gamma (IFNγ) Enzyme-Linked 
Immuno Spot (ELISPOT)), anti-Human Leukocyte Antigen (HLA) class II or anti-Donor-
Specific Antibodies (DSA), and gene expression of 6 specific genes in blood. The results of 
this study do not support routine use of the studied assays to predict BPAR or CAV, however 
the authors point out the heterogeneity due to different clinical practice among centers as 
a weakness of the study. Even though Starling et al.6 found no associations, other studies 
show promising results when analyzing gene expression in heart transplant patients, 
possibly due to a wider range of genes studied. Allomap® is a commercially available 
blood-based test to diagnose cardiac allograft rejection, based on gene expression 
levels of 11 genes7. It is developed based on results from the IMAGE (Invasive Monitoring 
Attenuation through Gene Expression)8 and CARGO (Cardiac Allograft Rejection Gene 
Expression Observational Study) trials9. In both studies gene expression analysis resulted 
in significantly fewer biopsies taken to monitor the allograft. However, its results are also 
critically discussed10 and we should be careful when extrapolating these results to high-
risk patients. Another promising approach is the analysis of cell-free donor derived DNA 
(cfdDNA) in the serum of transplant patients, which is based on the assumption that 
the concentration of the cfdDNA correlates with the severity of the cardiomyocyte and 
endothelial damage11. Levels of cfdDNA were significantly higher in patients during acute 
rejection compared to stable transplant patients12,13. The predictive value of these assays 
is now explored and additional validation is necessary before clinical implementation4,14.
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Biomarkers for the diagnosis and/or prediction of post-transplant complications should be 
accurate with high specificity, high sensitivity and its results should be reproducible. The 
goal is to find biomarkers that display changes at the molecular level as early indicator for 
these post-transplant complications, before the clinical signs appear, as this may prevent 
irreversible tissue damage15. In addition to the gene expression studies, mechanisms that 
regulate gene expression, the so-called epigenetic mechanisms, can be studied as well. 
Genome-wide analysis of epigenetic features in transplant recipients may lead to the 
discovery of new biomarkers for the identification of patients at risk for post-transplant 
complications. This will provide tools to improve diagnostics and current treatment 
strategies. The first indication that epigenetics can be used for the diagnosis of rejection 
comes from studies by Mehta et al.16. The authors propose hypermethylation of the 
CALCA gene in urine of kidney transplant recipients as a biomarker for acute kidney injury. 
Nevertheless, more research should be performed to explore the potential of epigenetics 
in transplantation17. Integration of molecular techniques to provide biomarkers for 
complications after organ transplantation holds potential to improve the currently used 
diagnostics7,11,15.
Epigenetic mechanism: DNA methylation
There are several epigenetic mechanisms which influence the condensation of the 
chromatin to make specific genes accessible or inaccessible to transcription factors, 
and thereby determine which genes are transcribed18. Histone modifications such as 
methylation or acetylation, non-coding RNA molecules which bind the DNA (siRNAs, 
lncRNAs, microRNAs) and methylation of DNA are the main epigenetic mechanisms19 
which are nicely illustrated in an extensive review by Portela et al.20. In the current review, 
we focus on DNA methylation which is the methylation of a cytosine (C) followed by a 
guanine (G), a CpG dinucleotide (Figure 1A). A methyl group is added to the DNA by DNA 
methyltransferases (DNMT) (Figure 1B), these are specific enzymes. CpG dinucleotides are 
unequally distributed across the genome and regions with a high number of CpG sites are 
called CpG islands which are mostly located in promoter regions21. High methylation of 
promoter CpG sites is associated with a tight, closed chromatin structure and transcriptional 
silencing of the associated gene (Figure 1C)22. DNA methylation is thereby responsible for 
the fine control of different cellular functions, including T cell differentiation during an 
immune response23,24. It is a dynamic feature, susceptible to cues from the environment25, 
infections, chemical agents and drugs are examples of external factors that can influence 
methylation. Also internal stimuli like cytokines and hormones influence DNA methylation 
profiles26,27.
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Recent evidence indicates that functional DNA methylation also occurs outside of promoters 
in intra- and intergenic regions28,29, affecting the three-dimensional organization of the 
DNA30. This is especially interesting because changes in methylation on CpG sites outside 
promoters might be associated with a specific disease, highlighting their potential as 
biomarker21,31. Smyth et al.27 found intragenic CpG sites of which the DNA methylation was 
associated with chronic kidney disease without a significant change in the gene expression, 
suggesting a more distant function of the DNA methylation. 
DNA methylation is one of the most studied epigenetic mechanism since it can be quantified 
relatively easy32. Bisulfite sequencing is currently the golden standard and a costly but 
more comprehensive approach is provided by Illumina for genome-wide DNA methylation 
analysis33. The advantage of studying DNA methylation over the whole epigenome is that 
not only DNA methylation on CpG islands and promoter regions is quantified but also 
intra- and intergenic regions are represented on the microarray. Due to cell-specific DNA 
methylation profiles it is recommended to focus DNA methylation studies on a specific 
cell type and not on a heterogeneous cell population as for example peripheral blood 
mononuclear cells (PBMCs)34-36. 
A T C G G T A C G T
T A G C C A T G C A
CH3
CH3
CpG dinucleo�des
DNMT
CH3
Gene promoter
Ac�ve gene
Gene promoter
Inac�ve gene
A
B C
Figure 1. DNA methylation A) A DNA strand with the nucleotides Adenosine (A), 
Thymidine (T), Cytosine (C) and Guanine (G). The red boxes highlight the CpG dinucleotides 
where the left is methylated and the right is demethylated. B) The addition of a methyl 
group to a cytosine is catalyzed by the enzyme DNA methyltransferase (DNMT). C) Two 
promoter regions where filled spots represent CpG sites which are methylated and empty 
spots represent CpG sites which are demethylated.
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DNA methylation in disease
Aberrant DNA methylation profiles have been associated with different types of complex 
diseases27,37,38. This was first discovered in oncology where they found global loss of 
DNA methylation and regional increase in methylation39. To date the use of epigenetic 
biomarkers is well established for detection and diagnosis of several cancers40. Some of 
these markers can be detected not only by analyzing the affected tissue but also by other, 
less invasive methods, e.g. detection in urine or peripheral blood41,42. Already in 1999 
Esteller et al. discovered hypermethylation of tumor suppressor genes in serum DNA as 
diagnostic marker for small-cell lung cancer43. 
In patients with immune disease such as systemic lupus erythematosus (SLE), diabetes, 
rheumatoid arthritis (RA) abnormal DNA methylation of immune cells is observed44-46. Heart 
failure is also associated with epigenetic changes and DNA methylation47,48. Differential 
DNA methylation of peripheral blood leukocytes (PBL) in repetitive elements ALU, Satellite 
2 and LINE-1, which is a measure for global DNA methylation, showed to be associated 
with ischemic heart disease and its risk factors49,50. However, exact cell composition was 
unknown in these PBL samples and the association was only significant in male subjects. 
Discovery of a comprehensive set of biomarkers for diagnostic purposes improves (early) 
detection of the disease but also opens up the possibility to use them as therapeutic 
targets39,51. In oncology, epigenetic drugs such as demethylating agents 5’-azacitidine 
and decitabine, have proven to be an effective treatment and are both FDA approved52. 
Costa et al.53 showed that 5’-azacitidine is effective in chronic myelomonocytic leukemia by 
decreasing activity of DNA methyltransferase, however its function is global and unspecific. 
For patients with cancer an epigenetic drug might be the last possible treatment, though 
the potential of these drugs for modulating DNA methylation in a more specific way should 
be carefully studied in a wider range of diseases.
DNA methylation in organ transplantation
Successful organ transplantation is the net-result of the overall cumulative injury caused 
by several events in the donor e.g. age, life-style, ischemia/reperfusion injury (IRI) and the 
immune response in the recipient54-57. Research shows that IRI causes epigenetic changes 
in the donor organ. Specifically the promoter region of the C3 gene becomes demethylated 
in the kidney, which is associated with chronic nephropathy post-transplantation58,59, a 
similar change in DNA methylation might occur during heart transplantation. The initial 
immune response by the recipient towards the transplanted organ largely depends on 
the IRI induced changes in the donor organ60. DNA methylation is a large contributor to 
the balanced immune response towards the graft as it regulates the function of cells of 
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the immune system26. B cells, NK cells, T cells and other immune cells are established 
during differentiation of hematopoietic stem cells resulting in distinct DNA methylation 
profiles for each cell type61,62. As in organ transplantation T cells play prominent roles in 
alloreactivity and are the key target for immunosuppressive drugs, we focus in this review 
on DNA methylation in T cells. 
A direct link between DNA methylation profiles and organ rejection is not yet established, 
however several genes involved in alloreactivity are under regulation of DNA methylation. 
A summary of relevant genes, which can potentially serve as biomarkers for acute cellular 
rejection and immune activation in organ transplant recipients, is provided in Table 1. During 
an immune response the T cell differentiation from naïve to memory cells is controlled by 
DNA methylation. When genes encoding effector molecules become transcriptionally 
upregulated, repressive epigenetic marks as DNA methylation are lost24,26,63. The presence 
of memory T cells is both associated with acute and chronic rejection after organ 
transplantation63-65. Memory T cells express chemokine receptor type 6 (CCR6) at a higher 
level compared to naïve T cells, which is the consequence of hypomethylation of CCR666. 
In CD8+ cytotoxic T cells the differentiation from naïve to effector cells is established 
by demethylation of the promoter region of specific effector genes as granzyme B and 
IFNγ67. The ability of memory CD8+ cells to rapidly demethylate effector genes on 
antigen re-exposure is most likely an interplay between DNA methylation and histone 
modifications67. The CD4+ T cell differentiation is more complex due to the T helper cell 
lineage diversity within the effector population23,24,68. For example, the promoter region 
of IFNγ is methylated in naïve CD4+ T cells and upon antigen stimulation, in the presence 
of Thelper1 (Th1) polarizing cytokines (e.g. Interleukin (IL)-12), the promoter region of 
IFNγ becomes demethylated enabling expression of IFNγ in CD4+ Th1 cells. Consequently, 
cellular instability and plasticity69 are both under control of DNA methylation. Cellular 
instability is a major concern in organ transplantation while considering regulatory T cell 
therapy. Under inflammatory conditions regulatory T cells can earn effector functions as 
IFNγ production70 and IL-17 production through demethylation71,72. 
Important regulators of the immune response are regulatory T cells (Treg; CD4+FOXP3+)100. 
The role of these Treg in the induction and maintenance of tolerance in organ transplantation 
has been demonstrated in several experimental models of transplantation101. In humans 
high urinary mRNA levels of FOXP3 have been associated with rejection reversal102 though 
on the contrary high FOXP3 expression in the allograft is found during acute rejection 
in transplanted organs94,103 ,104. Treg develop in the thymus, natural Treg (nTreg), and in 
addition Treg develop in the periphery (induced Treg; iTreg) under a variety of conditions 
including antigen stimulation in the presence of IL-2 and TGFβ105,106. The transcription 
factor FOXP3 is essential for the maintenance and immune suppressive function of Treg 
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and its expression is controlled by DNA methylation90,91. The FOXP3 gene contains one 
region, the Treg Specific Demethylated Region (TSDR), which is demethylated in nTreg 
and methylated in other peripheral blood leukocyte subtypes, including iTreg and recently 
activated T cells. Demethylation of this region results in a stable, constitutive expression of 
FOXP3 and is used as a marker to identify nTreg92,93. 
Recently, we studied demethylation of the FOXP3 gene in endomyocardial biopsies (EMB) 
after heart transplantation95. According to the International Society for Heart and Lung 
Transplantation (ISHLT) definition of rejection, only patients with EMB scored ≥ 2R are 
considered to experience a clinical relevant rejection requiring therapy107. Multiple EMB 
were analyzed of both patients who remained free from rejection (non-rejectors; 1R 
EMB) and patients who developed a histologically proven acute rejection (rejectors; 2R 
EMB and 1R EMB sampled 8 days before the 2R EMB). The percentage of demethylated 
FOXP3 was significantly higher in the 1R EMB collected before rejection compared to the 
1R EMB of the non-rejectors (Figure 2A). The question is whether this difference can be 
used to predict rejection which enables timely intensifying of the immunosuppressive 
therapy and possibly prevention of tissue damage. ROC analysis demonstrated a relatively 
good discrimination between the rejectors and non-rejectors (Figure 2B, area: 0.79, 95% 
confidence interval: 0.65-0.93). Nevertheless, the overlap between both groups is that large 
that at this moment a true cut-off point of % demethylated FOXP3 to predict rejection is 
impossible to identify. By studying larger cohorts of 1R EMB or in combination with other, 
Table 1. Genes involved in T cell alloreactivity under control of DNA methylation.
Gene product Gene T cell source Reference
Cytokines IFNγ CD4 (Th1)/CD8 73-77
IL2 T cells 78, 79
IL4 CD4 (Th2) 73, 80, 81
IL10 Treg 73, 82
IL17 CD4 (Th17)/CD8 83
Costimulatory molecules PD1 CD8 84
CD40L CD4 85, 86
Cytotoxic proteins Granzyme B CD4/CD8 87 in mice
Perforin 1 CD8 88, 89
Transcription factors FOXP3 Treg 90-95
RORC (RORγt) CD4 (Th17) 72, 77
TBX21 (T-bet) CD4 (Th1) 96, 97
GATA3 CD4 (Th2) 98, 99
Receptor CCR6 Memory T cells 66
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to be identified, predictive markers, the % of demethylated FOXP3 might be proven to be 
predictive for a clinical relevant rejection in the future.
Currently prescribed immunosuppressive drugs prevent the occurrence of rejection, 
however long-term complications of life-long use of these immunosuppressive drugs has 
become a major problem108. Demethylation of FOXP3 is not only studied for predicting 
rejection but also for predicting long-term complications. Organ transplant recipients 
are 200 times more likely to develop a cutaneous squamous cell carcinoma (cSCC)109, a 
specific type of skin cancer, for which immunosuppressive medication seems to be a large 
risk factor. Sherston et al.110 studied demethylation of the TSDR as a marker for cSCC in 
kidney transplant recipients. They followed a cohort of 58 kidney transplant recipients in 
time and found a significant increase in the proportion of demthylated CD4+ FOXP3+ cells 
in patients who had previously developed an cSCC. The immune phenotype was stable in 
time, emphasizing its potential as biomarker for cSCC post-transplantation110. 
After heart transplantation cardiac allograft vasculopathy (CAV) is a common reason for 
retransplantation111 and a common cause of death after 3 years, together with malignancy 
and renal failure112. Once CAV has been initiated in a patient it cannot be reversed, therefore 
early detection or prediction is important113. To date no reliable biomarkers have been found 
A B
Figure 2. FOXP3 demethylation in endomyocardial biopsies A) The percentage of 
demethylated FOXP3 is significantly higher in 1R EMB of rejectors collected before rejection 
(n=19) compared to 1R EMB of non-rejectors (n=20) B) Receiver operating characteristic 
(ROC) curve of the ability to predict rejection. Area under the ROC curve: 0.79 and the 
optimal threshold for predicting rejection is 0.088% of demethylated FOXP3 with 78,9% 
sensitivity and 65% specificity. ** indicates p<0.005
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to assess the risk for developing CAV6, possibly the study of epigenetics in patients with 
CAV could complement or improve current diagnostics and hopefully provide therapeutic 
targets114. 
Conclusion
Epigenetics is part of the molecular mechanisms underlying the functional processes 
we have been studying in the past. Studying epigenetics over the whole epigenome will 
unravel the clinical potential of DNA methylation in organ transplant recipients. Most likely 
these studies will lead to the discovery of novel biomarkers for the identification of patients 
at risk for post-transplant complications. The advantage of studying DNA methylation over 
the whole epigenome is that not only DNA methylation in promoter regions is quantified 
but also intra- and intergenic regions are included, the exact function of DNA methylation 
in these regions is not entirely known yet. CpG sites outside of the promoter, which do 
not directly have an influence on gene expression, might be a discriminating biomarker 
for certain diseases. We speculate that DNA methylation analysis in organ transplant 
recipients will contribute to improved diagnostics of post-transplant complications with 
earlier detection, prediction and possibly prevention.
In Figure 3 we illustrate three hypothetical situations where several risk factors are assessed 
by quantifying DNA methylation on specific places in the genome. When risk factors can 
be estimated for a patient their treatment strategy can be adjusted, not only by altering 
medication but also by providing more specific lifestyle advices. Hopefully treatment of 
transplant patients can be customized in the future, moving more towards personalized 
medicine. The discovery of new epigenetic biomarkers also opens the possibility to use 
them as therapeutic targets, epigenetic drugs are becoming available in oncology and 
these should be studied to explore their application in transplantation. 
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Figure 3. DNA methylation as biomarker in transplant patients. Illustration of the 
workflow when biomarkers would be used to assess risk factors in transplant patients. 
The use of a non-invasive sampling method and a specific cell population to infer DNA 
methylation on specific locations in the genome. When risk factors are assessed the 
treatment strategy could be adjusted.
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Abstract 
Background 
The role of DNA methylation in the regulation of the anti-donor directed immune 
response after organ transplantation is unknown. Here, we studied the methylation of two 
mediators of the immune response: the pro-inflammatory cytokine interferon γ (IFNγ) and 
the inhibitory receptor programmed death 1 (PD1) in naïve and memory CD8+ T-cell subsets 
in kidney transplant recipients receiving immunosuppressive medication. Both recipients 
experiencing an episode of acute allograft rejection (rejectors) as well as recipients without 
rejection (non-rejectors) were included.
Results 
CpGs in the promoter regions of both IFNγ and PD1 were significantly (p<0.001) higher 
methylated in the naïve CD8+ T cells compared to the memory T-cell subsets. The 
methylation status of both IFNγ and PD1 inversely correlated with the % of IFNγ or PD1 
producing cells. Before transplantation the methylation status of both IFNγ and PD1 
was not significantly different from healthy donors. At 3 months after transplantation, 
irrespective of rejection and subsequent anti-rejection therapy, the IFNy methylation was 
significantly higher in the differentiated effector memory CD45RA+ (EMRA) CD8+ T cells 
(p=0.01) whereas the PD1 methylation was significantly higher in all memory CD8+ T-cell 
subsets (CD27+ memory; p=0.02: CD27- memory; p=0.02: EMRA; p=0.002). Comparing the 
increase in methylation in the first 3 months after transplantation between rejectors and 
non-rejectors demonstrated a significantly more prominent increase in the PD1 methylation 
in the CD27- memory CD8+ T cells in rejectors (increase in rejectors: 14%, increase in non-
rejectors: 1.9%, p=0.04). The increase in DNA methylation in the other memory CD8+ T 
cells was not significantly different between rejectors and non-rejectors. At 12 months 
after transplantation the methylation of both IFNγ and PD1 returned to baseline levels. 
Conclusions
The DNA methylation of both IFNγ and PD1 increases the first 3 months after transplantation 
in memory CD8+ T cells in kidney transplant recipients. This increase was irrespective of a 
rejection episode indicating that general factors of the kidney transplantation procedure, 
including the use of immunosuppressive medication, contribute to these variations in DNA 
methylation. 
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Background
Kidney transplantation is currently the best treatment option for patients with irreversible, 
end-stage kidney disease1. Successful kidney transplantation is hampered by different 
complications including immune-mediated complications such as acute rejection2. Several 
non-invasive biomarkers for acute rejection have been studied, including proteins involved 
in cytotoxic lymphocyte function (e.g. perforin and granzyme B), cytokines (e.g. interferon 
(IFN) γ) and immune related chemokines (e.g. CXCL9 and CXCL10)3,4. Nevertheless it 
remains difficult to predict and regulate the host immune response after transplantation. 
The host immune response is orchestrated by a tightly regulated cascade of gene expression 
changes which are regulated by epigenetic mechanisms like histone modifications, DNA 
methylation, microRNA interactions and chromatin remodeling complexes5-8. Variations 
in these epigenetic mechanisms might serve as an additional marker to monitor the host 
immune response after organ transplantation.
An important player of the host immune response is the pro-inflammatory cytokine IFNγ 
and high expression of IFNγ is associated with both acute and chronic allograft rejection9-11. 
The expression of IFNγ is regulated by DNA methylation with the addition of methyl 
groups on cytosine phosphate guanine sites (CpGs) in the IFNγ promoter region silencing 
its expression. The CpG methylation pattern of IFNy discriminates different T-cell subsets. 
First, naïve (antigen unexperienced) T cells versus memory (antigen experienced) T cells 
(both CD4+ and CD8+ T cells) with memory T cells having a lower methylation profile12-14. 
Second, the different T helper cell (Th) subsets with Th1 cells being hypomethylated 
compared to the Th2 and Th17 subsets15-17. Another important molecule involved in the 
regulation of the anti-donor immune response is the inhibitory receptor programmed cell 
death (PD) 1. Aggressive recipient T cells that attack the transplanted organ, the so-called 
alloreactive T cells, are inhibited by PD1 signaling. In addition, PD1 signaling promotes the 
generation of induced regulatory T cells18,19. The expression of PD1 is also dependent on 
DNA methylation and while mainly methylated in naïve T cells, PD1 is demethylated during 
differentiation into memory T cells20.
Regulation of gene expression by DNA methylation is a well-known epigenetic mechanism 
with a critical role in physiological development and normal cell function by coordinating 
the lineage- and tissue-specific expression of genes21. DNA methylation is dynamic and 
susceptible to stimuli from the environment including internal stimuli like cytokines and 
hormones and external stimuli like chemical agents, pollutants, dietary components and 
chronic viral infections16,22-24. Aberrant DNA methylation profiles are associated with the 
pathogenesis of disease. Initially, DNA methylation was associated with tumor formation 
and progression25, but later on variations in DNA methylation have been associated with 
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other diseases26,27 including chronic kidney disease (CKD)28,29 and immune-mediated 
diseases such as rheumatoid arthritis30 and allergy31,32. In addition, variations in DNA 
methylation of immune related genes orchestrate the host immune response after organ 
transplantation5-8. 
Graft infiltrating cytotoxic CD8+ T cells play a major role in the rejection process and 
elevated numbers of effector and memory CD8+ T-cell subsets are associated with an 
increased risk for acute rejection33-35. Here we examined the influence of variations in 
DNA methylation of IFNγ and PD1 in different CD8+ T-cell subsets on allograft rejection. 
The DNA methylation of IFNγ and PD1 was determined in kidney transplant recipients 
before and 3 and 12 months after transplantation and both kidney transplant recipients 
who experienced a rejection episode within the first 3 months after transplantation and 
recipients who remained free from rejection were included. To exclude gender-32 or chronic 
viral infection-24 related differences we first analyzed whether the DNA methylation of 
either IFNγ or PD1 was different in males versus females or in cytomegalovirus (CMV) 
seropositive healthy donors versus CMV seronegative healthy donors. 
Results
IFNγ methylation is significantly decreased in CMV seropositive individuals
In PBMCs of CMV seronegative healthy donors, the DNA methylation of IFNy was 51.2 ± 
4.4 % (mean ± SD). The IFNy methylation was significantly lower in PBMCs of age-matched 
CMV seropositive healthy kidney donors (45.1 ± 7.2%, p = 0.009; Figure 1A). In both males 
and females, the methylation of IFNy was lower in the CMV seropositive individuals 
(Figure 1A) and there was no significant difference between males and females. The DNA 
methylation of PD1 in PBMCs of CMV seronegative healthy donors was comparable to the 
PD1 methylation in CMV seropositive healthy donors (40.5 ± 5.3% versus 38.9 ± 6.3%; Figure 
1B). Subdividing the PBMCs into the different CD8+ T-cell subsets (Figure 1C) demonstrated 
significantly lower methylation of IFNγ in naïve, CD27+ memory and CD27- memory CD8+ 
T cells in CMV seropositive individuals compared to CMV seronegative individuals (Figure 
1D). The methylation of PD1 was not significantly different between the CMV seropositive 
individuals and CMV seronegative individuals in all the studied CD8+ T-cell subsets (Figure 
1E). 
DNA methylation inversely correlates with protein expression
To determine whether variations in DNA methylation at the described CpGs20,36 are 
associated with changes in protein expression, we measured the expression of IFNγ and 
PD1 in the different CD8+ T-cell subsets (Figure 2A). A clear-cut difference was observed 
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between the naïve CD8+ T cells compared to the memory CD8+ T cells where 14.6 ± 
16.4% (mean ± SD) of naïve CD8+ T cells expressed IFNγ versus 50.3 ± 18.9% of the CD27+ 
memory, 52.6 ± 20.6% of the CD27- memory and 66.1 ± 19.8% of the EMRA CD8+ T cells 
expressed IFNγ (p<0.0001; Figure 2B). In parallel, a significantly lower percentage of naïve 
CD8+ T cells expressed PD1 compared to the memory CD8+ T-cell subsets (naïve: 27.3 ± 
16.5%, CD27+ memory: 67.9 ± 5.1%, CD27- memory: 68.4 ± 12.2% and EMRA: 51.4 ± 20.1; 
p<0.0001; Figure 2E). The highest percentage of IFNγ expressing cells was found within the 
EMRA CD8+ T cells while the CD27+ and CD27- memory CD8+ T-cell subsets contained the 
Figure 1. IFNγ and PD1 methylation in CMV seropositive and CMV seronegative 
healthy kidney donors. The percentage of DNA methylation of IFNγ A) and of PD1 B) in 
CMV seronegative (n=15; open bars) and CMV seropositive healthy donors (n=15; grey bars) 
in PBMCs (mean ± SD) and stratified by gender (box and whiskers min to max). C) Gating 
strategy of the different CD8+ memory T-cell subsets. The percentage of DNA methylation 
of IFNγ D) and of PD1 E) in CMV seropositive (n=5; open bars) and CMV seronegative 
healthy donors (n=5; grey bars) in cell sorted CD8+ T-cell subsets; naïve, CD27+ memory, 
CD27- memory and differentiated effector memory CD45RA+ (EMRA). Box and whiskers 
(min to max); * p < 0.05 and ** p < 0.01
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highest percentages of PD1 expressing cells. The DNA methylation of both IFNγ and PD1 
demonstrated the opposite pattern with the highest percentage of methylation in naïve 
CD8+ T cells. Naïve CD8+ T cells were methylated for 55.2 ± 18.3% at the IFNγ locus and for 
43.1 ± 10.7% at the PD1 locus. This methylation was significantly higher (p<0.0001 for both 
IFNγ and PD1) compared to the different memory CD8+ T-cell subsets (Figure 2C and F). 
A
B C D
E F G
Figure 2. IFNγ and PD1 protein expression and IFNγ and PD1 DNA methylation. 
FACS plots of IFNγ and PD1 expression in naïve, CD27+ memory, CD27- memory, and 
differentiated effector memory CD45RA+ (EMRA) CD8+ T cells in (A; representative 
example). Mean protein expression and percentage of DNA methylation in the different 
CD8+ T-cell subsets in kidney transplant recipients before transplantation (n=10; IFNγ in 
B-D and PD1 in E-G; mean ± SD). *** p < 0.001.
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This inverse relation between the DNA methylation and protein expression confirms the 
regulatory capacity of the studied CpGs (Figure 2D and G). 
Variations in DNA methylation in kidney transplant recipients before transplantation
Before kidney transplantation, the methylation of IFNγ in CMV seronegative kidney 
recipients was comparable to the methylation levels in CMV seronegative healthy donors 
for naïve, CD27+ memory, CD27- memory and EMRA CD8+ T cells (Figure 3A). The same 
pattern was seen for the methylation of PD1 (Figure 3B). Subdividing the transplant 
recipients into the ones that went on to experience a rejection after transplantation, the 
rejectors, and the non-rejectors, did not reveal any significant differences in methylation 
of IFNγ nor PD1, either between the two recipient groups nor in comparison to the healthy 
donors (data not shown). 
Variations in DNA methylation in kidney transplant recipients after transplantation
After kidney transplantation the percentage of methylation of IFNγ did not change 
significantly in the naïve, CD27+ memory and CD27- memory CD8+ T cells during the first 
year after transplantation (Figure 4A-C). In the EMRA CD8+ T cells, the methylation of IFNγ 
was significantly higher at 3 months after transplantation compared to the methylation 
before transplantation irrespective of rejection and the subsequent anti-rejection therapy 
(p=0.01; Figure 4D). Focusing on rejection demonstrated that the methylation of IFNγ was 
significantly higher at 3 months after transplantation in the rejectors (14.3% versus 6.3% 
before transplantation; p=0.01) while the non-rejectors increased from 4.9% to 8.6% (not 
significant). Both rejectors and non-rejectors demonstrated elevated IFNγ methylation 
A B
Figure 3. IFNγ and PD1 methylation in healthy donors and kidney transplant 
recipients before transplantation. The percentage of DNA methylation of IFNγ A) and 
PD1 B) in healthy controls (HC, n=5; open bars) and kidney transplant recipients before 
transplantation (preTx, n=10; grey bars) in cell sorted CD8+ T-cell subsets; naïve, CD27+ 
memory, CD27- memory and differentiated effector memory CD45RA+ (EMRA). Box and 
whiskers (min to max).
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Figure 4. IFNγ and PD1 methylation in kidney transplant recipients during the first 
year after transplantation. The percentage of DNA methylation of IFNγ (A-D) and of PD1 
(E-H) in kidney transplant recipients before and 3 and 12 months after transplantation in 
cell sorted CD8+ T-cell subsets; naïve (A and E), CD27+ memory (B and F), CD27- memory 
(C and G) and differentiated effector memory CD45RA+ (EMRA; D and H). * p < 0.05 and 
** p < 0.01.  
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levels in the EMRA CD8+ T cells at 3 months after transplantation but this increase in 
methylation was not significant different between rejectors and non-rejectors (p=0.3). At 1 
year after transplantation the methylation of IFNγ was comparable to the levels measured 
before transplantation.
The methylation of PD1 did not change significantly in the naïve CD8+ T cells during the 
first year after transplantation (Figure 4E). Irrespective of rejection, the methylation of PD1 
significantly increased during the first 3 months after transplantation in CD27+ memory 
CD8+ T cells with 7.2% (p=0.02), in CD27- memory CD8+ T cells with 7.9% (p=0.02) and in 
EMRA CD8+ T cells with 7.5% (p=0.002; Figure 4F-H)). Focusing on rejection demonstrated 
a more prominent increase in DNA methylation in the rejectors compared to the non-
rejectors in all memory CD8+ T-cell subsets (CD27+ memory: rejectors: 27.8% versus 17.6%, 
p=0.02 and non-rejectors: 18.9% versus 14.6% p=0.3; CD27- memory: rejectors: 25.4% 
versus 11.4%, p=0.002 and non-rejectors: 12.7% versus 10.9%, p=0.6; EMRA: rejectors: 
23.8% versus 13.2%, p=0.002 and non-rejectors: 16.5% versus 12.1%, p=0.2; methylation at 
3 months versus before transplantation respectively). The increase in PD1 methylation in 
rejectors during the first three months after transplantation was not significantly different 
from the increase in PD1 methylation in non-rejectors in both the CD27+ memory CD8+ T 
cells (p=0.3) and EMRA CD8+ T cells (p=0.2). In the CD27- memory CD8+ T cells the increase 
in PD1 methylation was significantly higher in the rejectors (14%) compared to the non-
rejectors (1.9%, p=0.04). In parallel with the methylation of IFNγ, the methylation of PD1 
returned to normal levels at 1 year after transplantation. 
Discussion
The clinical potential of DNA methylation in organ transplantation, either as diagnostic 
or prognostic biomarker or as therapeutic target has been proposed by many5-8,37,38. 
Nevertheless, this is the first study where DNA methylation of two selected genes, IFNγ 
and PD1, was actually studied in CD8+ T cells in a small cohort of human kidney transplant 
recipients over time in relation to acute allograft rejection. Irrespective of rejection, we 
observed at 3 months after transplantation significant elevated DNA methylation levels 
of IFNγ in the differentiated EMRA CD8+ T cells, while the DNA methylation of PD1 was 
significantly higher in all CD8+ memory T-cell subsets. This increase in IFNγ methylation 
was not significantly different between rejectors and non-rejectors, while the increase in 
PD1 methylation was significantly higher in the rejectors in the CD27- memory CD8+ T cells. 
In the other CD8+ memory T cells subsets (CD27+ memory and EMRA) the increase in DNA 
methylation of PD1 was not significantly different between rejectors and non-rejectors.
Kidney transplantation will activate the recipient’s immune system accompanied by an 
increase in cytokine production, including production of the pro-inflammatory IFNγ35,39,40, 
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and upregulation of PD1 expression41. As protein expression inversely correlates with DNA 
methylation levels at gene promoter sites, kidney transplantation induces demethylation 
of genes involved in immune activation. However, for both IFNγ and PD1 an increase 
in DNA methylation was observed in rejectors and non-rejectors in the first 3 months 
after transplantation, indicative for lower expression levels of IFNγ and PD1. Likely, the 
expected demethylation is only detectable in the donor-antigen specific T cells. The low 
percentage of these cells within the selected CD8+ T cells explains why the expected 
decrease in methylation was not observed. The observed increase in IFNγ and PD1 DNA 
methylation most likely does not reflect the immune response against the foreign donor 
antigen but demonstrates a down regulation of the immune system achieved by the given 
immunosuppressive medication which non-specifically block all T cell subsets. For example 
the usage of prednisolone. In this study, prednisolone was tapered to 5 mg at month 3 
and thereafter completely withdrawn. At 1 year after transplantation the DNA methylation 
levels returned to baseline. 
In a clinical transplantation setting it is impossible to measure the DNA methylation of 
either IFNγ or PD1 just before rejection. Currently rejection cannot be predicted as the 
moment of rejection strongly varies between individuals and therefore those samples 
are not available. Although material was only available of a small number of patients we 
had the unique opportunity the follow the same patients over time. Variations in DNA 
methylation are more profoundly found in the period after withdrawal of stress exposure 
(e.g. drugs) compared to the period during exposure42,43. Translation to the field of organ 
transplantation implies that after a rejection episode including anti-rejection therapy, 
rejectors would have more variations in DNA methylation compared to non-rejectors. 
However this was not true for the methylation of either IFNγ or PD1 at 12 months after 
transplantation, indicating that allograft rejection has no imprinted effect on the DNA 
methylation of those immune genes. 
Despite differences in immune activity of the distinct memory CD8+ T-cell subsets, the 
variations in DNA methylation in either memory subset were comparable. The EMRA CD8+ 
T cells are potentially the most aggressive subtype with a strong cytolytic activity, while 
the CD27+ memory cells display weak cytolytic activity producing effector cytokines such 
as interleukin (IL) 2, IFNγ, tumor necrosis factor (TNF) α and IL444,45. The CD27- memory 
CD8+ T cells, which are functionally in between the CD27+ memory CD8+ T cells and the 
EMRA CD8+ T cells, represents the smallest subpopulation and it is unclear why specifically 
these cells demonstrated a significant difference in increase in methylation of PD1 between 
rejectors and non-rejectors. 
DNA methylation is adjustable by cues from the environment, e.g. viral infections20,24,46, 
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though the exact cues and mechanisms remain largely unknown16,22,23. The uremic condition 
during chronic kidney disease (CKD) modifies DNA methylation profiles47-49. Although, 
before transplantation we did not observe significant changes in the methylation of either 
PD1 or IFNγ compared to age-matched healthy donors. Either the previously observed 
effect on DNA methylation is gene specific and not applicable to IFNy and PD1 or the 
included transplant recipients here had less severe kidney disease compared to the CKD 
patients studied previously.
In contrast to previous observations where males demonstrated a significantly higher DNA 
methylation of IFNγ compared to females32, significant differences in DNA methylation 
between males and females were not observed. However, we observed a significantly 
lower % of IFNγ methylation in CMV seropositive healthy donors compared to CMV 
seronegative healthy donors. The effect of chronic CMV infection on DNA methylation 
is not documented yet, but the change of the composition of the T cell pool with a 
permanent increase in highly differentiated T cells with a more memory phenotype in 
CMV seropositive individuals50 has been demonstrated repeatedly. Therefore, the lower % 
of IFNγ methylation in CMV seropositive individuals might be explained by the fact that 
memory T cells are less methylated at the IFNγ locus (Figure 2 and 12-14). Nevertheless, also 
in selected CD8+ memory T cells the methylation of IFNγ was significantly lower in the 
CMV seropositive individuals (Figure 1), indicating that CMV infection not only affects the 
composition of the T cell compartment but also induces a more aggressive T cell phenotype 
since demethylation is associated with an increased IFNγ production. 
Although we could not identify variations in DNA methylation of either IFNy or PD1 in CD8+ 
T cells which could either diagnose or predict allograft rejection after kidney transplantation 
further research is needed to appreciate the clinical significance of variations in DNA 
methylation and other epigenetic mechanisms in kidney transplantation. Epigenetic 
biomarkers, mainly based on variations in DNA methylation, are well established in the 
diagnosis of cancer and are not only detectable in the affected tissue as well as in the urine 
or the peripheral blood51,52. Currently the application of epigenetic biomarkers is extended 
to other complex diseases such as autoimmune diseases30,53,54. The increasing knowledge 
on the epigenetic regulation of immune cells will contribute to our understanding of 
the epigenetic regulation of the complex anti-donor immune response after kidney 
transplantation. Epigenetic variations precede changes in protein expression and cell 
function and thereby represent an early indicator of clinical complications. Accordingly, 
a more comprehensive understanding of the epigenetic regulation of the anti-donor 
immune response will learn whether variations in DNA methylation can serve as predictive, 
diagnostic or prognostic markers. Moreover, since DNA methylation is influenced by 
environmental cues it might serve as a target for therapeutic intervention. 
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A genome-wide approach instead of selected immunoregulatory genes are a good option 
for future research. Genome-wide analysis enables the identification of variations in DNA 
methylation in all promoter regions as well as other gene regions including intragenic and 
intergenic regions47,55,56. Since DNA methylation profiles are cell-type specific57, selected 
cell subsets involved in the anti-donor immune response (e.g. CD4+ T-cell subsets, B cells 
and macrophages), or even better the donor-antigen specific cells, should be analyzed. 
Another interesting, though technically more challenging option, is to analyze variations 
in DNA methylation in graft-infiltrating T cells. As variations in DNA methylation occur 
specifically in donor-antigen specific cells which are more abundantly present in the graft 
compared to the circulation. 
Conclusion
After kidney transplantation the DNA methylation of the promoter of both IFNγ and 
PD1 increases in the first 3 months and returns to baseline at 1 year after transplantation 
irrespective of rejection. These variations do not reflect the anti-donor immune 
response but are more likely the result of the transplantation procedure and the use of 
immunosuppressive medication. 
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Methods
Study population
Prior to the selection of kidney transplant recipients, we first determined whether 
cytomegalovirus (CMV) infection modulates DNA methylation of either IFNγ or PD1. 
Peripheral blood mononuclear cells (PBMCs) of 15 CMV seropositive healthy donors (age: 
52 years, range 38-71; 5 males and 10 females) and 15 age-matched CMV seronegative 
healthy donors (age: 52 years, range 44-59; 11 males and 4 females) were studied. Of these 
30 healthy donors in total, we selected 5 CMV seropositive and 5 CMV seronegative age-
matched individuals to study the methylation status in different CD8+ T-cell subsets. Based 
on the significant decrease in DNA methylation of IFNγ in CMV seropositive healthy donors, 
we included only CMV seronegative kidney transplant recipients who received their first 
kidney from a living donor. The DNA methylation of both IFNγ and PD1 was examined in 
different CD8+ T-cell subsets in 5 recipients who developed a biopsy proven acute cellular 
rejection within the first 3 months after transplantation (rejectors; Table 1) and 5 age-
matched recipients who remained free from rejection the first year after transplantation 
(non-rejectors) and was compared to 5 age-matched healthy donors (age: 54 years, range 
44-59). The different CD8+ T-cell subsets were analyzed at different time points; before 
transplantation and 3 months and 12 months after transplantation. The selected CMV 
seronegative recipients all received a kidney from a CMV seronegative donor and received 
basiliximab as induction therapy. After transplantation, recipients received standard triple 
maintenance therapy consisting of prednisolone (tapered after 3 months), mycophenalate 
mofetil (MMF) and tacrolimus. Anti-rejection therapy consisted of methylprednisolone 
(1 gram per day) on three consecutive days followed in some cases by anti-thymocyte 
globulin (ATG; n=2) or alemtuzumab (n=1). 
Isolation of peripheral blood mononuclear cells and CD8+ T-cell subsets
Peripheral blood mononuclear cells (PBMCs) were isolated from heparinized blood 
samples by density gradient centrifugation using standard Ficoll-Paque (GE Healthcare, 
Uppsala, Sweden) procedures. Since DNA methylation profiles are cell type specific57 
we examined naïve (antigen unexperienced; CD27+CD45RA+) CD8+ T cells and memory 
(antigen experienced) CD8+ T cells separately. The memory CD8+ T cells were subdivided 
into the differentiated effector memory CD8+ T cells (EMRA: CD27-CD45RA+, with a strong 
cytolytic activity), CD27+ memory T cells (CD27+CD45RA-; with weak cytolytic potential) 
and CD27- memory T cells (CD27-CD45RA-; functionally in between CD27+ memory CD8+ 
T cells and EMRA CD8+ T cells)44,45. The different CD8+ T-cell subsets were isolated using 
cell sorting (BD FACSAriaTM II SORP, BD Biosciences, San Jose, CA, USA) with a mean purity 
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of 96%. Total PBMCs were stained with the following monoclonal antibodies: Brilliant 
Violet 510TM labeled CD3 (Biolegend, San Diego, CA, USA), APC-Cy7 labeled CD8 (BD), 
PE-Cy7 labeled CD27 (eBioscience, San Diego), APC labeled CD45RA (BD) and 7-amino-
actinomycin D (7-AAD, BD) for the exclusion of nonviable cells. 
Bisulfite conversion
PBMCs and the FACS-sorted CD8+ T-cell subsets were digested with proteinase K and 
treated with bisulfite using the EZ DNA Methylation-Direct Kit (Zymo Research from Base 
Clear Lab products, Leiden, The Netherlands), according to the manufacturer’s instructions. 
During bisulfite treatment unmethylated cytosines were converted into uracil, whereas 
methylated cytosines remained unchanged. 
PCR amplification and pyrosequencing
The DNA methylation of the IFNγ promoter was determined at 2 CpGs (CpG-186 and 
CpG-54) with transcription factor activity36 and for PD1 8 previously described20 CpG sites 
ranging between -914 and -738 bp from the start codon were studied (CpG-914, CpG-911, 
CpG-906, CpG-857, CpG-833, CpG-776, CpG-762, CpG-738). Since the methylation status 
at adjacent CpGs is correlated58, the mean % of methylation of either IFNγ or PD1 was 
calculated. Primers for PCR and pyrosequencing were designed using PyroMark Assay 
Design 2.0 software (Qiagen, Venlo, The Netherlands; Table 2).
PCR amplifications were performed with the Pyromark PCR Kit from Qiagen with each 
primer in a concentration of 0.2 µM. The PCR conditions were 15 minutes at 95 °C, 45 cycles 
Table 1. Clinical characteristics of kidney transplant recipients 
Rejectors Non-rejectors
No of subjects 5 5
Age at transplantationa (yr) 47 (43-54) 52 (44-66)
Gender (M/F) 4/1 5/0
Serum creatinina,b (µmol/l) 480 (270-1484) 532 (374-682)
Underlying kidney diseasec
       HN/PKD/other 3/1/1 0/4/1
Renal replacement therapyd
       HD/PD/pre-emptive 1/2/2 1/1/3
Number of HLA-A/B mismatchese 2.2±0.4 2.8±0.8
Number of HLA-DR mismatchese 2.0±0 1.0±0.7
amedian with range, bbefore transplantation, cHN: hypertensive nephropathy; PKD:polycystic 
kidney disease, dHD: hemodialysis; PD: peritoneal dialysis, emean±SD
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of 30 seconds 94 °C, 30 seconds 58 °C for IFNγ and 56 °C for PD1 and 30 seconds 72 °C 
followed by 10 minutes at 72 °C and on hold at 21 °C. After visualisation of the appropriately 
sized PCR product on a 1% agarose gel, the PCR product was sequenced using a PyroMark 
Q24 pyrosequencer (Qiagen) with the following minor revisions to the manufacturer’s 
instructions: to immobilize the PCR product 1µl Streptavidin Sepharose High Performance 
Beads (GE Healtcare) were used per sequence reaction and annealing of the sequence 
primers was done for 3 minutes at 80 0C. The bisulfite conversion and the subsequent 
PCR amplification and pyrosequencing were performed in duplicate. Human low and high 
methylated DNA from EpigenDx (Hopkinton, MA, USA) were used as controls. 
IFNγ and PD1 protein expression
To determine IFNγ and PD1 protein production by the different CD8+ T-cell subsets, total 
PBMCs were either not stimulated or stimulated in the presence of 1 µg/ml Brefeldin A 
(GolgiPlug; BD Biosciences) with PMA (50 ng/ml, Sigma-Aldrich, St. Louis, MO, USA) 
and ionomycin (1 µg/ml, Sigma-Aldrich) for 4 hours at 37 °C in 5 % CO2. For IFNγ, cells 
were stained for 30 minutes for the following surface markers: Brilliant Violet 510TM 
labeled CD3 (Biolegend), APC-Cy7 labeled CD8 (BD Biosciences), PE-Cy7 labeled CD27 
(eBioscience), APC labeled CD45RA (BD Biosciences) and 7-amino-actinomycin D (7-AAD, 
BD Biosciences), fixed, permeabilized and stained with FITC-labeled IFNγ (BD Biosciences) 
for 30 minutes. Frequencies of IFNγ producing CD8+ T-cell subsets were corrected for 
background determined with the unstimulated condition. For PD1, cells were stained with 
the previously described surface markers while PE-labeled PD1 (Biolegend) was added. 
For PD1 expression a Fluorescence-Minus-One (FMO) was used to correct for background 
Table 2. Primers for PCR amplification and pyrosequencing
Gene Primers CpGs
IFNγ F: 5’-ATGGTATAGGTGGGTATAATGG-3’
R: 5’-biotin-CAATATACTACACCTCCTCTAACTAC-3’
S: 5’- GGTGGGTATAATGGG-3’ CpG-186
S: 5’- ATTATTTTATTTTAAAAAATTTGTG-3’ CpG-54
PD1 F: 5’- AGTATAGAATATAAGGAGATAAGTAAGT-3’
R: 5’-biotin- CCATAACCACAATTCCAAATCTTT-3’
S: 5’-AGAATATAAGGAGATAAGTAAGTT’-3’ CpG-914, CpG-
911, CpG-906
S: 5’-GGATTTTTTGAATTATTTTATTTTG’-3’ CpG-857, CpG-833
S: 5’- TTAGTTTTATAGTTAGTTTTTG-3’ CpG-776, CpG-762, 
CpG-738
F: forward primer, R: reverse primer, S: sequencing primer, CpGs: cytosine phosphate guanine sites
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staining. Samples were measured on the FACSCanto II (BD) and analyzed using FACSDiva 
software version 6.1.2. (BD). 
Statistical analysis
To identify differences between groups the unpaired t-test, Mann-Whitney U test and 
ANOVA were used as appropriate. To determine differences after kidney transplantation 
over time between rejectors and non-rejectors we used multilevel analysis with the 
percentage of DNA methylation as outcome. Predictors were different individuals (rejectors 
and non-rejectors), time also as categorical predictor (levels 0 (before transplantation), 3 
and 12 months after transplantation) and individuals as random intercept. Each model was 
applied for the 4 different cell types studied; naïve, CD27+ memory, CD27- memory and 
EMRA CD8+ T-cell subsets. Afterwards we added models with interaction between type of 
individual and time. The first model describes the same pattern over time for both rejectors 
and non-rejectors while the second one enables to estimate and test different trends in 
time for rejectors and non-rejectors. The estimates and standard errors were transformed 
to CI’s and p-values. We used the package R version 3.1.2 and libraries lmer and lmerTest. A 
p-value of <0.05 was considered statistically significant.
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Abstract 
Background
Cutaneous squamous cell carcinoma (cSCC) occurs 65-200 times more in immunosuppressed 
organ transplant patients than in the general population. T cells, which are targeted by 
the given immunosuppressive drugs, are involved in anti-tumor immune surveillance and 
are functionally regulated by DNA methylation. Prior to kidney transplantation, we aim 
to discover differentially methylated regions (DMRs) in T cells involved in de novo post-
transplant cSCC development.
Methods
We matched 27 kidney transplant patients with a future de novo cSCC after transplantation 
to 27 kidney transplant patients without cSCC and studied genome-wide DNA methylation 
of T cells prior to transplantation. From 11 out of the 27 cSCC patients the DNA methylation 
of T cells after transplantation was also examined to assess stability of the observed 
differences in DNA methylation. Raw methylation values obtained with the 450k array 
were confirmed with pyrosequencing.
Results
We found 16 DMRs between patients with a future cSCC and those who do not develop this 
complication after transplantation. The majority of the DMRs were located in regulatory 
genomic regions such as flanking bivalent transcription start sites and bivalent enhancer 
regions, and most of the DMRs contained CpG islands. Examples of genes annotated to 
the DMRs are ZNF577, coding for a zinc-finger protein, and FLOT1, coding for a protein 
involved in T-cell migration. The longitudinal analysis revealed that DNA methylation of 9 
DMRs changed significantly after transplantation. DNA methylation of 5 out of 16 DMRs 
was relatively stable, with a variation in beta-value lower than 0.05 for at least 50% of the 
CpG sites within that region. 
Conclusions
This is the first study demonstrating that DNA methylation of T cells from patients with 
a future de novo post-transplant cSCC is different from patients without cSCC. These 
results were obtained before transplantation, a clinically relevant time point for cSCC 
risk assessment. Several DNA methylation profiles remained relatively stable after 
transplantation, concluding that these are minimally affected by the transplantation and 
possibly have a lasting effect on post-transplant cSCC development.
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Background
The risk of developing cancer is markedly higher in organ transplant patients than in the 
general population1. The most common cancer in transplant patients is non-melanoma 
skin cancer whereby cutaneous squamous cell carcinoma (cSCC) occurs most frequently2, 
with an increased risk of 65-200 fold2-4. Not only the incidence of cSCC increases after 
organ transplantation, the skin cancer also behaves more aggressively. Transplant patients 
experience more metastasis and more recurrence of the cSCC: 70% of the patients develop 
a subsequent skin cancer within 5 years5,6. Identification of transplant patients at increased 
risk for cSCC may allow early intervention and will improve the quality of life for these 
patients.
Transplant patients are at high risk for cSCC because of their impaired immune system 
due to lifelong immunosuppressive therapy7-9. Immunosuppressive drugs used after organ 
transplantation suppress T-cell activity10. T cells are an important cell type for anti-tumor 
immune surveillance (CD8+), but can also provide a more immune-tolerant environment 
for the tumor (regulatory T cells)11,12. Carroll et al.13 showed that high numbers of peripheral 
regulatory CD4+FOXP3+ cells predicted the development of a new cSCC in kidney 
transplant patients who had a previous cSCC. Also the presence of CD8+CD57hi cells, a 
phenotype associated with T-cell senescence, was shown to predict development of a 
subsequent cSCC in kidney transplant patients14. These studies both predicted recurrence 
of the cSCC, tools to predict de novo cSCC after transplantation are currently unavailable.
Considering the recurrent nature of cSCC and the increased incidence in 
immunocompromised transplant patients, we hypothesized that there is a systemic 
defect in patients who will develop cSCC due to an altered state of T-cell function. Such 
an altered state of T-cell function is a well-known consequence of loss of kidney function15. 
T-cell function is determined by the chromatin state of its DNA, which is a combination 
of epigenetic features such as DNA methylation, DNA accessibility, histone modifications 
and RNA expression16,17. DNA methylation is an important epigenetic regulator of cellular 
function18,19 and high methylation in the transcription start site (TSS) of a gene is in most 
cases associated with transcriptional silencing of the corresponding gene20. 
Differential DNA methylation between transplant patients with or without a future 
post-transplant cSCC might provide insight in the pathogenesis of cSCC. However, DNA 
methylation is a dynamic feature and significantly influenced by the environment21. 
After kidney transplantation, immunosuppressive therapy is given and the metabolic 
complications associated with loss of kidney function largely disappear. Therefore, it can 
be expected that changes in DNA methylation will occur and this may also affect any 
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DNA methylation profiles identifying patients at risk for de novo post-transplant cSCC. By 
comparing these DNA methylation profiles before and after transplantation, the extent of 
their functional effect on post-transplant cSCC development could be assessed.
In this retrospective study, we aimed to identify kidney transplant patients at risk for de 
novo post-transplant cSCC by studying genome-wide DNA methylation of T cells. We 
analyzed samples collected before transplantation and compared patients with a future 
de novo post-transplant cSCC to patients without cSCC. Highly enriched T cell populations 
were isolated from these patients and genome-wide DNA methylation was measured. We 
then searched for differentially methylated regions (DMRs) by comparing the future cSCC 
patients’ methylation profiles to the non-cSCC profiles. For a subset of cSCC patients, a 
post-transplantation sample was available which enabled us to compare DNA methylation 
before and after transplantation. A technical validation of the raw methylation values on 
the array was performed with pyrosequencing.
Methods
Patients samples
Anonymized biobank samples were used in this study, this approach had been approved 
by the local ethical committee (MEC-2015-642). Kidney transplant patients with a future 
post-transplant cSCC were matched to kidney transplant patients who have not developed 
an cSCC based on gender, age (±2 years), ethnicity, cytomegalovirus (CMV) status 
and availability of biobank material. We included patients with at least one cSCC after 
transplantation and patients with cSCC in situ (Bowen’s disease). Patients with a previous 
kidney transplantation or another donor organ such as liver, heart or lung were excluded, 
as well as patients with a history of malignancy prior to transplantation. Non-cSCC patients 
with actinic keratosis, a pre-cancerous lesion, were excluded. 
The patient cohort consisted of 27 cSCC patients and 27 non-cSCC patients who had been 
transplanted between 1997 and 2014. No statistical differences were found between the 
clinical characteristics of the cSCC and non-cSCC patients, however after cell sorting the 
composition of CD4+ and CD8+ T cells significantly differed between the cSCC and non-
cSCC patients (Table 1). One cSCC patient had received immunosuppressive drugs prior to 
an AB0-incompatible transplantation. 
From 11 cSCC patients, material collected after transplantation was available for a 
longitudinal analysis, characteristics of this subset of patients are given in Table 2. The 
post-transplantation samples were collected based on availability of biobank material 
and are therefore at different time points after transplantation (Table 3). Three of the 
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post-transplant samples were taken after diagnosis of the first cSCC. All of these patients 
received treatment, patient “p1” was treated with a topical chemotherapeutic agent 
5-fluorouacil, patient “p2” was treated with photodynamic therapy and surgical excision 
and patient “p4” was treated with a surgical excision. 
Peripheral blood mononuclear cells (PBMCs) were isolated by density gradient 
centrifugation using standard Ficoll-Paque procedures (GE Healthcare, Chicago, IL, US). 
Isolated PBMCs were stored at -140°C until further use. T cells were isolated from the PBMCs 
using fluorescence-activated cell sorting (FACS) by the BD FACSAriaTM ll (BD Biosciences, 
San Jose, CA, US). PBMCs were stained with anti-CD3 Brilliant Violet 510 (Biolegend, San 
Diego, CA, US), anti-CD4 Pacific Blue (BD Biosciences), anti-CD8 APC-cy7 (BD Biosciences) 
and to exclude nonviable cells 7AAD PerCP (BD Biosciences) was used. After cell sorting the 
purities were >92% for CD3+ cells, samples below 90% were excluded for further analysis.
Table 1. Patient characteristics
cSCC
N = 27
non-cSCC
N = 27
Age (years)a 61.7 (27-77) 61.3 (27-77) p=0.802
Gender (male) 19 (70.4%) 19 (70.4%) p=1
Years between Tx and first cSCCa 5.4 (0.9-12.5) - -
CMV status p=0.46
       Negative 12 (44.4%) 9 (33.3%)
       Positive 15 (55.6%) 17 (63.0%)
       Unknown - 1 (3.7%)
Dialysis pre-transplantation p=0.783
       Yes 16 (59.3%) 15 (55,6%)
       No 11 (40.7%) 12 (44.4%)
ESRD diagnosis p=0.058
       Polycystic kidney 6 (22.2%) 1 (3.7%)
       Hypertension 6 (22.2%) 3 (11.1%)
       Diabetic nefropathy 1 (3.7%) 6 (22.2%)
       Glomerulonefritis 3 (11.1%) 6 (22.2%)
       Other 11 (40.7%) 11 (40.7%)
% CD3a 97.4 (92.4-99.5) 98.0 (95.1-99.5) p=0.225
% CD4a 73.0 (45.1-91.4) 60.3 (34.8-80.7) p=0.000
% CD8a 20.7 (5.8-46.2) 32.8 (14.8-60.6) p=0.000
amedian and range; cSCC: cutaneous squamous cell carcinoma, CMV: cytomegalovirus, ESDR: end 
stage renal disease
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Before isolating DNA from the T cells, all patient samples were randomized to minimize 
batch effects. DNA was isolated using the QIAamp DNA Micro kit (Qiagen, Venlo, The 
Netherlands) according to the manufacturer’s protocol. Purity and concentration of the 
isolated DNA was assessed with the NanoDrop ND-8000 (Isogen Life Science, Utrecht, 
The Netherlands). DNA degradation was determined by gel electrophoresis, none of the 
samples showed significant degradation. 
Table 2. Patient characteristics longitudinal analysis
N = 11
Age at Tx (years)a 65.4 (47-75)
Gender (male) 8 (72.7%)
Years between Tx and first cSCCa 2.6 (1.1-11.5)
Years between Tx and post-Tx samplea 2.1 (0.3-13.0)
CMV acceptor
       Negative 4 (36.4%)
       Positive 7 (63.6%)
CMV donor
       Negative 7 (63.6%)
       Positive 4 (36.4%)
HLA mismatchesa 2 (0-6)
Type of immunosuppression directly after transplantation
       Corticosteroids 10 (90.9%)
       Tacrolimus 10 (90.9%)
       MMF 10 (90.9%)
       Cyclosporine 1 (9.1%)
       Sirolimus 1 (9.1%)
       Basiliximab induction 3 (27.3%)
       ATG induction 1 (9.1%)
ESRD diagnosis
       Polycystic kidney 5 (45.5%)
       Hypertension 1 (9.1%)
       Other 5 (45.5%)
Dialysis pre-transplantation
       Yes 8 (72.7%)
       No 3 (27.3%)
amedian and range; cSCC: cutaneous squamous cell carcinoma, CMV: 
cytomegalovirus, ESDR: end stage renal disease
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DNA methylation microarrays
To generate genome-wide DNA methylation data, 500 ng of genomic DNA was treated with 
sodium-bisulfite to induce methylation-dependent changes in the DNA sequence, using 
the EZ DNA Methylation kit (Zymo Research, Irvine, CA, US). DNA was then hybridized 
on Infinium HumanMethylation450 arrays (Illumina, San Diego, CA, US) according to the 
manufacturer’s protocol and IDAT files were generated by the iScan BeadChip scanner 
(Illumina). 
Data quality was examined using the MethylAid R package22,23. All samples passed the five 
quality controls performed using the default MethylAid thresholds. Probes with a detection 
P value>0.01 were removed from the dataset as well as probes containing single nucleotide 
polymorphisms. Since our patient population was a mixture of male and female, all probes 
on the sex chromosomes were also removed. A between-array normalization was applied 
to the Type Ι and Type ΙΙ probes separately using the DASEN method within the wateRmelon 
Bioconductor R package23-25. The methylation level for each cytosine-phosphate-guanine 
(CpG) site was calculated as the ratio of the methylated probe intensity and the overall 
intensity. This is presented as a beta-value, a value between 0 (unmethylated) and 1 (fully 
methylated). After the quality controls and normalization, beta-values of 423,289 CpG 
sites remained for further analysis. Both the raw and normalized data are available via the 
NCBI Gene Expression Omnibus (GEO) database with accession number GSE103911.
Table 3. Time points longitudinal analysis
Patient Time after 
Tx (y)
Time between Tx 
and first cSCC (y)
Comment
p1 13 11 Material obtained after diagnosis of first cSCC
p2 7.7 4.1 Material obtained after diagnosis of first cSCC
p3 6.9 7.7
p4 3.4 2.4 Material obtained after diagnosis of first cSCC
p5 0.9 4.7
p6 2.1 2.6
p7 0.3 1.6
p8 1.1 2
p9 1.1 1.1
p10 0.6 2.2
p11 5 11.5
Tx: Transplantation, cSCC: cutaneous squamous cell carcinoma, y: years
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Data analysis DNA methylation microarrays
To identify DNA methylation differences between the future cSCC and non-cSCC patients, 
we fitted a linear mixed-effect model using the lme4 R package26. The fixed effects included 
age, percentage CD4, percentage CD8 and CMV status. %CD4 and %CD8 were included in 
the model because we found that the composition was different between the cSCC and 
non-cSCC patients after cell-sorting (Table 1). Array IDs were included as a random effect 
to account for technical variation between the arrays. Single site-specific p-values were 
obtained and these p-values together with the genomic location of the CpG sites, were 
used as input into comb-p27.
Comb-p is a command-line tool based on a python library to spatially correlate p-values27. 
Since DNA methylation at adjacent CpG sites is correlated it strengthens the data to study 
regions that are differentially methylated instead of single sites28,29. Comb-p calculates a 
weighted correlation between the p-values from the single CpG site-specific analysis and 
combines adjacent p-values based on this correlation. A sliding window of 500 base pair 
(bp) was used and the seed was set at p<0.01. It then performs a false discovery rate (FDR) 
adjustment to this new correlation adjusted p-values, finds regions of enrichment at an 
FDR cut off of 0.05 and assigns significance to those regions. Multiple testing correction 
in this analysis is done using a Šidák correction (Šidák<0.05)30. The resulting DMRs were 
annotated to ROADMAP reference data of primary CD3+ cells16 to determine the CpG 
island content and the chromatin state of the DMRs. 
Longitudinal analysis
For 11 cSCC patients (Table 2 and 3), we compared DNA methylation values of the DMRs 
before and after transplantation. A paired statistical analysis was done per region. To 
improve clarity, only those CpG sites within a DMR with a Δbeta-value larger than 0.05 
(5% methylation) were used for detailed graphical representation and the patients were 
evenly divided in 4 time segments after transplantation. The CpG sites within a region that 
increased or decreased less than 0.05 in beta-value per patient were considered stable in 
time.
Technical validation
Performing methylation arrays for a risk assessment is not easily applicable to clinical 
practice due to high costs and labor-intensive workflow. Therefore we tested whether we 
could obtain the same methylation values with bisulfite pyrosequencing, an easy technique 
to quantitatively measure single-site DNA methylation31. CpG sites within the DMRs 2 and 
3 were analyzed in the same DNA samples that were used for the array analysis. Of 10 
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patients, a mixture of cSCC and non-cSCC patients, 200 ng genomic DNA was bisulfite 
converted using the EZ DNA Methylation-Direct kit (Zymo Research) according to the 
manufacturer’s protocol. The bisulfite treated DNA was then amplified by polymerase chain 
reaction (PCR) using the Pyromark PCR kit (Qiagen). Primers for PCR and pyrosequencing 
were designed using PyroMark Assay Design 2.0 software (Qiagen). The PCR primers, 
melting temperatures and amplicon sizes for the different PCR products can be found in 
Supplementary Table S1 together with the specific PCR programs for each DMR.
After confirming the amplicon size by gel electrophoresis, the PCR products were sequenced 
using a PyroMark Q24 pyrosequencer (Qiagen). Minor adjustments were made to the 
manufacturer’s protocol: to immobilize the PCR product 1 µL Streptadivin Sepharose High 
Performance Beads (GE Healthcare) was used per sequence reaction and annealing of the 
sequence primers was done for 3 minutes at 80°C. The sequence primers were added at a 
concentration of 10 µM. Human high and low methylated DNA (EpigenDx, Hopkinton, MA, 
USA) were used as controls. DNA methylation percentages were calculated by PyroMark 
Q24 software (Qiagen).
Statistical analysis
Differences in characteristics between the future cSCC and non-cSCC patients were 
statistically tested using SPSS version 21.0 (IBM Corp., Armonk, NY, US). The Mann-Whitney 
U test was used for the continuous variables and χ2 test for the categorical variables. Data 
processing and statistical analysis of all the microarray data was done in RStudio version 
1.0.136 (Rstudio Inc., Boston, MA, US) with R version 3.2.524. Cohen’s D was calculated on 
the residuals of the linear mixed-effect model by the formula D = (meancSCC-meannon-cSCC)/
sdpooled in R. Analysis of the differences between methylation in pre-transplantation and 
post-transplantation samples was done using a paired Wilcoxon ranked sum test using R. 
Correlation between the DNA methylation levels quantified by pyrosequencing and the 
beta-values of the Illumina 450k arrays was calculated using Spearman’s rank correlation 
coefficient using SPSS. All statistical tests were two-tailed and a p<0.05 was considered 
statistically significant.
Results
Differentially methylated regions 
To identify DMRs in T cells between patients who will develop cSCC after kidney 
transplantation and those without cSSC, we analyzed genome-wide DNA methylation of 
kidney transplant patients before transplantation. After cell sorting the T cells, we observed 
a difference in CD4/CD8 composition between the future cSCC and non-cSCC patients’ T 
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cells. The future cSCC patients had a higher percentage of CD4+ cells than the non-cSCC 
patients (p<0.001; Table 1). For this reason we included the percentage CD4+ and CD8+ 
in the linear mixed model as covariates, thereby avoiding potentially biased results with 
respect to the differences in DNA methylation. None of the single-site p-values passed 
the multiple testing correction (Supplementary Figure S1) therefore we continued to DMR 
analysis.
We found 16 regions significantly differentially methylated between the future cSCC and 
non-cSCC patients. In Table 4, the genes annotated to the DMRs, the genomic location of 
the DMRs according to the hg19 genome build (UCSC Genome Browser) and the number 
of array probes within the regions are presented, and the gene functions are shortly 
described. Also the Cohen’s D is presented per region which is a measure for effect size 
taking into account the standard deviation in the two groups . Out of the 16 DMRs, 5 were 
hyper methylated and 11 were hypo methylated in the future cSCC patients. 
Table 4. Resulting differentially methylated regions of the pre-transplantation analysis
Genomic location (hg19) Length 
DMR
no. of 
probes
Regional 
p-value
Cohen’s 
D
DMR 
state 
1 chr19:4531638-4531962 324 bp 4 3.57·10-11 0.95 Hyper
2 chr5:63461216-63461931 715 bp 10 5.51·10-10 -0.54 Hypo
3 chr3:44753865-44754399 534 bp 11 8.18·10-10 -0.6 Hypo
4 chr2:3699195-3699564 369 bp 5 9.35·10-10 0.81 Hyper
5 chr6:168197177-168197700 523 bp 6 6.54·10-9 -0.68 Hypo
6 chr4:165898666-165898968 302 bp 8 1.49·10-8 0.54 Hyper
7 chr5:140305947-140306459 512 bp 10 2.38·10-8 -0.53 Hypo
8 chr2:177014555-177015126 571 bp 12 4.35·10-8 0.41 Hyper
9 chr1:185703201-185703689 488 bp 12 1.89·10-7 -0.42 Hypo
10 chr6:30698584-30698988 404 bp 11 2.90·10-7 -0.48 Hypo
11 chr19:52391078-52391606 528 bp 12 6.59·10-7 0.58 Hyper
12 chr8:54164051-54164443 392 bp 8 1.20·10-6 -0.48 Hypo
13 chr7:51539131-51539584 453 bp 5 1.61·10-6 -0.64 Hypo
14 chr6:88757302-88757704 402 bp 6 1.80·10-6 -0.55 Hypo
15 chr2:74875227-74875549 322 bp 8 1.45·10-6 -0.47 Hypo
16 chr8:96085385-96085690 305 bp 3 1.22·10-5 -0.74 Hypo
DMR: differentially methylated region, chr: chromosome, bp: base pair
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Genomic characteristics of the DMRs
Since CpG islands are often found near transcription start sites (TSS) and are involved in 
transcription initiation32, methylation of CpG islands could have a downstream effect on 
gene activity. Together with the cell-type specific chromatin state of the DNA, this could 
indicate the biological function of a genomic region. In Figure 1A the CpG island content 
is depicted for all regions together and the individual DMRs separately, the array content 
is given as reference. The 16 DMRs are enriched for CpG islands, slightly less CpG sites are 
within the shores (<2kb flanking CpG islands) and CpG sites within shelves (<2kb flanking 
shores) are absent in these DMRs. For the chromatin state, we annotated the CpG probes 
within each DMR to ROADMAP epigenomics reference data of primary T cells using the 
15-state model16 (Figure 1B). Although this might not be an accurate representation of the 
chromatin state within the T cells we analyzed, it does provide a general perspective on 
functional and primary T-cell specific characteristics of the genomic region where the DMRs 
are located. The chromatin states ‘flanking bivalent TSS/enh’ and ‘bivalent enhancer’ are 
enriched in our results, also 7 out of the 16 DMRs are within repressed or weakly repressed 
polycomb which is a slight enrichment compared to the array content. 
DNA methylation of the DMRs after transplantation
To study whether DNA methylation of the 16 DMRs changed after transplantation, we 
compared beta-values of 11 cSCC patients before and after transplantation. Figure 2A 
shows the mean difference in beta-value which is an average of all CpG sites per region 
for all 11 patients together. Overall mean beta-value increased after transplantation. In 
most regions there were CpG sites that increased and CpG sites that decreased, therefore 
showing a mean difference close to zero. All differences in beta-value per DMR and per 
patient can be found in Supplementary Figure S2. A paired Wilcoxon ranked sum test per 
region resulted in 9 regions that were significantly different after transplantation, after a 
Bonferroni multiple testing correction (Table 5).
All CpG sites showed variation within all patients, therefore to reduce noise and improve 
clarity we considered a CpG site that increased or decreased less than 0.05 in beta-value 
stable. None of the DMRs were 100% stable in time (Figure 2B) however, some regions 
showed more stability than others. DMRs 1, 5, 9, 14 and 16 showed at least 50% stable CpG 
sites whereas in DMRs 4, 11 and 13 none of the sites were stable in time. A more detailed 
graphical representation of the changes in beta-value per region, per patient and in time 
can be found in Supplementary Figure S3.
We also analyzed the mean methylation differences per patient to examine a possible 
relationship with time after transplantation and with time to clinical onset of the cSCC 
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A
B
Figure 1. The genomic characteristics of the CpG sites within each DMR. A) CpG island 
content for all regions together and the individual DMRs separately, the array content is 
given as reference. The color represents the CpG island content of each CpG site within 
that region according to the legend below the graph. B) Primary T-cell specific chromatin 
state according to the 15-state model of the ROADMAP epigenomics reference data16 for 
all regions together and the individual DMRs separately, the array content is given as 
reference. The color represents the primary T-cell specific chromatin state of the CpG sites 
within that region according to the legend below the graph.
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(Table 3). These mean differences were 
relatively small in 5 out of 11 patients (Δbeta-
value<0.01) (Figure 3). Mean methylation 
differences were not significantly correlated 
to the time between transplantation and 
clinical onset of cSCC (p=0.46), nor to time 
after transplantation (p=0.50), nor to time 
between post-transplant sample and the 
clinical onset of cSCC (p=0.09). 
Technical validation
To confirm the raw beta-values obtained 
with the 450k array, we performed 
pyrosequencing analysis of two DMRs 
(6 CpG sites) on the same DNA samples 
that were analyzed on the array. The 
DNA methylation values obtained with 
pyrosequencing were slightly lower than 
the beta-values obtained with the arrays, 
this was a consistent deviation across all 
samples (Figure 4). There was a strong 
correlation between the results obtained 
with the two different techniques; the two sites within DMR 2 had a Spearman correlation 
coefficient (r) of 0.95 (p<0.0001) and the 4 sites within DMR 3 had an r of 0.88 (p<0.0001).
Discussion
Our results demonstrate that the T cells of patients with a future post-transplant cSCC 
have different DNA methylation profiles compared to the T cells of kidney transplant 
patients without cSCC. To our knowledge this is the first study to show DNA methylation 
differences in peripheral T cells between patients who develop a post-transplant cSCC 
and those who do not develop cSCC. In addition, we were able to obtain these results at a 
clinically relevant time point, before transplantation. The retrospective nature of this study 
allowed us to carefully match the future cSCC patients to non-cSCC patients and examine 
the DNA methylation within a highly enriched T-cell population. 
The observed differences in DNA methylation are predominantly located in CpG islands 
and bivalent enhancer regions (Figure 1). Since these are both regulatory genomic regions, 
it is likely that these differences have a downstream effect in T cells and that differential 
Table 5. Results of statistical tests between 
pre-transplant and post-transplant beta-
values per region
DMR P value Bonferroni 
correction
1 0.87
2 1.83·10-6 2.92·10-5
3 2.03·10-5 3.25·10-4
4 0.002 0.038
5 0.082
6 0.55
7 8.09·10-8 1.29·10-6
8 0.002 0.033
9 1.51·10-5 2.41·10-4
10 3.71·10-13 5.93·10-12
11 0.028
12 9.42·10-5 0.002
13 0.14
14 0.32
15 5.48·10-5 8.78·10-4
16 0.33
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DNA methylation within these regions could affect T-cell function. Though, the effect 
of differential methylation at enhancer regions is difficult to assess since enhancers can 
regulate genes at large distances in the genome33. RNA sequencing would reveal any distal 
gene regulation by these enhancers, however that was outside the scope of this study. 
Here we focus on the genes that were annotated solely on the basis of close proximity to 
the DMR. 
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Figure 2. Stability of the 16 DMRs. A) Mean difference in beta-value per region between 
pre-transplant and post-transplant samples. The difference is calculated per CpG site for 
each individual patient and is then averaged over all CpG sites per region for all 11 cSCC 
patients together. B) Percentage of CpG sites that show a Δbeta-value of less than 0.05 
presented per region. The numbers within each bar represent the number of stable CpG 
sites from the total sites within that region.
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Out of the 16 DMRs a few could be associated to cancer by studying literature. Even though 
these studies were not performed in T cells but mostly in the tumor tissue itself, we can 
speculate on a possible relationship with post-transplant cSCC development. An example 
is DMR 11 (annotated to ZNF577) which was hypermethylated in our future cSCC patients, 
showed to be hypermethylated in SCC and adenocarcinoma of the lungs34. In addition, 
an inverse correlation between ZNF577 gene expression and its DNA methylation was 
found35. DMR 10, which was situated within the actively transcribed gene FLOT1, was hypo 
methylated in our cSCC patients. At first sight an interesting gene due to its involvement 
in migration of hematopoietic cells36 and it showed to promote invasion and metastasis of 
several SCC subtypes when overexpressed37,38. However, in the longitudinal analysis this 
was the most varying region (Table 5) with the majority of CpG sites increasing in DNA 
methylation after transplantation (Figure S2J). This suggests that this region is greatly 
influenced by transplantation and it remains unsure how this differential methylation at 
time of transplantation could affect post-transplant cSCC development.
A kidney transplantation is a procedure with major health effects for an end-stage renal 
disease (ESRD) patient and these effects influence DNA methylation. Several studies have 
shown that blood DNA methylation is associated to kidney function39,40. In addition to that, 
we showed in a previous study that DNA methylation of T cells can also be modulated 
by the immunosuppressive medication that kidney transplant patients receive after 
transplantation41. We therefore expected variation between the pre-transplant and post-
transplant DNA methylation values in the longitudinal analysis. Indeed, we see that beta-
values were significantly different in 9 of the 16 DMRs (Table 4). More interestingly, all but 
one region increased in mean DNA methylation after transplantation (Figure 2). This could 
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Figure 3. Mean difference in beta-value per patient between pre-transplant and post-
transplant sample. The difference was calculated per CpG site for each individual patient 
and was then averaged over all CpG sites per patient.
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be a general effect of the transplantation and is in line with findings by Boer et al.42 showing 
increased DNA methylation at the PD1 and IFNγ gene 3 months after transplantation.
To determine which regions could have a lasting effect on post-transplant cSCC 
development, we examined stability of the 16 DMRs after transplantation and considered 
the CpG sites that stayed within a Δbeta-value of 0.05 stable. DMRs 1, 5, 14 and 16 have 
50% or more stable CpG sites and were also not significantly different in a paired statistical 
analysis (Table 4), suggesting that these differential methylation profiles might have a 
prolonged effect after transplantation. Considering the possibility of distal gene regulation 
by these DMRs, their functional effect could be determined by a genome-wide RNA and 
protein analysis within these T cells. Additionally, to overcome the variability in sampling 
time points within this study, a prospective study with sampling at regular intervals after 
transplantation would further assess stability of these DMRs and their function in post-
transplant cSCC development. 
The development of post-transplant cSCC is the result of a series of events involving 
different risk factors2. Known examples are age, skin type, gender and possibly immune 
phenotype43. After cell-sorting the T cells, we found significantly higher percentages 
of CD4+ T cells and consequently lower percentages of CD8+ T cells in the future cSCC 
patients (Table 1). This suggests that an altered CD4/CD8 ratio might be another risk 
factor for post-transplant cSCC. There is no consensus in literature on the CD4/CD8 ratio 
in relation to post-transplant cancer development. In contrast to our findings Thibaudin et 
al.44 found, over a 10-year observation period, consistently lower counts of CD4+ T cells in 
patients with future post-transplant malignancy. Although this was not evident at time of 
transplantation but occurred thereafter. Whereas Bottomley et al.14 found no significant 
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Figure 4. Methylation values on the array and by pyrosequencing of 6 CpG sites within 
two DMRs. A) DMR 2 (r=0.95; p<0.0001) B) DMR 3 (r=0.88; p<0.0001). The CpG sites 
correspond to the CpG sites within the DMRs (Table 4). 
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difference in CD4+ T cell and CD8+ T cell counts or percentages between SCC and non-
cSCC kidney transplant patients. 
The relative small sample size in this study is a consequence of selective matching and 
availability of biobank material. This combined with the single-center design of the study 
leads to cautious interpretation of the findings. Moreover, we acknowledge that patient 
pairs can never be perfectly matched. Since we are studying T cells and not skin tissue, 
where the differences between healthy and malignant tissue are much larger, it was 
expected that the differences would be subtle. Despite these limitations the results of this 
study are a promising first step towards early risk assessment for post-transplant cSCC. To 
assess the clinical value of these findings, a validation in a different and larger cohort of 
transplant patients is necessary in addition to our technical validation45,46. 
Conclusion
The findings presented here demonstrate the potential of studying DNA methylation of the 
T cells to identify kidney transplant patients at risk for de novo post-transplant cSCC 47. We 
showed that there were systemic differences between future cSCC and non-cSCC patients 
prior to transplantation. A longitudinal analysis showed that several DNA methylation 
profiles remained relatively stable after transplantation, suggesting a lasting effect on the 
development of de novo cSCC after transplantation. In the future, identification of patients 
at increased risk for post-transplant cSCC before transplantation will allow for early clinical 
interventions such as regular visits to the dermatologist and stricter life-style advise to the 
patient to minimize additional sun-exposure 48. Ultimately it may lead to adjustment of 
the immunosuppressive load but this remains a fine balance between reducing the risk for 
cancer and causing irreversible damage to the allograft.
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Supplementary Tables 
Table S1. PCR primers, sequence primers and PCR programs for technical validation
DMR Primers (Forward, Reverse and Sequence) Amplicon 
size
CpG sites 
(Illumina ID)
RNF180 F: 5’-GGTGGAATTTTAGGTATAAGAAGGTAA-3’ 229 bp
R: 5’-biotin-AAACCACAAAAATTATCCCTATAATCTCC-3’
S: 5’-ATTTTAGGTATAAGAAGGTAAG-3’ cg17621438 , 
cg07850154
PCR program: 15 min at 95°C, 45 cycles of 30 s 94°C, 30 s 58°C, 30 s 72°C followed by 
10 min at 72°C
ZNF502 F: 5’-TTTAGAGGTGGATTGGGGTTAGGATATTA-3’ 159 bp
R: 5’-biotin-AAATACCTTCTTCTAAAATCCCATAAAA-3’
S: 5’-GGATATTAGTTTTAATTTTTGAAAT-3’ cg21672276, 
cg10263370, 
cg11003573, 
cg15687855
PCR program: 15 min at 95°C, 45 cycles of 30 s 94°C, 30 s 58°C, 30 s 72°C followed by 
10 min at 72°C
F: Forward primer, R: Reverse primer, S: Sequence primer, bp: basepair, min: minutes, s: seconds
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Supplementary Figures
Manha�an plot
Figure S1: A Manhattan plot showing all individual CpG sites and their p-values. On the 
y-axis the –log10 of the p-value is depicted, the genome wide significance line in red is on 
–log10(1.18·10
-7), and on the x-axis is the genomic location of all the sites, split up in the 
different chromosomes. The dots in green represent the CpG sites that are in the significant 
DMRs.
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Figure S3A-F. CpG sites within DMR 1-6 that differ more than 0.05 in beta-value, 
colored per patient. The y-axis shows  beta-value and the x-axis time in years after 
transplantation. Time points after transplantation are clustered in 0-1 years (N=3), 1-3 
years (N=3), 3-5 years (N=2) and 5+ years (N=3).
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Figure S3G-L. CpG sites within DMR 7-12 that differ more than 0.05 in beta-value, 
colored per patient. The y-axis shows  beta-value and the x-axis time in years after 
transplantation. Time points after transplantation are clustered in 0-1 years (N=3), 1-3 
years (N=3), 3-5 years (N=2) and 5+ years (N=3).
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Figure S3M-P. CpG sites within DMR 13-16 that differ more than 0.05 in beta-value, 
colored per patient. The y-axis shows  beta-value and the x-axis time in years after 
transplantation. Time points after transplantation are clustered in 0-1 years (N=3), 1-3 
years (N=3), 3-5 years (N=2) and 5+ years (N=3).
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Abstract 
Cutaneous squamous cell carcinoma (cSCC) is a serious complication after organ 
transplantation and patients benefit from an early risk assessment. We hypothesized that 
functional differences in circulating T cells may represent risk factors for post-transplant 
cSCC development. Here we analyzed genome-wide DNA methylation of circulating T cells 
of kidney transplant recipients before the clinical onset of cSCC, to identify differences 
associated with post-transplant cSCC development. This analysis identified higher DNA 
methylation of SERPINB9, which is an intracellular inhibitor of granzyme B, a protein 
that induces apoptosis in target cells. High DNA methylation of SERPINB9 in circulating 
T cells was confirmed in a second patient cohort, during recurrent cSCC, indicating that 
high SERPINB9 methylation represents a persistent risk factor for cSCC development. At 
the functional level, the inverse correlation between DNA methylation and messenger 
RNA expression present in non-cSCC patients was absent in the cSCC patients. Also, a 
significant difference in serpinB9 protein expression between cSCC patients and non-cSCC 
patients was observed. Concluding that disturbed regulation of serpinB9 in circulating T 
cells represents a novel risk factor for post-transplant cSCC in kidney transplant recipients.
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Introduction
Immunosuppression after organ transplantation is associated with a higher prevalence 
of cancer1,2. Especially non-melanoma skin cancer such as cutaneous squamous cell 
carcinoma (cSCC) occurs up to 200 times more in the transplanted population than in the 
general population3-5. Transplant recipients also experience more metastasis and over 70% 
of the patients develop a subsequent cSCC within 5 years6. Although immunosuppressive 
treatment is recognized as an important risk factor for the development of cSCC after 
solid organ transplantation, not much is known on the immune regulation leading up to 
formation of cSCC.
Most cSCCs are surrounded by immune cell infiltrates, however, these cells are incapable 
of mounting an effective immune response directed against the cSCC7. The role and 
phenotype of T cells surrounding an cSCC lesion has been studied extensively8-10; high 
numbers of FOXP3+ regulatory T cells are associated with higher metastasis of cSCCs11,12 
whereas increased activity of effector and cytotoxic T cells often associates with better 
prognostic outcomes13,14. 
The function of cells, including T cells, is regulated by epigenetic mechanisms such as 
DNA methylation, which is the addition of a methyl group to a cytosine (C) followed by 
a guanine (G; CpG dinucleotide) in the DNA. DNA methylation controls gene expression, 
is a dynamic feature and can be influenced by environmental cues15. DNA methylation is 
also known to be dysregulated in disease such as cancer, however it is often difficult to 
determine whether it is a driver or a consequence of the disease16,17. 
Here, we hypothesized that functional differences in circulating T cells represent risk 
factors in the development of a de novo post-transplant cSCC. To address this hypothesis, 
we took an unbiased approach and performed genome-wide DNA methylation analysis 
of circulating T cells after kidney transplantation but before the clinical onset of cSCC 
(discovery phase). DNA methylation profiles of kidney transplant recipients with a future 
cSCC were compared to those of matched kidney transplant recipients without cSCC. The 
prominent finding of this analysis was higher methylation of a region within SERPINB9 in 
cSCC patients. SerpinB9 is an intracellular serine protease inhibitor that inhibits granzyme 
B18,19, which is an important protease in the effector function of cytotoxic T cells by inducing 
apoptosis in target cells20. Cytotoxic T cells express serpinB9 to protect themselves against 
the activity of granzyme B, therefore high expression of serpinB9 in cytotoxic T cells makes 
them more potent killers21,22. Given these data, the finding on SERPINB9 DNA methylation 
prompted us to further study SERPINB9 methylation in a second cohort of kidney transplant 
recipients with recurrent cSCC, as well as the functional role of SERPINB9 in cSCC on the 
level of mRNA and protein expression. 
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Materials and methods
Study design
Anonymized retrospective biobank samples were used in the discovery phase of the study, 
this included kidney transplant recipients before the diagnosis of their first post-transplant 
cSCC. A second cohort of patients was used to confirm findings from the discovery phase 
and this included kidney transplant recipients during recurrent post-transplant cSCC. 
The use of biobank material and the inclusion of new patients had been approved by the 
local medical ethical committee (MEC-2015-642). All kidney transplant recipients with a 
(future) post-transplant cSCC were matched to kidney transplant recipients who did not 
develop an cSCC within a similar time period after the first transplant. Matching criteria 
included gender, age (± 4 years), ethnicity, cytomegalovirus (CMV) status and type of 
immunosuppressive drugs directly after transplantation. We included patients with at least 
one cSCC after transplantation and patients with cSCC in situ (Bowen’s disease). Patients 
with another donor organ such as liver, heart or lung were excluded, as well as patients with 
a history of malignancy prior to transplantation. Non-cSCC patients with actinic keratosis, 
a pre-cancerous lesion, were also excluded. 
T cell isolation
Peripheral blood mononuclear cells (PBMCs) were isolated using standard Ficoll-Paque 
procedures. T cells were isolated from the PBMCs using fluorescence-activated cell sorting 
(FACS) with the BD FACSAriaTM ll (BD Biosciences, San Jose, CA, US). Total PBMCs were 
stained with CD3 Brilliant Violet 510 (Biolegend, San Diego, CA, US), CD4 Pacific Blue (BD 
Biosciences), CD8 APC-cy7 (BD Biosciences), CD45RO APC (Biolegend), CCR7 PE-cy7 (BD 
Biosciences), CD25 PE (BD Biosciences), CD127 FITC (eBioscience, Waltham, MA, US) and 
to exclude nonviable cells Via-Probe 7AAD (BD Biosciences) was used. After cell sorting the 
purities were >96% for CD3+ cells, samples below 95% were excluded for further analysis.
Genome-wide DNA methylation arrays
Before isolating DNA from the T cells in the discovery cohort, all patient samples were 
randomized to minimize batch effects. DNA was isolated using the QIAamp DNA Micro 
kit (Qiagen, Venlo, The Netherlands) according to the manufacturer’s protocol. Purity 
and concentration of the isolated DNA was assessed with the NanoDrop ND-8000 
(Isogen Life Science, Utrecht, The Netherlands). DNA degradation was determined by gel 
electrophoresis, none of the samples showed significant degradation. 
The Infinium HumanMethylation450 arrays (Illumina, San Diego, CA, US) were performed 
as described previously23. Data quality was examined using the MethylAid R package24,25 
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and all samples passed quality controls using the default MethylAid thresholds. Probes with 
a detection p-value>0.01, probes containing single nucleotide polymorphisms and probes 
on the sex chromosome were removed from the dataset. A between-array normalization 
was applied to the Type Ι and Type ΙΙ probes separately using the DASEN method within the 
wateRmelon Bioconductor R package25-27. The methylation level of a CpG site is presented 
as a beta-value, a value between 0 (unmethylated) and 1 (fully methylated). After the 
quality controls and normalization, beta-values of 423,289 CpG sites remained for further 
analysis. Both the raw and normalized data are available via the NCBI Gene Expression 
Omnibus (GEO) database with accession number GSE117050.
Data analysis DNA methylation arrays
To identify DNA methylation differences between the future cSCC and non-cSCC patients, 
we performed the data analysis as previously described23. First, a linear mixed-effect model 
was performed using the lme4 R package28. The fixed effects included age, percentage 
CD4, percentage CD8 and CMV status. Percentage CD4 and CD8 were included to correct 
for differences in T-cell composition between individuals and CMV is known to affect DNA 
methylation at specific genes29. Array IDs were included as a random effect to account for 
technical variation between the arrays. This resulted in single site-specific p-values and 
these p-values together with their genomic location, were used as input into comb-p30 to 
find differentially methylated regions (DMRs). A sliding window of 500 base pair (bp) was 
used and the seed was set at p<0.01. A stringent multiple testing correction was applied 
using a Šidák correction (Šidák<0.05)31.
DNA methylation analysis by pyrosequencing
After the discovery phase we continued measuring DNA methylation of T cells with 
bisulfite pyrosequencing, an easy technique to quantitatively measure single-site DNA 
methylation32, but first we tested whether pyrosequencing resulted in the same methylation 
values as with the microarrays. Therefore CpG sites within DMR 1 (SERPINB9) and DMR 2 
(VTRNA2-1) were analyzed in the same DNA samples that were used for the array analysis 
of 10 patients, a mixture of cSCC and non-cSCC patients.
Pyrosequencing was performed as described previously23,33. The polymerase chain reaction 
(PCR) primers, melting temperatures and amplicon sizes for the different PCR products 
can be found in Supplementary Table S1 together with the specific PCR programs. For 
SERPINB9, 12 CpG sites of which 5 were array probes, were sequenced in two separate 
reactions and DNA methylation was averaged per sequence reaction (region 1 and region 
2). For VTRNA2-1, 5 CpG sites of which 3 were array probes, were measured and an average 
of those 5 sites is presented in the results. 
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mRNA analysis
Total RNA was isolated from T cells using the High Pure RNA Isolation kit (Roche Applied 
Science, Pennsburg, Germany) according to the manufacturer’s protocol. The quality 
and purity of the RNA was assessed using the NanoDrop ND-8000 (Isogen Life Science). 
Samples with a 260/280 ratio below 1.8 and a 260/230 ratio above 1 were excluded for 
further analysis. Messenger RNA (mRNA) of SERPINB9 and GRANZYME B (GZMB) was 
quantified by real-time quantitative PCR (qPCR) using a Taqman gene expression assay. 
Primers used were Hs00394497_m1 (SERPINB9; Thermo Fisher Scientific, Waltham, MA, 
US) and Hs01554355_m1 (GZMB; Thermo Fisher Scientific), GAPDH (Hs99999905_m1, 
Thermo Fisher Scientific) was used as housekeeping gene. qPCR was performed on the 
StepOnePlus Real-Time PCR system (Applied Biosystems). Gene expression was then 
calculated by transforming the cycle threshold (Ct) to cDNA copies (240-Ct). Dividing the 
number of SERPINB9 and GZMB copies by the number of GAPDH copies resulted in a 
relative gene expression value.
Protein analysis
Protein levels of serpinB9 and granzyme B within T cells were assessed in cells before and 
after stimulation for 6 hours at 37°C with or without α-CD3/CD28 coated Dynabeads® 
(Gibco, Waltham, MA, US). The cells were measured by flow cytometry directly after 
defrosting the PBMCs. Monensin was added after 1 hour of stimulation, by this newly 
synthesized granzyme B could be measured. CD107a APC (BD Biosciences) was added to 
the cell cultures to assess degranulation of the cells. Cells were stained with the following 
surface antibodies: CD3 Brilliant Violet 510 (Biolegend), CD4 APC-cy7 (Biolegend), CD8 
PE (Thermo Fisher Scientific) and Via-Probe 7AAD (BD Biosciences) was used to exclude 
nonviable cells. After surface staining the cells were fixed, permeabilized and stained 
for intracellular serpinB9 labelled with Alexa Fluor 488 (Bio-rad, Hercules, CA, US) and 
granzyme B labelled with Brilliant Violet 421 (BD Biosciences). Isotype controls for AF488 
(Bio-rad) and BV421 (BD Biosciences) were used as negative controls for serpinB9 and 
granzyme B expression. The cells were then analyzed on the FACSCanto ll (BD Biosciences) 
with FACSDiva software. Data was analyzed blind, without knowledge on cSCC status of 
the samples, using Kaluza software 1.5a (Beckman Coulter, Brea, CA, US).
Statistical analysis
Differences in clinical characteristics, DNA methylation, mRNA and protein expression 
between the cSCC and non-cSCC patients were statistically tested using SPSS version 
21.0 (IBM Corp., Armonk, NY, US). The Mann-Whitney U test was used for the continuous 
variables and χ2 test for the categorical variables. Data processing and statistical analysis of 
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all the microarray data was done in RStudio version 1.0.136 (Rstudio Inc., Boston, MA, US) 
with R version 3.2.526. Multiple testing correction of the microarray data was done using a 
Šidák correction (Šidák<0.05)31. Correlation between the DNA methylation levels quantified 
by pyrosequencing and the beta-values of the Illumina 450k arrays was calculated using 
Spearman’s rank correlation coefficient using SPSS as well as correlations between DNA 
methylation and mRNA expression. All statistical tests were two-tailed and a p<0.05 was 
considered statistically significant.
Results
Patients
The discovery cohort consisted of 19 future cSCC and 19 non-cSCC patients who had been 
transplanted between 1997 and 2012. All patients in the discovery cohort were Caucasian-
European. No statistical differences were found between the patient characteristics of the 
future cSCC and non-cSCC patients (Table 1). A detailed overview of the time between 
transplantation, sample and first diagnosis of cSCC can be found in Figure S1A.
The second cohort consisted of 37 non-cSCC and 45 cSCC patients during recurrent cSCC, 
who had been transplanted between 1976 and 2014. Six cSCC patients and 5 non-cSCC 
patients received a second kidney transplant. All patients in the second cohort were 
Caucasian-European. There was a small statistical difference in the end-stage renal disease 
(ESRD) diagnosis between the cSCC and non-cSCC patients (p=0.04; Table 2), no other 
statistical differences were found. A detailed overview of the time between transplantation, 
sample and first diagnosis of cSCC can be found in Figure S1B.
Discovery of significant DMRs in circulating T cells before cSCC
To identify differentially methylated regions (DMRs) in circulating T cells associated 
to future cSCC development, we compared genome-wide DNA methylation of kidney 
transplant recipients with and without a post-transplant cSCC, before the clinical onset of 
the cSCC. None of the single-site CpGs were statistically significant after multiple testing 
correction. However, we found 7 regions significantly differentially methylated. In Table 
3 the different DMRs, the genes annotated to these DMRs based on genomic location, 
the genomic location of the DMRs according to the hg19 genome build (UCSC Genome 
Browser), the number of probes (CpG sites on the array) within the regions and the effect 
size is presented. Out of the significant DMRs, 5 were hyper methylated and 2 were hypo 
methylated in the future cSCC patients.
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Table 1. Patient characteristics of the discovery cohort before cSCC
cSCC
N = 19
non-cSCC
N = 19
Age (years)a 64.8 (45-77) 63.5 (45-80) p=0.49
Gender (male) 14 (73.7%) 14 (73.7%) p=1
Years post Txa 1.5 (0.1-6.9) 1.3 (0.1-6.3) p=0.93
Years between Tx and first cSCCa 5.4 (0.9-12.5) -
Biopsy proven rejection - 3 (15.8%) p=0.07
Immunosuppressive treatment
       Induction therapy (ATG/
       Basiliximab)
7 (36.8%) 5 (26.3%)
       Calcineurin inhibitors (Tacrolimus/
       Cyclosporine)
19 (100%) 18 (94.7%)
       Proliferation inhibitors (MMF/ 
       Sirolimus)
18 (94.7%) 19 (100%)
       Antimetabolites (Azathioprine) 1 (5.3%) -
       Corticosteriods 18 (94.7%) 19 (100%)
HLA mismatchesa 3.11 (0-6) 3.11 (0-6) p=0.94
CMV serostatus acceptor p=1
       Negative 4 (21.1%) 4 (21.1%)
       Positive 15 (78.9%) 15 (78.9%)
CMV serostatus donor p=0.11
       Negative 12 (63.2%) 7 (36.8%)
       Positive 7 (36.8%) 12 (63.2%)
ESRD diagnosis p=0.26
       Polycystic kidney 7 (36.8%) 2 (10.5%)
       Hypertension 3 (15.8%) 6 (31.6%)
       Diabetic Nefropathy 1 (5.3%) 1 (5.3%)
       Glomerulonefritis 1 (5.3%) 0 (0%)
       Other 7 (36.8%) 10 (52.6%)
Dialysis pre-transplantation p=0.49
       Yes (PD/HD) 14 (73.7%) 12 (63.2%)
       No 5 (26.3%) 7 (36.8%)
amedian and range; cSCC: cutaneous squamous cell carcinoma, Tx: transplantation, ATG: anti-
thymocyte globulin, MMF: mycophenolate mofetil, HLA: human leukocyte antigen, CMV: 
cytomegalovirus, ESDR: end stage renal disease, PD: peritoneal dialysis, HD: hemodialysis
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Table 2. Patient characteristics of the second cohort during cSCC
cSCC
N=45
non-cSCC
N=37
Age (years)a 66.4 (34-84) 64.0 (28-75) p=0.20
Gender (male) 30 (66.7%) 25 (67.6%) p=0.93
Years post Txa 8.5 (0.4-40.5) 9.5 (0.1-35.9) p=0.89
Years between Tx and first cSCCa 4.7 (0-33) -
Biopsy proven rejection 12 (26.7%) 13 (35.1%) p=0.41
Immunosuppressive treatment
       Induction therapy (ATG/
       Basiliximab)
1 (2.2%) 6 (16.2%)
       Calcineurin inhibitors (Tacrolimus/
       Cyclosporine)
37 (82.2%) 34 (92%)
       Proliferation inhibitors (MMF/
       Sirolimus)
27 (60%) 22 (59.5%)
       Antimetabolites (Azathioprine) 9 (20%) 4 (10.8%)
       Corticosteriods 44 (97.8%) 37 (100%)
HLA mismatchesa 3.0 (0-6) 3.0 (0-6) p=0.86
CMV serostatus acceptor p=0.74
       Negative 17 (37.8%) 11 (29.7%)
       Positive 22 (48.9%) 20 (54.1%)
       Unknown 6 (13.3%) 6 (16.2%)
CMV serostatus donor p=0.62
       Negative 15 (33.3%) 14 (37.8%)
       Positive 18 (40%) 11 (29.7%)
       Unknown 12 (26.7%) 12 (32.4%)
ESRD diagnosis p=0.04
       Polycystic kidney 11 (24.4%) 5 (13.5%)
       Hypertension 8 (17.8%) 7 (18.9%)
       Diabetic Nefropathy - 7 (18.9%)
       Glomerulonefritis 7 (15.6%) 4 (10.8%)
       Other 19 (42.2%) 14 (37.8%)
Dialysis pre-transplantation p=0.83
       Yes (PD/HD) 22 (48.9%) 19 (51.4%)
       No 23 (51.1%) 18 (48.6%)
amedian and range; cSCC: cutaneous squamous cell carcinoma, Tx: transplantation, ATG: anti-
thymocyte globulin, MMF: mycophenolate mofetil, HLA: human leukocyte antigen, CMV: 
cytomegalovirus, ESDR: end stage renal disease, PD: peritoneal dialysis, HD: hemodialysis
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Genomic characteristics of DMR 1, 2 and 3
To understand the potential regulatory effect of the DMRs in T cells, the genomic location 
of the DMR and characteristics of that location are important. In Figure 1 we visualized the 
top three DMRs with DNA methylation, of both cSCC and non-cSCC patients expressed in 
beta-value, the genomic location of the DMRs and the primary T-cell specific chromatin 
state, which is a cell-type specific combination of epigenetic features obtained from the 
ROADMAP reference data34. DMR 1, annotated to SERPINB9, is located intragenic and 
within an actively transcribed region (Figure 1A). DMR 2, annotated to VTRNA2-1, is located 
in the coding region and a bivalent/poised transcription start site (TSS) of the gene (Figure 
1B). DMR 3, also annotated to VTRNA2-1, is located further away from the VTRNA2-1 gene 
and partly within a bivalent enhancer region and partly within a repressed area (Figure 1B). 
All three DMRs overlap with a CpG island and those are often involved in the regulation of 
gene expression.
Confirmation of microarray methylation values by pyrosequencing
To confirm that the above described findings can also be found with a different technique, 
DNA methylation of DMRs 1 and 2 was measured by pyrosequencing in the same DNA 
samples. Correlation between DNA methylation values obtained with the microarray and 
pyrosequencing was strong in both DMRs (Supplementary Figure S2). Spearman r for 
SERPINB9 was 0.86 (p<0.0001) and for VTRNA2-1 r was 0.96 (p<0.0001). As a result of this 
strong correlation, we measured DNA methylation with pyrosequencing throughout the 
rest of the study. 
High intragenic SERPINB9 methylation during cSCC
To assess the stability of the DNA methylation profiles identified before development of 
cSCC, we included a second patient cohort during recurrent cSCC (Table 2). VTRNA2-1 was 
measured and was not significantly different between cSCC and non-cSCC patients (data 
not shown). When SERPINB9 was measured it was significantly different between cSCC 
and non-cSCC patients. Median DNA methylation of SERPINB9 was 58.7% (range: 32.5%-
81.3%) for region 1 and 54.4% (30.0%-78.5%) for region 2 in the cSCC patients and 50.2% 
(21.8%-77.5%) for region 1 and 46.4% (22.1%-74.0%) for region 2 in the non-cSCC patients 
(region 1: p=0.004; region 2: p=0.008) (Figure 2). 
Similar as in our discovery cohort, cSCC patients demonstrated higher SERPINB9 
methylation values than non-cSCC patients. In addition, serpinB9 has a strong relation 
to T-cell functions, as a regulator of cytotoxicity21,22. Together, these findings warranted 
further investigation into the role of SERPINB9 in controlling the cytotoxic T cells that are 
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Figure 1. Genomic characteristics of DMR 1 to 3. The chromatin state specific for primary 
T cells of SERPINB9 A) and VTRNA2-1 B) is depicted with the CpG islands below in purple. 
The location of the DMRs are highlighted by the orange dotted lines. The graphs present 
the raw beta-values (y-axis) and the genomic location of the single CpGs (x-axis), cSCC 
patients are depicted in red and the non-cSCC in green. The transcription start site (TSS) 
is the promoter of a gene, enhancers are locations that bind gene activating or repressing 
proteins such as transcription factors and repressed polycomb represents inactive DNA.
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key for immunosurveillance in post-
transplant cSCC. 
mRNA expression negatively 
correlates to DNA methylation only 
in the non-cSCC patients
To study the translation from DNA 
to protein of serpinB9, we analyzed 
mRNA expression of SERPINB9 in T 
cells. Relative mRNA expression of 
SERPINB9 was not significantly 
different between cSCC (N=30) and 
non-cSCC patients (N=27; Figure 
3A). When we zoom in and study 
the correlation between DNA methylation and mRNA expression of SERPINB9 in the total 
patient population this was statistically significant (p=0.004,Figure 3B). However, when 
we stratified the data by cSCC status the correlation remained significant only in the non-
cSCC patients (p=0.0003; Figure 3C,D) and not in the cSCC patients, indicating a disrupted 
transcriptional regulation in the cSCC patients.
Lower serpinB9 expression in circulating T cells of cSCC patients
To investigate the functional impact of differentially methylated SERPINB9 on cytotoxicity, 
we analyzed the expression of the following markers: granzyme B (inhibited by serpinB9) 
and degranulation of T cells by CD107a expression before and after stimulation. Gating 
strategies for granzyme B and CD107a are presented in Supplementary Figure S3. The 
percentage of CD3+granzyme B+ cells was not significantly different between the cSCC 
patients and non-cSCC patients (Supplementary Figure S4A) and neither was degranulation 
of the T cells as determined by CD107a staining (Supplementary Figure S4B). 
SerpinB9 expression was also measured in the T cells. Gating strategy for serpinB9 is 
presented in Supplementary Figure S5. The percentage of CD3+serpinB9+ cells before 
stimulation was not significantly different between cSCC and non-cSCC patients (Figure 
4A). After stimulation serpinB9 expression in all T cells was upregulated to 98.2% (93.0%-
99.0%) for the cSCC patients and 99.1% (97.2%-99.7%) for the non-cSCC patients and 
this was significantly different even though the differences were small (p=0.006; Figure 
4B). When analyzing serpinB9 expression in the CD4+ and CD8+ population separately, 
we observed that the percentage of CD4+serpinB9+ cells was significantly lower in the 
cSCC patients than in the non-cSCC patients after stimulation (Figure 4C). In the CD8+ 
Region 1 Region 2
%
 m
et
hy
la
�
on
** **
DNA methyla�on
SERPINB9
cSCC pa�ents
non-cSCC pa�ents
Figure 2. DNA methylation in T cells of cSCC 
and non-cSCC patients for region 1 and 2 
of SERPINB9 measured by pyrosequencing. 
**p<0.01
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population this difference was not observed (Figure 4D). These results show that the CD4+ 
population is the main contributor to the difference observed in the total T-cell population. 
Discussion
In this study we demonstrate high DNA methylation of SERPINB9 in circulating T cells 
before the clinical onset of cSCC in kidney transplant recipients and, in a different patient 
cohort, during recurrent post-transplant cSCC. These data identify high DNA methylation 
of SERPINB9 as a novel risk factor for development of both de novo and subsequent post-
transplant cSCC. In addition to that, T cells of cSCC patients were unable to fully upregulate 
serpinB9 expression in vitro, which might provide insight in the role of the peripheral 
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Figure 3. Relative mRNA expression of SERPINB9 A) in cSCC versus non-cSCC patients, 
B) as correlated to SERPINB9 DNA methylation (x-axis) within all patients, C) within the 
cSCC patients and D) within the non-cSCC patients. 
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immune system in development of an cSCC in kidney transplant recipients. 
In a previous study, where we identified DMRs associated with post-transplant cSCC 
before transplantation23, SERPINB9 was not significantly different between T cells of future 
cSCC patients and non-cSCC patients. Thus, differences in SERPINB9 DNA methylation 
that identify patients at risk for cSCC arise after kidney transplantation. Likely kidney 
transplantation and the use of immunosuppressive therapy affect DNA methylation profiles 
of the T cells35. However, since we demonstrated high SERPINB9 methylation in patients 
before and after development of a de novo post-transplant cSCC, it seems a persistent risk 
factor for cSCC after transplantation. 
Based on the differential DNA methylation of SERPINB9, one could expect differences in 
Figure 4. Quantified flow cytometry data on serpinB9 expression by T cells. A) 
Percentage of T cells that expressed serpinB9 before stimulation in the cSCC and non-
cSCC patients and B) after stimulation. C) Percentage of CD4 T cells and D) CD8 T cells that 
expressed serpinB9 after stimulation in the cSCC and non-cSCC patients. **p<0.01
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mRNA expression of SERPINB9. Nevertheless, when SERPINB9 mRNA expression was 
measured in the T cells, this was not significantly different between cSCC patients and 
non-cSCC patients. This is comparable to findings by Ryer et al.36, who identified higher 
methylation of the same region within SERPINB9 in PBMCs of patients with abdominal 
aortic aneurysm. Despite the differential DNA methylation, they also did not detect 
a difference in mRNA expression. This is most likely due to the intragenic location of 
the DMR, outside of the promoter region of SERPINB9. The effect of intragenic DNA 
methylation on gene expression is still debated37 though here we demonstrated an inverse 
correlation between intragenic SERPINB9 DNA methylation and mRNA expression in the T 
cells of non-cSCC patients. Surprisingly, this inverse correlation was absent in the T cells of 
cSCC patients. This illustrates a disturbed transcriptional regulation of SERPINB9 in cSCC 
patients and a clear difference between these two patient groups.
Previous studies have shown that higher expression of serpinB9 increased the potency of 
cytotoxic T cells21,22. We observed a slightly lower expression of serpinB9 in the T cells of 
our cSCC patients, which was mainly due to the CD compartment of the T cells, although 
it is questionable whether a difference between 98% and 99% serpinB9 positive cells is 
biologically relevant. In addition, the regulation of serpinB9 seems independent from 
the regulation of cytotoxic markers of T cells since we did not identify differences in the 
expression of granzyme B and CD107a between cSCC patients and non-cSCC patients. 
SerpinB9 is an intracellular protein inactivating granzyme B once it is released into the 
cytoplasm38 and therefore serpinB9 exerts its effect on cytotoxicity only after granzyme B 
is synthesized to its active form. The absence of differences in cytotoxicity, which is in most 
cases restricted to the CD8+ T cells, and the serpinB9 differences in the CD4+ T cells may 
lead to the conclusion that the CD4+ T cells are the population of interest in post-transplant 
cSCC.
DNA methylation of SERPINB9 might represent a future treatment target for cSCC in 
transplant recipients. It would be interesting to decrease SERPINB9 DNA methylation in 
cSCC patients to the level observed in non-cSCC patients and study whether that affects 
future cSCC development in those patients. DNA methylation can be edited by use of the 
CRISPR/cas9 system, a technique called epigenetic editing39. Although this novel technology 
is far from a clinical application it is a promising concept for the future. Additionally, this 
approach will reveal whether SERPINB9 DNA methylation plays a causal role in cSCC 
development or whether it is a consequence of another, yet unknown, mechanism leading 
to post-transplant cSCC development.
We are aware that the single-center design and small sample size may be a limitation of 
this study. Details such as sun exposure were unknown and dosages of immunosuppression 
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were often adjusted or immunosuppressive regimens were changed during the course of 
post-transplant treatment. It was therefore not possible to take these factors into account. 
Nevertheless, we show a promising proof-of-concept that studying DNA methylation of 
SERPINB9 in peripheral T cells can identify kidney transplant recipients at risk for cSCC. 
The disturbed transcriptional regulation of SERPINB9 and the lower protein expression 
of serpinB9 warrant further investigation to fully understand the relation with cSCC 
development in kidney transplant recipients.
All together these findings demonstrate that DNA methylation, transcriptional regulation 
and protein expression of serpinB9 differ between cSCC and non-cSCC patients. This 
identifies a novel risk factor for the development of post-transplant cSCC and may provide 
mechanistic insight in the role of circulating T cells in cSCC development. Future studies 
will identify whether serpinB9 plays a causal role in cSCC development and if it is a suitable 
treatment target to prevent cSCC development after kidney transplantation.
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Supplementary Tables
Table S1. PCR and sequence primers of genes for validation
Gene PCR primers Amplicon 
size
450k probe 
names by 
Illumina
SERPINB9 F: 5’-GGAGGAGTAAAGGTTAGTGTAGA-3’ 290 bp
R: 5’-biotin-CCCAACRCCAAATACCTACACAAT-3’
S1: 5’-GAGTGTTATTTTTATTTTTTATAT-3’ cg20726195, 
cg10863922, 
cg01345354
S2: 5’-AGTTGAGTTTGTTGGT-3’ cg22376758
S3: 5’-GATGATGTATTAGGAGGT-3’ cg09046168
PCR program: 15 min at 95°C, 45 cycles of 30 s 94°C, 30 s 57°C, 30 s 72°C followed by 
10 min at 72°C 
VTRNA2-1 F: 5’-GGAAGGGGGTAAAATTTATTTATTGG-3’ 318 bp
R: 5’-biotin-ATACCCTACTAATCACTCATTAATTCATTC-3’
S: 5’-GGAGGGGAGGTAGGA-3’ cg08745965, 
cg16615357, 
cg18797653
PCR program: 15 min at 95°C, 45 cycles of 30 s 94°C, 30 s 59°C, 30 s 72°C followed 
by 10 min at 72°C 
F: forward primer. R: reverse primer, S: sequence primer, bp: basepair, min: minutes, s: seconds
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Figure S1. Detailed time schedule of A) the discovery patient cohort and B) the second 
patient cohort. On the Y-axis are all the cSCC patients and their matched controls and on 
the X-axis is the time in months from the transplantation (Tx) onwards. 
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Figure S2. Correlation between methylation values obtained by pyrosequencing and 
microarray. A) XY plot of DMR 1 (SERPINB9) with array values on the X-axis and pyro 
values on the Y-axis. B) Detailed graph for each of the 5 sites within DMR 1 (SERPINB9) 
with in red the cSCC patients and in green the non-cSCC patients. C) XY plot of DMR 2 
(VTRNA2-1) with pyro values on the X-axis and array values on the Y-axis. D) Detailed 
graph for each of the 3 sites within DMR 2 (VTRNA2-1) with in red the cSCC patients and 
in green the non-cSCC patients.
Disrupted regulation of serpinB9 in T cells
7
167
Figure S3. Gating strategy for granzyme B expression and CD107a by T cells. 
Representative examples of A) lymphocyte gate from forward scatter (FSC) and sideward 
scatter (SSC), B) living T cells gated from 7AAD-CD3 staining, C) granzyme B+ cells gated 
within the living T cells at 0 hours, D) granzyme B+ cells gated within the living T cells at 6 
hours, E) CD107a+ cells gated within the living T cells at 0 hours , F) CD107a+ cells gated 
within the living T cells at 6 hours, G) isotype control in green and granzyme B stained 
sample in red at 0 hours and H) isotype control in green and granzyme B stained sample 
in red at 6 hours.
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Figure S4. Quantified flow cytometry data on granzyme B and CD107a expression by 
T cells. A) Percentage of T cells that expressed granzyme B before and after stimulation 
in the cSCC and non-cSCC patients. B) Percentage of T cells that expressed CD107a before 
and after stimulation in the cSCC and non-cSCC patients.
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Figure S5. Gating strategy for serpinB9 expression by T cells. Representative examples 
of A) lymphocyte gate from forward scatter (FSC) and sideward scatter (SSC), B) living T 
cells gated from 7AAD-CD3 staining, C) serpinB9+ cells gated within the living T cells at 
0 hours, D) serpinB9+ cells gated within the living T cells at 6 hours, E) isotype control in 
green and serpinB9 stained sample in red at 0 hours and F) isotype control in green and 
serpinB9 stained sample in red at 6 hours.
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Summary
Epigenetic mechanisms determine the gene expression levels within the cell without 
changing the underlying DNA sequence. DNA methylation is currently the best understood 
epigenetic mechanism because it is biochemically stable and an easily measured epigenetic 
mark. DNA methylation profiles are crucial in determining the gene expression profiles of 
different cell types and are extensively studied in cell differentiation. This includes T cell 
differentiation, where antigen-naive T cells are characterized by high methylation of effector 
genes, which are demethylated upon antigen recognition and subsequent differentiation 
into effector T cells. DNA methylation profiles are dynamic and represent an interface 
between genomic information and the environment. It is known that DNA methylation is 
altered in disease and DNA methylation can therefore function as a biomarker for disease 
diagnosis, disease prognosis or risk assessment. A well-known and clinically applied 
example is methylation of the MGMT gene promoter which predicts whether patients with 
glioblastoma, an aggressive brain tumor, respond to a specific chemotherapy.
Organ transplantation is the preferred treatment option for patients with end-stage organ 
failure. Despite immunosuppressive treatment, approximately 20% of kidney transplant 
recipients experience a rejection episode. Rejection is a complex interplay of both innate 
and adaptive immune cells where T cells play an important role. Since rejection may 
cause irreversible damage to the transplanted organ one of the current challenges is to 
find a biomarker that precedes tissue damage and identifies recipients at increased risk 
for rejection. Besides rejection, transplant recipients may experience other complications 
after transplantation and these often relate to the general suppression of the immune 
system. Common complications are infections and the development of malignancies. The 
most common post-transplant malignancy is skin cancer, specifically cutaneous squamous 
cell carcinoma (cSCC), which is associated with high morbidity and increased mortality 
in transplant recipients. The large incidence of cSCC in immune suppressed individuals 
indicates the critical role of the immune system in the development of cSCC.
In general, there is a demand for innovative methods to identify patients at increased risk 
for developing complications after transplantation such as rejection or cSCC. If patients at 
an increased risk of complications are closely monitored, early clinical intervention may 
prevent negative consequences of the complication and thereby benefit the patients well-
being. One such clinical intervention might be adjustment of the immunosuppressive load, 
however, there is a fine line between reducing the risk on cSCC and increasing the risk on 
rejection and vice versa. 
In this thesis we aim to identify patients at increased risk for rejection or skin cancer by 
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studying DNA methylation profiles of the circulating T cells. To substantiate the validity 
of the DNA methylation profiles, we also investigated the stability of DNA methylation in 
experimental systems, evaluating the effect of immunosuppressive drugs and cytokines on 
DNA methylation profiles. 
Tacrolimus and mycophenolate mofetil (MMF; active ingredient MPA) are most often 
prescribed as maintenance immunosuppressive therapy in our clinic. These compounds are 
designed to suppress T-cell activity within the recipient. However, it is not known whether 
they initiate changes on the epigenetic level to perform their function. To investigate this, 
we cultured total T cells, naive T cells and memory T cells in the presence of tacrolimus or 
MPA and measured interferon gamma  (IFNγ) DNA methylation, T cell phenotype and IFNγ 
protein expression. In chapter 2 we describe that MPA affected IFNγ DNA methylation of 
the naive T cells but not that of memory T cells after in vitro stimulation. Tacrolimus showed 
no effect on IFNγ DNA methylation of the T cells after stimulation.
To further investigate environmental effects on DNA methylation, mesenchymal stromal 
cells (MSCs) were cultured in the presence of cytokines, IFNγ, transforming growth 
factor β (TGFβ) and a combination of factors, that are known to induce phenotypic and 
functional changes in MSCs. Also methylation profiles before and after 14 days of culture 
were studied to infer the effect of culture expansion. Chapter 3 describes that the changes 
in genome-wide DNA methylation induced by the cytokines IFNγ, TGFβ or a multi-factor 
combination (MC; IFNγ, TGFβ and retinoic acid) were minor. The stimulation with IFNγ and 
MC resulted in decreased methylation of a single CpG site. Interestingly, culture expansion 
led to differential methylation of >4,000 CpG sites. These sites were located within or near 
genes associated to membrane composition, cell adhesion and transmembrane signaling. 
In the second section of this thesis the possible clinical applications of DNA methylation 
in organ transplantation are described. Chapter 4 reviews the current literature on DNA 
methylation and describes how it could be applied as an early biomarker for complications 
such as rejection in a non-invasive and quantitative manner. We speculated that DNA 
methylation testing in a clinical setting will improve future treatment of transplant 
recipients.
The study into the relation between DNA methylation profiles and rejection in kidney 
transplantation is described in chapter 5. Here we measured IFNγ and programmed 
death 1 (PD1) DNA methylation in CD8+ T cells before, at 3 months and 12 months after 
transplantation in rejecting and non-rejecting kidney transplant recipients. We observed 
an increase in DNA methylation for both genes within the EMRA CD8+ T cell subset and 
for PD1 also in the CD27- and CD27+ memory subsets. In addition, the increase in PD1 DNA 
methylation in the CD8+CD27- memory population was more prominent in the rejecting 
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patients than in the non-rejecting patients. There was no difference between rejecting and 
non-rejecting patients before transplantation, thus predicting rejection was not possible 
with these data.
Due to the suppressed immune system, kidney transplant recipients are more prone to 
develop cancer, especially cSCC is a common complication after transplantation. We 
hypothesized that there is a systemic defect in the circulating T cells in patients that 
develop cSCC after transplantation. Chapter 6 demonstrates that genome-wide T-cell 
DNA methylation was different between kidney transplant recipients with a future post-
transplant cSCC and those without cSCC. Sixteen differentially methylated regions 
(DMRs) were found prior to transplantation, which is a clinically relevant time point for risk 
assessment. For a subset of cSCC patients a post-transplant sample was available which 
allowed us to identify several DMRs that were stable after transplantation. These stable 
DMRs might have a lasting effect on the development of cSCC after kidney transplantation. 
In chapter 7 we continued to study differential methylation associated to cSCC after kidney 
transplantation. Here we identified, after transplantation, a DMR within SERPINB9, a 
protein-coding gene that acts as an intracellular inhibitor of granzyme B. This genomic 
region was higher methylated in T cells of patients before they developed a first cSCC 
as well as in T cells of patients that already developed cSCC. At the functional level, we 
observed a disturbed transcriptional regulation of SERPINB9 and a lower protein expression 
of serpinB9 in the patients with cSCC.
Discussion
This thesis describes differences in DNA methylation associated to complications after 
kidney transplantation and explores whether DNA methylation profiles can be used as a 
tool for risk assessment. Before DNA methylation analysis can be clinically utilized it is 
important to know to which extent DNA methylation is influenced by environmental factors 
that are relevant in organ transplantation. Therefore, we first assessed the changes in DNA 
methylation induced by immunosuppressive drugs, cytokines and culture expansion in 
activated cells. 
For several medical drugs it is known that these agents alter DNA methylation. Examples 
are the antihypertensive drug hydralazine1,2 and valproate which is used in treatment of 
epilepsy3. When we studied the effect of the two commonly prescribed immunosuppressive 
drugs tacrolimus and MPA on IFNγ promoter DNA methylation in T cell cultures, only the 
lymphocyte proliferation inhibitor MPA had an effect (chapter 2). Also, the suppression of 
IFNγ protein production by tacrolimus was not mediated by DNA methylation changes. 
Since this was a targeted analysis focusing on a single gene promoter, there is a chance 
Chapter 8
8
180
that other genomic regions are affected more prominently by these compounds. 
Nevertheless, when umbilical-cord derived MSCs (ucMSCs) were primed with IFNγ and in 
combination with soluble factors (IFNγ, TGFβ and retinoic acid) that are known to affect 
phenotype and function of MSCs4,5, the genome-wide changes in DNA methylation were 
minor (chapter 3). Similar findings have been described for vitamin D. In vitro exposure 
of vitamin D on immune cells altered gene expression of known vitamin D responsive 
genes without substantial genome-wide DNA methylation changes and without DNA 
methylation changes in the vitamin D responsive genes6. It is likely that in the absence of 
DNA methylation changes, other epigenetic mechanisms, such as histone modifications7, 
may play a leading role in changing gene expression patterns. This would also explain why 
we observed a discrepancy between T-cell phenotype and IFNγ DNA methylation after 
stimulation (chapter 2), and functional and phenotypical changes upon priming of MSCs 
without major DNA methylation changes (chapter 3).
MSCs have great therapeutic potential due to their regenerative capacities, 
immunosuppressive effect and low immunogenicity as demonstrated in vitro8. The number 
of MSCs that can be isolated from human tissue is low, therefore in vitro expansion is 
necessary to generate sufficient cell numbers for therapeutic purposes. Surprisingly, our 
results show that culture expansion leads to widespread changes in genome-wide DNA 
methylation (chapter 3). In literature DNA methylation changes during culture expansion 
are often attributed to cellular senescence9,10 and aging of the MSCs11,12 and those epigenetic 
changes associated with a declining function of the MSCs. However, in our study, surface 
marker expression and immunosuppressive capacities of the MSCs were similar before 
and after 14 days of culture expansion. Indicating that culture-induced epigenetic changes 
do not necessarily affect the intended function of the cells. It is therefore important to 
know the effect of epigenetic changes on cellular function before a cellular product can 
be clinically utilized. Stability and standardization of the cellular product are crucial and 
DNA methylation analysis may serve as an additional quality control for the cellular end-
product. An example of this can be found in another form of cellular therapy: regulatory T 
(Treg) cell therapy13. Tregs have immunosuppressive capacities and are therefore proposed 
as a cellular immunotherapy in transplantation. An important characteristic of stable Tregs 
is a demethylated region within the transcription factor FOXP314, but often only surface 
marker expression is assessed after culture expansion of Tregs15. Concluding that analyzing 
DNA methylation changes during culture expansion of cells in parallel with cell function, 
could improve standardization of the cellular product.
In the second section of this thesis we explored the value of DNA methylation for kidney 
transplantation. There are several examples available where DNA methylation profiling 
is successfully applied in a clinical framework, most of these are in the field of oncology. 
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Examples are the methylation of the MGMT promoter in glioma16, which is a crucial factor 
in clinical decision-making17, and methylation of SHOX2 which is used as a biomarker for 
lung cancer18 and is explored for other tumor types as well19. Recently, it was described that 
ischemia during kidney transplantation induced genome-wide hyper methylation measured 
in kidney biopsies20. It is known that procedures during kidney transplantation such as cold 
ischemia time and ischemia-reperfusion-injury (IRI) negatively affect the outcome of the 
transplantation21. In the study by Heylen et al.20, the time of cold ischemia directly correlated 
with the degree of hyper methylation. The degree of hyper methylation also predicted 
reduced allograft function 1 year after transplantation, thereby outperforming established 
clinical variables. This is strong evidence that DNA methylation is one of the molecular 
mechanisms underlying functional behavior of the cells and shows that DNA methylation 
could be a tool to predict risk for post-transplant complications. Unfortunately, this study 
was performed on kidney biopsies and therefore issues with cellular heterogeneity and 
sampling error still remain. Ideally, risk on post-transplant complications can be assessed 
non-invasively in blood or urine (chapter 4). In our studies we focused on DNA methylation 
profiles of peripheral T cells associated with acute rejection and skin cancer.
A pilot study on DNA methylation of the IFNγ and PD1 promoters in peripheral CD8+ T cells 
before, at 3 months and 12 months after kidney transplantation identified only a minor 
difference between rejecting patients and non-rejecting patients (chapter 5). Since T cells 
play a crucial role in the rejection process, a difference in epigenetic regulation of T cell 
function between rejecting patients and non-rejecting patients may be expected. However, 
our results demonstrate that the promoter regions of these two well-known genes are not 
differentially methylated at the time of sampling. Possibly, at the exact time of rejection, 
DNA methylation changes take place at the promoter regions of IFNγ and PD1, since both 
molecules play a role in the rejection process22. DNA methylation changes preceding a 
rejection may be more subtle and probably occur at different genomic regions. This pleads 
for moving from a targeted approach to an unbiased genome-wide approach to find the 
regions of interest, thereby including DNA methylation outside promoter regions. The 
functional effect of DNA methylation outside promoters is not fully elucidated23 but studies 
show that inter-individual variation in DNA methylation is much higher in gene bodies than 
in gene promoters24,25. It may be those variable regions26 where we could find the subtle 
differences in DNA methylation that identify kidney transplant recipients at increased risk 
for rejection. 
Besides rejection, a common complication after transplantation is cSCC, affecting up to 
30% of the transplant population27-29. Biomarkers for post-transplant cSCC described in 
literature are most often related to T-cell phenotypes. T regulatory (Treg) cells, identified 
as CD3+CD4+FOXP3+CD25hiCD127lo, were associated to higher cSCC risk30 as well as Tregs 
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identified by demethylation of the Treg specific demethylated region (TSDR)31. Also the 
presence of senescent T cells defined as CD8+CD57+ was described as a strong predictor 
for recurrence of cSCC32. In these studies high risk patients were identified as those with 
a previous cSCC and T-cell phenotypes of these high risk patients were associated to a 
recurrent cSCC. In contrast, our study was designed in a retrospective manner which 
allowed us to analyze T cells before development of a first cSCC (chapter 7) and even 
before transplantation (chapter 6), a novel approach in the field of post-transplant cSCC. In 
addition, the genome-wide approach identified DNA methylation differences of the T cells 
in an unbiased manner. Of the 16 identified DMRs before transplantation, several regions 
remained relatively stable after transplantation and these present interesting targets to 
study in relation to cSCC development (chapter 6). 
When comparing DNA methylation of the pre- and post-transplant samples within the 
same patients, we observed an overall increase in DNA methylation after transplantation 
(chapter 6). This is similar to what we observed in the gene promoters of IFNγ and PD1, 
where DNA methylation also increased in patients after kidney transplantation (chapter 
5). In addition, even though measured in a very different compartment, kidney biopsies 
also showed increased methylation induced by ischemia injury during the transplantation 
procedure20. Apart from the ischemia induced hyper methylation, attributing this increase 
in DNA methylation of T cells to a specific component of the transplantation is difficult since 
these patients experience many changes, ranging from improved kidney function, to the 
surgical procedure and the immunosuppressive therapy they receive after transplantation. 
Though these changes could explain why we did not identify the same cSCC-associated 
DMRs before and after transplantation (chapter 6 and 7).
None of the genes annotated to the pre-transplant DMRs showed a clear link to T cell 
function. Also all DMRs were outside promoter regions which makes it difficult to predict 
their function solely based on the DNA methylation results23. This was also evident 
when we identified differential methylation in an intragenic region of SERPINB9 after 
transplantation but before the clinical onset of the cSCC (chapter 7). Despite the difference 
in DNA methylation, there was no significant difference in mRNA expression of SERPINB9 
between the cSCC and non-cSCC patients. However, upon closer examination of the data 
we observed an inverse correlation between DNA methylation and mRNA expression of 
SERPINB9 in the non-cSCC patients, but not in the cSCC patients. An inverse correlation 
between DNA methylation and mRNA expression is normally observed in the context of 
promoter methylation but these data indicate that intragenic DNA methylation can also 
work as a repressor for gene expression. Since this inverse correlation was not observed 
in the cSCC patients, we speculate that other epigenetic mechanisms may overrule 
this effect. To reliably assess the effect of genome-wide differential methylation, RNA 
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sequencing would be a useful addition to DNA methylation analysis. Combining these 
two technologies will shed light on possible distal gene regulation and makes it more 
straightforward to interpret DNA methylation findings on a functional level. 
Our findings on the disturbed regulation of serpinB9 in cSCC patients are a first step 
towards unraveling the pathogenesis of post-transplant cSCC (chapter 7). SerpinB9 has 
not previously been described in relation to cSCC but many reports are available on its 
function both in T cells as well as in tumor cells. Bladergroen et al.33 demonstrated the 
expression of serpinB9 in several types of lymphoma and proposed this as a novel protective 
mechanism for tumor cells to escape cytotoxic elimination via granzyme B-induced 
apoptosis. SerpinB9 expression also showed an association with unfavorable outcome in 
metastatic melanoma34, demonstrating its prognostic value. On the other hand, serpinB9 
is an essential protein in cytotoxic T cells to perform its function. Endogenous serpinB9 
protects the cells from self-inflicted damage by misdirected granzyme B. Transgenic 
upregulation of serpinB9 in T cells significantly improved their cytotoxic potency35, in 
theory increasing their ability to eliminate tumor cells36. This dual role makes serpinB9 an 
interesting target to study further. Our study demonstrated that transcriptional regulation 
was significantly different between cSCC and non-cSCC patients (chapter 7). Additional 
experiments will unravel which epigenetic mechanism is leading in regulating expression 
of SERPINB9 and what this means for the development of post-transplant cSCC. Also the 
relation between peripheral T cells and T cells surrounding the cSCC lesion is unclear. The 
histological analysis of an cSCC showed hardly any serpinB9 positive T cells surrounding 
the cSCC lesion, suggesting that the tumor-specific T cells that migrate to the tumor are 
serpinB9 negative and cannot perform any cytotoxic activity. Whilst the peripheral T cells, 
a pool of all T cells, expressed serpinB9 at levels between 40-90% (chapter 7). If serpinB9 
can be induced in tumor-specific T cells, it would be interesting to see if, as a result, the 
cytotoxic activity of these T cells increases. 
Although there are many reviews published on the potential of epigenetics in 
transplantation37-41, the actual research papers are scarce. With this thesis we hope to 
have demonstrated the potential that DNA methylation analysis holds for improving 
transplantation research and patient care. Hopefully this work leads to increased 
recognition for the wide range of possibilities of DNA methylation research in the field of 
transplantation. 
Future directions
The results discussed in this thesis are representing a novel tool in transplantation research. 
We believe that DNA methylation analysis in the field of transplantation will improve the 
research and patient care throughout the coming years. Due to the explorative nature 
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of the research, the sample sizes were small and the studies were performed in a single-
center study design. To build upon these promising results, we recommend to validate 
the findings in a larger cohort and preferably in a multi-center setting. In addition, our 
studies have been focused on peripheral T cells but the frequency of antigen-specific T 
cells (e.g. to the allograft or to the cSCC) is low in the total T-cell population. Analyzing 
the parameters studied in this thesis in antigen-specific T cells, will further unravel the role 
of DNA methylation in the process of rejection and development of post-transplant cSCC 
since these are the actual cells that will target either the allograft or the cSCC. 
We have shown that analyzing DNA methylation in a targeted manner, by studying DNA 
methylation of genes known to play a role in the process of interest, may not identify the 
differences we are looking for. This could be due to timing, differences may occur during 
an event but not ahead of the event, making an early risk assessment difficult. Also, by 
studying DNA methylation of targeted genes, important variations in genomic regions of 
yet unknown genes or outside promoters could be missed. For these reasons, genome-
wide DNA methylation analysis should be the method of choice until it is well-established 
which genomic regions are of interest to study in relation to post-transplant complications. 
This genome-wide discovery process will reveal potential biomarkers that, after rigorous 
validation, could be implemented in the transplantation clinic. These DNA methylation 
biomarkers could be combined with well-established clinical risk factors in a computational 
model to generate personalized risk profiles for each transplant recipient.
If we can reliably asses the risk on cSCC before or shortly after transplantation, patients 
could receive personalized life-style advice or a therapeutic intervention. Several studies 
demonstrated a beneficial effect of switching from a calcineurin inhibitor to sirolimus on 
the recurrence of the skin cancer42,43. It could also be considered to lower the dosage of 
immunosuppression but only if a patient has a low risk profile for rejection simultaneously. 
Future studies will reveal whether these interventions also have an effect on DNA 
methylation profiles, which due to their dynamic nature, could be a potential monitoring 
tool for treatment responses. 
Besides the potential to serve as a biomarker, analyzing DNA methylation profiles will 
help understand the mechanisms that lead to complications after transplantation. In our 
search for DNA methylation differences associated to post-transplant cSCC, we identified 
SERPINB9 as a genomic region of interest. Due to the important role of serpinB9 in 
cytotoxic T cell function, we propose two additional studies to further unravel the role of 
serpinB9 in cSCC development. 
First, the correlation between SERPINB9 DNA methylation, mRNA expression and protein 
expression of the peripheral T cells and the T cells present around the cSCC lesions is 
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unknown. It could be that the serpinB9 negative cells are the tumor specific T cells that 
are recruited to the cSCC lesion, or that the T cells lose their serpinB9 expression upon 
migration to the cSCC. Identifying the tumor specific T cells in the pool of peripheral T 
cells and comparing the functional and molecular characteristics with those of the T cells 
surrounding the cSCC will reveal the similarities or dissimilarities between the two T-cell 
compartments.
Second, we observed higher SERPINB9 DNA methylation in two different patients 
cohorts, one cohort after transplantation and before development of the first cSCC, and 
one cohort after development of a first cSCC. However, no such differences in SERPINB9 
DNA methylation were found in a pre-transplant cohort, suggesting that these differences 
arise after transplantation. Measuring SERPINB9 DNA methylation in a prospective cohort 
before and at regular intervals after transplantation, will unravel the dynamics of DNA 
methylation in this specific genomic region. This prospective study would also address 
whether SERPINB9 DNA methylation could serve as a tool for early risk assessment for 
post-transplant cSCC. 
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Samenvatting
In iedere cel van het menselijk lichaam zit DNA. Dit DNA bevat alle informatie die nodig 
is voor het opbouwen, in stand houden en functioneren van een organisme, dus ook voor 
de mens. Het DNA is opgebouwd uit vier bouwstenen die we aanduiden met de letters A 
(adenine), T (thymine), C (cytosine) en G (guanine). In het DNA bevinden zich regio’s die de 
code bevatten voor het maken van eiwitten, moleculen die belangrijk zijn voor de functie 
van een cel. Deze regio’s noemen we genen. De volgorde van de vier letters in een gen 
bepaalt bijvoorbeeld of je blauwe of bruine ogen hebt. Het is belangrijk om het aflezen van 
deze genen, de zogenoemde genexpressie, goed te reguleren, want dit zorgt ervoor dat 
elke cel in het lichaam de juiste functie uitvoert. 
Een belangrijke manier om genexpressie te reguleren is het koppelen van moleculen aan 
het DNA, zoals bijvoorbeeld een methyl-groep. Deze vorm van regulatie wordt epigenetica 
genoemd. Epigenetische mechanismen reguleren genexpressie door te bepalen of deze 
regio’s in het DNA beschikbaar zijn om afgelezen te worden. Van alle epigenetische 
mechanismen wordt DNA-methylatie het meest bestudeerd. Voornamelijk omdat dit een 
biochemisch stabiel kenmerk is en relatief makkelijk te meten is. DNA-methylatie is de 
toevoeging van een molecuul, een methyl-groep, op het DNA. Deze methyl-groep zit altijd 
op een C die gevolgd wordt door een G in het DNA, dit noemen we een CpG-site. 
DNA-methylatie profielen reguleren dus genexpressie in verschillende cel types en zijn 
belangrijk in de differentiatie van cellen. Een voorbeeld hiervan is de T-cel rijping waarbij 
naïeve T-cellen, welke nog geen lichaamsvreemde stoffen (antigenen) zijn tegen gekomen, 
gekarakteriseerd worden door hoge methylatie van genen die coderen voor signaalstoffen, 
ook wel cytokines genoemd. Deze hoge DNA-methylering zorgt ervoor dat naïeve T cellen 
deze cytokines niet produceren. Zodra naïeve T-cellen een antigeen herkennen, zullen 
de T-cellen veranderen naar T-cellen die actief cytokines gaan produceren. Dit proces 
gaat gepaard met een vermindering van de methylatie op de genen die coderen voor de 
cytokines. 
DNA-methylatie profielen zijn beïnvloedbaar door factoren van buitenaf zoals voeding, 
medicijnen en chemische stoffen en door factoren van binnenuit zoals hormonen en 
cytokines. Om deze reden geeft DNA-methylatie een raakvlak weer tussen de genetische 
informatie van een individu en de omgeving waar een individu, en dus ook de cellen van het 
individu, zich in bevinden. Ook weten we dat er vaak veranderingen plaatsvinden in DNA-
methylatie voorafgaand aan of ten tijde van een ziekte. Hierdoor kan DNA-methylatie 
toegepast worden als meetbare biologische indicator (biomarker) voor de diagnose, 
prognose of risicobepaling voor verschillende ziektes. Een bekend voorbeeld van een 
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klinische toepassing van DNA-methylatie onderzoek is de analyse van methylatie van het 
MGMT-gen. Methylatie van dit gen bepaalt welke behandeling het beste werkt bij een 
agressieve vorm van hersenkanker. 
Niertransplantatie is momenteel de beste behandeloptie voor mensen met eindstadium-
nierfalen. Ondanks dat transplantatiepatiënten medicijnen krijgen die het afweersysteem 
onderdrukken, ontwikkelt ongeveer 20% van de patiënten een afstotingsreactie 
tegen de nier. Een afstoting is een complex samenspel van verschillende cellen van het 
afweersysteem, waarin de T-cellen een belangrijke rol spelen. De T-cellen herkennen 
het lichaamsvreemde weefsel en starten een immuunreactie. Hierbij gaan de T-cellen 
cytokines produceren, vermeerderen ze in aantal en zullen ze differentiëren van de naïeve 
T-cel naar actieve en geheugen T-cellen. Een afstotingsreactie na transplantatie kan leiden 
tot onomkeerbare schade aan het getransplanteerde orgaan en daarom is het belangrijk 
om een biomarker te vinden die een afstoting in een vroeg stadium kan voorspellen. 
Naast het ontwikkelen van een afstotingsreactie, zijn er meerdere complicaties 
die transplantatiepatiënten kunnen ontwikkelen. Vaak zijn deze gerelateerd aan 
de afweeronderdrukkende medicijnen die deze patiënten moeten slikken om het 
getransplanteerde orgaan te behouden. Hierdoor hebben patiënten vaker infecties 
en zijn ze gevoeliger voor het ontwikkelen van kanker. Het meest voorkomende type 
kanker na transplantatie is huidkanker, specifiek het plaveiselcelcarcinoom (PCC). Dit 
type kanker komt 65 tot 200 keer vaker voor bij transplantatiepatiënten dan bij andere 
mensen. PCC zorgt voor groot ongemak bij patiënten en verlaagt de kwaliteit van leven. 
Deze sterk verhoogde kans op PCC na een transplantatie geeft aan dat het onderdrukte 
afweersysteem een essentiële rol speelt in de ontwikkeling van een PCC. 
Er is veel vraag naar nieuwe methodes die patiënten identificeren met een verhoogd 
risico op het ontwikkelen van complicaties na een orgaantransplantatie, bijvoorbeeld 
een afstotingsreactie of PCC. Als patiënten met een verhoogd risico op complicaties 
nauwlettend gevolgd worden door de arts, kan er in een vroeg stadium worden ingegrepen 
door bijvoorbeeld de dosis afweeronderdrukkende medicijnen aan te passen. Alhoewel 
voorzichtigheid hierbij geboden is want er is een dunne lijn tussen het verlagen van risico 
op een PCC en het verhogen van het risico op afstoting en andersom.
In dit proefschrift zijn DNA-methylatie profielen van T-cellen in het bloed bestudeerd in de 
hoop hiermee patiënten te kunnen identificeren met een verhoogd risico op afstoting of 
PCC na niertransplantatie. Voordat dit toegepast zou kunnen worden in de kliniek is het 
belangrijk om de stabiliteit van DNA-methylatie profielen te weten. Daarom hebben we 
eerst DNA-methylatie gemeten in experimentele systemen en bepaald wat de invloed is 
van afweeronderdrukkende medicijnen en cytokines op DNA-methylatie profielen.  
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Tacrolimus en mycofenolate mofetil (MMF; actieve ingrediënt MPA) zijn de meest 
voorgeschreven afweeronderdrukkende medicijnen in ons centrum. Deze medicijnen 
worden voorgeschreven om de activiteit van T-cellen te onderdrukken, maar het is 
onbekend of ze ook een effect hebben op DNA-methylatie. Om dit te bestuderen hebben 
we T-cellen gekweekt, zowel totale T-cellen als geïsoleerde naïeve en geheugen T-cellen, 
in de aanwezigheid van tacrolimus of MPA. Op verschillende tijdspunten hebben we DNA-
methylatie van interferon-gamma (IFNγ) gemeten. IFNγ is een ontstekingsbevorderende 
(pro-inflammatoir) cytokine dat een belangrijke rol speelt in de functie van T-cellen. Ook 
hebben we verschillende oppervlaktekenmerken van de T-cellen gemeten en de productie 
van het IFNγ-eiwit door de T-cellen. In hoofdstuk 2 beschrijven we dat enkel MPA de IFNγ 
DNA-methylatie van de naïeve T-cellen beïnvloedde na het stimuleren van de cellen. De 
DNA-methylatie in de geheugen T cellen veranderde niet door het toevoegen van MPA. 
Tacrolimus had geen effect op IFNγ DNA-methylatie van de T-cellen.
Vervolgens zijn we het effect van omgevingsfactoren op DNA-methylatie verder 
gaan bestuderen. Hiervoor hebben we mesenchymale stam cellen (MSC) gekweekt 
samen met cytokines waarvan we weten dat ze de functie van MSC beïnvloeden: IFNγ, 
transformerende-groeifactor β (TGFβ) en de combinatie IFNγ, TGFβ met retinol. Daarnaast 
hebben we ook de veranderingen in DNA-methylatie gemeten voor en na een periode van 
14 dagen kweken, om het effect van vermenigvuldiging van de cellen op methylatie te 
bepalen. DNA methylatie werd op 850.000 CpG-sites gemeten, verdeeld over het gehele 
DNA (genoom-breed). Hoofdstuk 3 beschrijft dat er minimale veranderingen plaatsvonden 
in genoom-brede DNA methylatie onder invloed van de cytokines IFNγ, TGF-β of een 
combinatie van factoren (IFNγ, TGF-β en retinol). De toevoeging van IFNγ en de combinatie 
van factoren aan de MSC leidde tot een verlaging van de methylatie op een enkele CpG-
site, terwijl het bekend is dat deze factoren de functie van MSC kunnen beïnvloeden. Een 
opvallende bevinding was dat de vermenigvuldiging van de cellen voor een periode van 14 
dagen leidde tot een verschil in methylatie op meer dan 4.000 CpG-sites. Deze plekken in 
het DNA reguleren waarschijnlijk genen die te maken hebben met samenstelling van het 
celmembraan, het vermogen van de cel zich te hechten en signalen van buiten de cel naar 
binnen door te geven. 
In het tweede deel van dit proefschrift gaan we in op de mogelijke klinische toepassingen 
van DNA-methylatie in relatie tot orgaantransplantatie. Hoofdstuk 4 bevat een overzicht 
van de huidige literatuur over DNA-methylatie. We beschrijven hoe dit kan worden 
toegepast als biomarker voor complicaties zoals afstoting op een manier waarbij de 
patiënt weinig last ondervindt van het onderzoek, zoals bijvoorbeeld enkel de afname van 
een buisje bloed. We speculeren dat DNA-methylatie onderzoek in een klinische context 
de toekomstige behandeling van transplantatiepatiënten zal verbeteren. 
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Het onderzoek naar de relatie tussen DNA-methylatie profielen en afstoting na 
niertransplantatie wordt beschreven in hoofdstuk 5. In deze studie hebben we DNA-
methylatie gemeten van IFNγ en programmed-death 1 (PD1). PD1 is een eiwit wat zich 
op de oppervlakte van T-cellen bevindt en een immuunreactie kan reguleren. IFNγ en 
PD1 DNA methylatie werd gemeten in CD8+ T-cellen vóór de transplantatie, en drie en 
vervolgens 12 maanden ná de transplantatie. Dit hebben we zowel bij patiënten die een 
afstotingsreactie ondergaan, als bij patiënten die niet afstoten, gemeten. We vonden een 
verhoging van DNA-methylatie op beide genen in de EMRA CD8+ T-cel populatie, dit zijn 
ver doorgedifferentieerde geheugen T-cellen. Bij het gen PD1 was er ook een verhoging 
van DNA-methylatie in de CD27- en CD27+ T-cel populaties, twee type geheugen T-cellen. 
Vóór transplantatie was er geen verschil tussen patiënten die later een afstotingsreactie 
ontwikkelden en patiënten zonder afstoting, het voorspellen van een afstotingsreactie was 
met deze gegevens dus niet mogelijk.
PCC komt erg veel voor na een niertransplantatie. Wij denken dat er een defect is in de 
circulerende T-cellen in het bloed van patiënten die PCC ontwikkelen na transplantatie. 
Hoofdstuk 6 laat zien dat de genoom-brede DNA methylatie verschillend was tussen 
niertransplantatiepatiënten met een toekomstige PCC en niertransplantatiepatiënten 
die geen PCC ontwikkelden na transplantatie. Zestien gebieden in het DNA vertoonden 
verschillen in DNA-methylatie. Deze verschillen werden gemeten vóór de transplantatie, 
wat een klinisch relevant tijdspunt is voor een risicobepaling bij transplantatiepatiënten. 
Van een deel van de PCC-patiënten was ook materiaal aanwezig van ná de transplantatie. 
Hierdoor konden we DNA-methylatie in de tijd volgen. Van een aantal van de 16 gebieden 
bleef DNA-methylatie stabiel na transplantatie. Dit zou kunnen betekenen dat deze 
gebieden een rol spelen in de ontwikkeling van PCC na een transplantatie. 
In hoofdstuk 7 gaan we verder met het bestuderen van DNA-methylatie profielen die 
geassocieerd zijn met PCC na een niertransplantatie. Hier vonden we, ná de transplantatie 
maar vóór het ontwikkelen van de PCC, een verschillend gemethyleerde gebied in het gen 
SERPINB9 in T-cellen. SERPINB9 codeert voor een eiwit dat de werking van granzyme 
B remt en granzyme B, wat voornamelijk geproduceerd wordt door CD8+ T-cellen, 
kan celdood veroorzaken in cellen die herkend worden door het immuunsysteem. Het 
geïdentificeerde gebied in het SERPINB9 gen had een hogere methylering in patiënten die 
een PCC ontwikkelden, zowel voor als na het ontwikkelen van de PCC. Verder onderzoek 
toonde aan dat de relatie tussen DNA-methylatie en genexpressie verstoord was en dat er 
een lagere eiwit-expressie van serpinB9 was in de patiënten met PCC. 
In het eerste deel van dit proefschrift wordt beschreven dat afweeronderdrukkende 
medicijnen en cytokines een minimale invloed hebben op DNA-methylatie, terwijl deze 
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factoren de celfunctie wel kunnen beïnvloeden. De verandering in celfunctie kan misschien 
verklaard worden doordat, in sommige gevallen, andere epigenetische mechanismes 
een belangrijkere rol spelen dan DNA methylatie. Daarnaast leidde het kweken van MSC 
tot grote veranderingen in DNA methylatie. Deze bevinding kan belangrijk zijn als MSC 
worden toegepast als celtherapie. Een goede kwaliteitscontrole is belangrijk voordat een 
celtherapie aan de patiënt gegeven wordt en DNA methylatie kan hier in de toekomst 
wellicht een rol in spelen.
In het tweede deel van dit proefschrift beschrijven we verschillen in DNA-methylatie 
tussen patiënten die wel of geen PCC ontwikkelden na niertransplantatie. Deze resultaten 
zijn nieuwe bevindingen binnen het transplantatieveld en zullen hopelijk het onderzoek en 
patiëntenzorg in de komende jaren verbeteren. De verschillen in DNA-methylatie vonden 
we door een genoom-brede analyse van DNA-methylatie uit te voeren. In de studie waarbij 
we op een toegespitste manier naar DNA-methylatie keken konden we de complicatie 
afstoting niet voorspellen. Om die reden moet er in de toekomst meer onderzoek gedaan 
worden naar genoom-brede veranderingen van DNA-methylatie die associëren met 
complicaties na transplantatie, in plaats van te focussen op specifieke genen. Dit kan leiden 
tot ontdekking van nieuwe gebieden in het genoom die, na uitgebreide validatie, kunnen 
functioneren als biomarker voor complicaties na transplantatie. 
Naast de potentie die DNA-methylatie heeft om te functioneren als biomarker, zal 
het onderzoeken van DNA-methylatie ook helpen de mechanismes te begrijpen die 
voorafgaan aan complicaties na transplantatie. De studie naar verschillen in DNA-
methylatie geassocieerd met PCC, leidde tot de bevinding dat SERPINB9, een molecuul 
dat een belangrijke functie heeft in T-cellen, anders gemethyleerd was in patiënten met 
PCC. SerpinB9 inactiveert granzyme B, een molecuul dat celdood kan veroorzaken in 
cellen die herkend worden door het immuunsysteem en dus belangrijk is in de afweer 
tegen kankercellen. Vervolgstudies waarbij de rol van serpinB9 in de huid wordt bestudeert 
en studies naar de dynamiek van SERPINB9 DNA-methylatie na transplantatie zullen 
leiden tot meer kennis over welke rol dit molecuul speelt in de ontwikkeling van PCC na 
transplantatie. 
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List of abbreviations
ACR  acute cellular rejection
APC  antigen presenting cell
ATG  anti-thymocyte globulin
bp  base pairs
BPAR  biopsy proven acute rejection
CAV  cardiac allograft vasculopathy
cDNA  complementary DNA
cfdDNA  cell free donor-derived DNA
CKD  chronic kidney disease
CMV  cytomegalovirus
CNI  calcineurin inhibitor
CpG  cytosine-phosphate-guanine 
cSCC  cutaneous squamous cell carcinoma
DMR  differentially methylated region
DMS  differentially methylated site
DNA  deoxyribonucleic acid 
DNMT  DNA methyltransferase
DSA  donor specific antibody
EMB  endomyocardial biopsy
ESRD  end-stage renal disease
EWAS  epigenome-wide association study
FACS  fluorescence-activated cell sorting
IFNγ  interferon gamma
IL  interleukin
IMPDH  inosine monophosphate dehydrogenase
IRI  ischemia-reperfusion injury
HD  hemodialysis
HLA  human leukocyte antigen
HPV  human papilloma virus
MFI  median fluorescence intensity
MMF  mycophenolate mofetil
MPA  mycophenolate acid
mRNA  messenger RNA
MSC  mesenchymal stromal cell
NFAT  nuclear factor of activated T cells
PBL  peripheral blood lymphocytes
PBMC  peripheral blood mononuclear cells
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Abbreviations
PCR  polymerase chain reaction
PD  peritoneal dialysis
PD1  programmed death 1
RNA  ribonucleic acid
TCR  T cell receptor
TET  ten-eleven translocating
TGFβ  transforming growth factor β
TNFα  tumor necrosis factor α
Treg  regulatory T cell
TSS  transcription start site
TSDR  Treg-specific demethylated region
Tx  transplantation
ucMSC  umbilical cord-derived MSC
UV  ultraviolet
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researcher at the Amsterdam UMC (location AMC). 
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Daar is het dan, het hoofdstuk van het proefschrift dat iedereen ongegeneerd als eerste 
openslaat. De afgelopen vier jaar zijn ontzettend snel gegaan. Ik ben trots op het resultaat 
en de ontwikkeling die ik als wetenschapper heb doorgemaakt. Dit was onmogelijk 
geweest zonder de ondersteuning van velen die ik hieronder graag wil bedanken. 
Prof. dr. C.C. Baan, beste Carla, allereerst bedankt voor de mogelijkheid om op het 
transplantatie lab te promoveren. Het is inspirerend om te zien hoe je altijd op zoek 
bent naar innovatieve onderzoeks-ideeën en deze een kans geeft, zo ook het DNA 
methylatie onderzoek binnen het transplantatie veld. Je kritische blik stimuleerde mij 
om weloverwogen keuzes te maken en tilde het werk naar een hoger niveau. Bedankt 
dat ik altijd bij je binnen kon lopen en veel succes met alle toekomstige studies op het 
transplantatie lab.
Dr. ir. K. Boer, lieve Karin, ik heb het getroffen met jou als mijn co-promotor en het is een 
eer om je eerste promovenda te zijn. Vaak zaten we op dezelfde lijn en zo niet, dan leverde 
dat altijd goede discussies op. Je windt er geen doekjes om en dat waardeer ik. Samen 
hebben we het epigenetica onderzoek op de kaart gezet binnen het transplantatie veld. 
Zonder jouw steun was dat niet mogelijk geweest. Bedankt dat je altijd bereikbaar was 
voor een snelle vraag of een inhoudelijk overleg. Naast de leuke tijd op het werk, denk ik 
met veel plezier terug aan onze gezamenlijke tripjes; Cambridge, Londen en de reis naar 
Canada was een absoluut hoogtepunt! Bedankt voor alles en veel succes met alle volgende 
projecten.
Dr. M.G.H. Betjes, beste Michiel, bedankt voor de kans om te promoveren en voor het 
mogelijk maken van het vierde jaar. Je jarenlange ervaring in het vakgebied en scherpe blik 
zijn waardevol geweest tijdens mijn project. Je kon vaak met een paar kleine aanpassingen 
significante verbeteringen aanbrengen in mijn manuscripten. Daarnaast was het ook 
fijn om een mede-Amsterdammer te hebben in 010! Veel succes in de kliniek en met je 
projecten daaromheen.
Ik wil graag de overige commissieleden bedanken voor het plaatsnemen in mijn commissie.
Lieve paranimfen, Annemiek en Roos, bedankt voor alle steun en hulp die jullie mij gaven 
tijdens mijn promotie en met het voorbereiden van de verdediging. Annemiek, je bent een 
onmisbare kracht geweest de afgelopen vier jaar. We hebben samen vele uren doorgebracht 
in het lab, lange dagen gemaakt voor het sorten van de T cellen en je hebt vele PCR’s en 
pyro-runs voor mij uitgevoerd. Bedankt voor alles! Naast je steun in het lab vind ik het heel 
fijn dat je nu ook bij de verdediging aan mijn zijde zult staan. Roos, naast mijn (kleine) zus 
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ben je ook een hele goede vriendin. Onze reisjes naar St. Petersburg en Ibiza, gezamenlijke 
sport of yoga sessies en de eindeloze koffies en ontbijtjes zijn waardevolle momenten. 
Ik had niemand liever naast mij willen hebben tijdens m’n verdediging. Dit is een mooie 
aanvulling op alle andere bijzondere dingen die we samen hebben meegemaakt en nog 
voor ons in het verschiet liggen. 
Dear PhDs, thank you all for the wonderful time together. I have great memories from 
all the conferences we visited together and the fun we had in the office and on the lab. 
Kitty, wij gingen gelijk op in onze promotie en dat bracht ons samen in vele cursussen, 
congressen en tijdens de afronding van het proefschrift. Dat was een fijne steun en altijd 
gezellig! Daarnaast was onze samenwerking binnen het Young Professionals netwerk 
ontzettend leuk en hebben we mooie activiteiten neergezet. Ik ga je missen als buurvrouw 
en als collega. Veel succes met je opleiding in de klinische chemie. Marieke, ik vind het 
jammer dat ik je eigenlijk pas echt goed leerde kennen toen we in hetzelfde “kantoor” 
kwamen te zitten. Je bent een goede, kritische onderzoeker die zich niet gek laat maken 
en dat zal je goed van pas komen in het vervolgen van je klinische loopbaan. Bedankt voor 
de gezellige tijd, met als hoogtepunt de TTS in Madrid; en succes met de laatste fase van je 
promotie. Jesus, you are a great person to have around on the lab and you managed very 
well in an almost all-women PhD group! I enjoyed your jokes and good times. Many thanks 
for being our Spanish tour guide in Madrid. Anusha, jij hebt een onwijs uitdagend project 
en je pakt het vol overtuiging en optimisme aan. Heel knap! Daarnaast was je ook altijd 
in voor een gezellig gesprek of kon ik bij je terecht voor pathologie-gerelateerde vragen. 
Bedankt en succes verder met je promotie. Rens, bedankt voor het tolereren van al mijn 
frustratie rondom de FACS. Tegen het eind van m’n project had ik eindelijk het idee het 
onder de knie te hebben en dat was niet mogelijk geweest zonder jouw geduld en uitleg. 
Dank daarvoor. Nu zit je sinds een tijdje zelf als PhD-er op het lab, heel veel succes met je 
project! Jeroen, jij neemt toch een beetje het stokje van mij over binnen de “epigenetica 
groep”. Je zit vol goede ideeën en bent hard op weg om mooie resultaten te behalen met je 
PhD. Heel veel succes. Wouter, wie had dat gedacht bijna 11 (!) jaar geleden op onze eerste 
dag van bio-exact! Het is ontzettend gaaf om te zien hoe jij je project met beide handen 
aanpakt. Je enthousiasme is aanstekelijk. Wij gaan elkaar nog wel vaker tegenkomen, zo 
niet in het onderzoek dan wel in de kroeg met een biertje. Succes op het Tx lab. Aleixandra, 
je bent een vrolijke en relaxte aanwinst bij het Tx lab! Bedankt voor de gezelligheid en 
heel veel succes met je promotie. Nynke, ik vond het bijzonder om mee te maken hoe 
jij gegroeid bent tijdens je promotie. Na die vier jaar stond je als een zelfverzekerde 
vrouw en wetenschapper je proefschrift te verdedigen, iets om trots op te zijn! Bedankt 
voor alle gezellige gesprekken en het delen van onze kattenliefde. Samantha, bedankt 
voor je oneindige enthousiasme en optimisme. Gaaf om te zien dat je je droombaan hebt 
Acknowledgements (Dankwoord)
207
gevonden als klinisch embryoloog, heel veel succes. Franka, je was een fijne buurvrouw 
bij wie ik altijd terecht kon. Je liet me zien hoe handig Photoshop en Illustrator zijn en daar 
heb ik nog steeds profijt van. Ook je voorliefde voor reizen, duiken, true-crime podcasts 
(ik luister nog steeds wekelijks) en katten heb ik ontzettend gewaardeerd! Burç, jouw 
humor en danspasjes zijn van ongekend niveau. Je aanstekelijke lach was zelfs in onze 
kamer regelmatig te horen. Ik denk met plezier terug aan de congressen samen en dan 
vooral die waarbij er ‘s avonds gedanst kon worden. Dank voor alle lol op het lab en je 
nuchtere manier van denken. Gretchen, ik heb ontzettend genoten van je droge humor 
en bewonder je toewijding aan Hello Kitty en de kleur roze. Je was een echte sfeermaker 
op het lab, dank voor alle leuke momenten! Ling, thank you for being always so kind and 
helpful. I wish you all the best!
De postdocs wil ik ook graag bedanken. Nicolle, bij presentaties of werkbesprekingen wist 
je altijd een verbeterpunt aan te wijzen of iets ter discussie te stellen. Dit heb ik altijd zeer 
gewaardeerd. Daarnaast was je altijd bereikbaar voor vragen of om even mee te kijken 
naar m’n FACS data. Dank daarvoor! Martin, ook jij wist altijd een goede vraag te stellen of 
een nuttig advies te geven tijdens presentaties. Ook ben ik je dankbaar voor het initiëren 
van een Young Professionals netwerk bij de NTV en jouw steun bij het uitbouwen van het 
netwerk. Ana, you were a bright and shining personality in the lab, which I very much 
enjoyed. I will miss your humor and amazing Spanish cooking skills! Apart from that you 
are also a very good researcher, keep up the good work and good luck with everything. 
Nicole, bedankt voor je geduld tijdens mijn overleggen met Karin. Succes met je projecten. 
Fabiany, I am so happy for you that you are back at the lab and what a shame that I just 
left before you started. I wish you all the best with your research and a wonderful time in 
the Netherlands. 
Analisten, bedankt voor alle hulp en technische ondersteuning op het lab. Wenda, niet 
alleen voor bestellingen, sorten of vakantiedagen kon ik bij je terecht maar ook voor alles 
daaromheen. Bedankt voor je vrolijkheid, ondersteuning en luisterend oor. Marjolein, 
naast je bijdrages aan het Tx onderzoek, coördineerde je ook vakkundig het lab. Het feit 
dat alles altijd op orde was maakte het lab-werk een stuk gemakkelijker. Bedankt voor de 
gezelligheid op het lab en daarbuiten. Mariska, het maakte niet uit of het over voetballen 
ging, kapotte knieën of vermiste ficolbuizen, je bleef altijd nuchter en ontspannen. 
Bedankt daarvoor. Derek, als jongeling binnen het lab heb je snel je plek gevonden. 
Bedankt voor alle gezelligheid binnen en buiten het lab. Sander, ik heb veel moeten lachen 
om je bijzondere humor. Ook kon ik je altijd aanschieten voor een vraag over de qPCR, 
dank daarvoor. Ronella, van jou leerde ik ficollen in het allerbegin van mijn promotie. Ook 
daarna was je altijd behulpzaam, bedankt.
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Ook wil ik graag een aantal ex-collega’s nog even benoemen. Elly, bedankt dat je mij de 
fijne kneepjes van het pyrosequencen aanleerde. Het was heel fijn om met jou te werken! 
Jeroen, je was altijd in voor een kop koffie, zelfs toen je niet meer bij ons werkte. Bedankt 
voor alle gezelligheid op het lab en daarbuiten. Lin, Marcella, Tanja, dr. Wu, Ruud, Joke, 
Frieda, Ruben, Thea bedankt. 
Ik wil graag alle nefrologen en poli-assistenten bedanken voor hun inzet bij het includeren 
van nieuwe patiënten voor de studie. Jacqueline, bedankt voor je betrokkenheid bij mijn 
project en je klinische blik op het onderzoek. Ook bedank ik alle niertransplantatie 
patiënten voor het afstaan van bloed. Zonder jullie was dit onderzoek niet mogelijk was 
geweest. 
Lieve vriendinnen, jullie waren een welkome afleiding van het promoveren. De vele 
eetclub-avonden, Miggelenbergjes en vakanties zijn dierbare herinneringen. Sanacha, 
na zo’n lange vriendschap kan ons niks meer gebeuren. Bedankt voor al je woordgrapjes, 
gezelligheid en positieve kijk op het leven, al meer dan 20 jaar! Nienke, we delen al jaren 
een liefde voor dansen en zijn de laatste tijd nog veel meer naar elkaar toe gegroeid. Een 
hele waardevolle vriendschap! Daphne, je bent altijd te porren voor een avondje uit en je 
droge opmerkingen zijn ongeëvenaard. Beide worden in gelijke mate gewaardeerd! Anne, 
je neemt initiatief en bent naast lekker doortastend, ook altijd gezellig om mee te hebben. 
Je was al een fantastische kattenmoeder en ik weet zeker dat je dat ook zult zijn voor je 
baby girl! Roos, je bent altijd geïnteresseerd in hoe het gaat en ontzettend betrokken, zelfs 
vanuit Londen. Dank daarvoor. Daarnaast zal je prachtige bruiloft altijd een hoogtepunt 
blijven! Lotte, die eindeloze dagen in de bieb hebben ons geen windeieren gelegd! Bedankt 
voor de fijne tijd op de Westlandgracht en alle gezelligheid. Simone, Roselyne, Tessel: 
bedankt voor alle avondjes kolonisten, wijn drinken en onze onvergetelijke tripjes. Ik weet 
zeker dat we nog jaren kunnen terugblikken en lachen om de horéca-man, brandblusser en 
Bacardi met cola. Annelot, ik keek altijd ontzettend uit naar onze sportsessies in de Basic-
Fit. Niet alleen was dat goed voor onze conditie, het was ook een moment om stoom af 
te blazen en onze promotie-perikelen uitgebreid te bespreken. Nu starten we allebei een 
prachtige vervolg carrière, ik weet zeker dat je een fantastische arts zal worden! Bedankt 
voor alle lol samen en je wijze adviezen. 
Lieve familie: tantes, ooms, neefjes, nichtjes en aanhang. We zijn een bijzonder hechte 
familie en dat waardeer ik immens. Dank dat jullie zoveel interesse tonen en altijd voor 
me klaar staan. Ik heb ontelbare goede herinneringen aan alle gezellige feestdagen, 
verjaardagen en uitjes met elkaar. Paul, je bent niet meer weg te denken uit onze familie 
en geen moment is saai met jou. Ik bewonder je aandachtigheid en interesse. Lieve Oma, 
wat een gemis dat je dit niet meer mee kon maken, je bent altijd in onze gedachten.
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Lieve Hannie, Eric-Jan en Nancy, bedankt dat jullie mij zo liefdevol in jullie gezinnen 
hebben opgenomen. Ik denk met een warm hart terug aan de uitjes die we gehad hebben 
en hoop dat er nog veel zullen volgen. Floor en David, bedankt voor alle gezelligheid met 
als hoogtepunt (tot nu toe) onze ontmoeting in Frankrijk!
Lieve papa en mama, jullie hebben mij een warm en onbezorgd nestje gegeven om in 
op te groeien. Oneindig veel liefde, trots en kracht stralen jullie uit en jullie zijn beide een 
voorbeeld voor mij. Pap, ik ging net als jij de technische kant op en hier kunnen we dan ook 
eindeloos over discussiëren. Jij leerde mij om kritische vragen te stellen en altijd te blijven 
leren. Mam, ik bewonder je doortastendheid en drive om mensen om je heen te helpen. Je 
bewaart kundig het overzicht (lijstjes!) en biedt altijd een luisterend oor. Bedankt voor jullie 
onvoorwaardelijke steun en liefde.
Lieve Jeroen, het moment dat wij elkaar aankeken op de dansvloer heeft m’n leven 
voorgoed verandert. Je bent mijn rots in de branding. Jouw oplossingsgerichte manier 
van denken brengt rust in hectische of stressvolle tijden. Bedankt voor je geduld en wijze 
commentaar als ik weer eens een presentatie wilde oefenen. Ik ben ongelooflijk trots op 
de wetenschappelijke carrière die je nog voor je hebt, de steun die we elkaar daarin kunnen 
geven is heel bijzonder. Je geeft mij zelfvertrouwen en ik heb zin in alles wat het leven ons 
te bieden heeft. Ik hou van je.
